Chemicals From China
Chemicals From China
Chemicals From China
REPORT FOR
APIs & INTERMEDIATES MANUFACTURING
INDUSTRY
At
Plot No. 1A, 1A"P", 1B, 2, 2A, 2B, 3A to 3E,
4A, 4B, 4C, 5A & 5B,
Deosugar Industrial Area, Raichur, Karnataka
For
M/s. SHILPA MEDICARE LIMITED – UNIT I
Proposal number: IA/KA/IND2/75276/2018
Prepared by
SAMRAKSHAN
F- 4, I Floor, Swastik Manandi Arcade,
S C Road, Sheshadripuram,
Bangalore - 560 020
Ph.: 080-41466009
E mail id: [email protected]; [email protected]
CONTENTS
Index no. Description Page no.
Executive summary 01 - 10
CHAPTER 1
INTRODUCTION
1.1 Purpose of the report 11
1.2 Identification of project and project proponent 13
1.3 Brief description of nature, size, location of the project and its 15
importance to the country, region
1.3.1 Nature, size and location of the project 15
1.3.2 Importance of the project to the country, region 16
1.4 Scope of study – details of regulatory scoping carried out (as 18
per terms of reference)
1.4.1 Scope of study 18
1.4.2 Details of the study 18
1.4.3 Methodology of the study 19
1.4.4 Study area details 19
1.4.5 Terms of Reference (TOR) 19
CHAPTER 2
PROJECT DESCRIPTION
2.1 Type of project 32
2.2 Need for the project 32
2.3 Location (maps showing general location, specific location, 32
project boundary and project site layout)
2.4 Size or magnitude of operation 38
2.5 Proposed schedule for approval and implementation 38
2.6 Technology and process description 39
2.6.1 Products with production capacities 39
2.6.2 List of raw materials required and their source along with 40
mode of transportation
2.6.2.1 Raw materials, sources and supply 49
2.6.2.2 Storage facilities for raw materials, products 56
2.6.3 Reactor details 57
2.6.4 Manufacturing process description 57
2.6.4.1 Acebrophylline 58
2.6.4.2 Ambroxol HCl 64
2.6.4.3 Buflomedil HCl 71
2.6.4.4 Nifedipine 80
2.6.4.5 Phenyl ephrine HCl 89
2.6.4.6 Sildenafil citrate 104
2.6.4.7 Ticlopidine HCl 113
2.6.4.8 Ursodeoxycholic acid 123
2.6.4.9 Anastrozole 139
ii
2.6.4.10 Bendamustine HCl 149
2.6.4.11 Bicalutamide 153
2.6.4.12 Bortezomib 158
2.6.4.13 Capecitabine 168
2.6.4.14 Carboplatin 179
2.6.4.15 Cisplatin 186
2.6.4.16 Docetaxel trihydrate 192
2.6.4.17 Epirubicin HCl 201
2.6.4.18 Gefitinib 210
2.6.4.19 Gemcitabine HCl 217
2.6.4.20 Imatinib mesylate 226
2.6.4.21 Irinotecan HCl trihydrate 232
2.6.4.22 Lenalidomide 241
2.6.4.23 Letrozole 248
2.6.4.24 Oxaliplatin 256
2.6.4.25 Paclitaxel 263
2.6.4.26 Pemetrexed 273
2.6.4.27 Temozolomide 282
2.6.4.28 Thalidomide 289
2.6.4.29 Topotecan HCl 294
2.6.4.30 Zoledronic acid 301
2.6.5 Green chemistry 308
2.7 Project description including drawings showing project layout, 308
components of the project etc.
Schematic representations of the feasibility drawings which
give information important to EIA purpose
2.7.1 Project drawing 308
2.7.2 Schematic representations of the feasibility drawings which 308
give information important to EIA purpose
2.8 Mitigation measures to meet environmental standards, 309
environmental operating conditions or other EIA requirements
2.8.1 Source of water supply 309
2.8.2 Water demand and wastewater discharge 310
2.8.2.1 Flow chart of ETP at Unit II 314
2.8.3 Product-wise process water consumption and effluent 316
discharge
2.8.4 Effluent characteristics 319
2.8.5A A solvent recovery and recycling 319
2.8.5.1 Solvent recovery system 324
2.8.5.2 Solvents storage 325
2.8.5.3 Solvents management 326
2.8.5.4 Measures to control evaporation losses and fugitive emissions 327
for few raw materials and solvents
2.8.5B Rainwater management 328
2.8.6 Air pollution sources and their management 329
iii
2.8.6.1 Ambient air quality and stack emission monitoring 333
2.8.6.2 Specifications of air pollution control units provided 333
2.8.6.3 Power requirement 335
2.8.7 Noise generation and its management 335
2.8.8 Solid waste generation and its management 335
2.8.9 Hazardous waste generation and its management 336
2.8.9.1 Storage and disposal of hazardous waste 337
2.8.10 By- products generation and management 338
2.8.10.1 Other materials generated during manufacturing process 342
2.9 Assessment of new and untested technology for the risk of 343
technological failure
CHAPTER 3
DESCRIPTION OF THE ENVIRONMENT
3.1 Study area, period, components and methodology 344
3.2 Status of environmental attributes 346
3.2.1 Meteorological data 346
3.2.1.1 Temperature 348
3.2.1.2 Relative humidity 348
3.2.1.3 Rainfall 348
3.2.1.4 Atmospheric pressure 348
3.2.1.5 Wind 348
3.2.1.6 Cloud cover 354
3.2.2 Geology of the study area 354
3.2.3 Hydrogeology of study area 354
3.2.4 Drainage pattern of the study area 355
3.3 Monitoring of environmental attributes 359
3.3.1 Sampling locations 359
3.3.2 Air quality 361
3.3.3 Noise environment 369
3.3.4 Water environment 376
3.3.4.1 Surface water 376
3.3.4.2 Ground water 385
3.3.5 Soil and geology 390
3.3.6 Ecology 394
3.3.6.1 Anticipated impacts 394
3.3.6.2 Flora 394
3.3.6.3 Fauna 396
3.3.7 Socio-economic environment 397
3.3.7.1 Demographic structure 397
3.3.7.2 Economic environment 398
3.3.8 Social infrastructure available 399
3.2.8.1 Connectivity 400
3.2.8.2 Surrounding industries 405
3.3 Base maps of all environmental components 406
iv
CHAPTER 4
ANTICIPATED ENVIRONMENTAL IMPACTS & MITIGATION MEASURES
4.1 Details of investigated environmental impacts due to project 410
location, possible accidents, project design, project
construction, regular operations, final decommissioning or
rehabilitation of completed project measures for minimizing
and/or offsetting adverse impacts identified
4.1.1 Environmental impacts due to project location, possible 410
accidents, project design and mitigation measures
4.1.2 Environmental impacts due to regular operations and 422
mitigation measures
4.1.2.1 Scope 423
4.1.2.2 Actions likely to affect the environment during operation phase 423
4.1.2.3 Measures for minimizing & / or offsetting adverse impacts 424
identified - mitigation measures
4.1.2.4 Implementation schedule 428
4.1.3 Environmental impacts due to final decommissioning and 428
mitigation measures
4.2 Irreversible & irretrievable commitments of environmental 428
components
4.3 Assessment of significance of impacts (criteria for determining 428
significance, assigning significance)
4.3.1 Impact matrix 429
CHAPTER 5 431
ANALYSIS OF ALTERNATIVES (TECHNOLOGY & SITE)
CHAPTER 6
ENVIRONMENTAL MONITORING PROGRAM
6.1 Technical aspects of monitoring the effectiveness of mitigation 431
measures (including measurement methodologies, frequency,
location, data analysis, reporting schedules, emergency
procedures, detailed budget and procurement schedules)
6.1.1 Measurement methodology 431
6.1.2 Frequency, location, data analysis, reporting schedules 431
6.1.3 Emergency procedures 433
6.1.4 Budget and procurement schedules 433
CHAPTER 7
ADDITIONAL STUDIES
7.1 Public consultation 434
7.2 Risk assessment 436
7.2.1 Introduction 436
7.2.2 HAZOP analysis 436
7.2.3 Introduction to risk assessment 436
7.2.4 Evaluation of risks 436
7.2.5 Minimization / avoidance of the risk 437
v
7.2.6 Quantitative risk analysis 437
7.2.7 Hazard identification 437
7.2.8 Risk assessment 438
7.2.9 Risk assessment for storage of materials 450
7.2.10 Major risk assessment 453
7.2.11 Worst case analysis-control measures 455
7.2.12 Hazard and severity mapping for hazardous raw materials 458
7.2.13 Mitigation measures for storage of hazardous raw materials 464
7.2.14 Safety precautions during solvents storage, handling, 465
transportation and recovery
7.2.14.1 MDC handling and precautions against anticipated hazards 465
7.2.14.2 MDC transportation 465
7.2.15 General safety measures / precautions 466
7.2.16 Safety measures taken in hydrogenation process 467
7.2.17 Occupational health & safety 468
7.3 Air pollution dispersion modeling studies 475
7.3.1 Introduction 475
7.3.2 Air modeling study 476
7.7.2 Meteorological data 477
7.7.3 Presentation of results 477
7.4 Social impact assessment, R&R action plans 488
CHAPTER 8
PROJECT BENEFITS
8.1 Improvements in the physical infrastructure, social 489
infrastructure
8.2 Tangible benefits 489
8.3 Intangible benefits 489
8.4 Other benefits 490
CHAPTER 9
ENVIRONMENTAL COST BENEFIT ANALYSIS
9.1 Natural resources 496
9.2 Air environment 499
9.3 Water environment 499
9.4 Soil environment 500
9.5 Socio-economic environment 500
9.6 Assessment of ecological damage to the environment 501
CHAPTER 10
ENVIRONMENTAL MANAGEMENT PLAN (EMP)
10.1 Introduction 502
10.2 Mitigation measures 502
10.3 Monitoring plans 502
10.4 Roles, responsibilities and resource allocation for monitoring 502
vi
CHAPTER 11
SUMMARY & CONCLUSION
11.1 Measures adopted to mitigate the impacts 503
CHAPTER 12
DISCLOSURE OF CONSULTANTS ENGAGED
CHAPTER 13
ASSESSMENT OF ECOLOGICAL DAMAGE WITH RESPECT TO AIR, WATER,
LAND AND OTHER ENVIRONMENTAL ATTRIBUTES. EMP COMPRISING
REMEDIATION PLAN & NATURAL & COMMUNITY RESOURCE AUGMENTATION
PLAN VIS-À-VIS ECOLOGICAL DAMAGE ASSESSED & ECONOMIC BENEFITS
DERIVED
13.1 Introduction 509
13.1. A. Historical and Current activities at the site 509
13.2 Preamble to assessment of ecological damage if any, EMP 510
comprising remediation plan & natural & community resource
augmentation plan & economic benefits due to violation
13.3 Brief description of the site 511
13.4 Assessment of ecological/ environmental damage 512
13.4.A. Introduction 512
13.4.B Present scenario 512
13.4.C Zone of influence 513
13.4.D. Environmental status of study 513
13.4.E. Impacts & mitigation measures for sources of pollution during 519
operation
13.4.F. Assessment of ecological damage and suggested remediation 522
measures
13.4.G Concerns raised during public consultation & response 528
13.5 Natural and community resource augmentation plan 545
13.6 Economic benefits derived due to violation 546
13.7 Cost of remediation & measures to improve surrounding areas 547
13.8 Implementation schedule of planned activities and related 547
bank guarantee
13.9 Conclusion and recommendation 548
vii
List of tables
Table Description Pg.
no. no
1.1 Terms of Reference (TOR) 20
2.1 Co-ordinates (latitude-longitude) of all four corners of the site 32
2.2 Immediate surroundings of project site 33
2.3 Land-use pattern 34
2.4 Value of the company as per CA certificate 38
2.5 APIs manufactured 39
2.6 A Raw materials requirement 40
2.6 B List of raw materials, their sources and mode of transportation 50
2.6 C Storage facilities for raw materials and products 56
2.7 Water consumption and wastewater discharge 310
2.8 Wastewater treatment and disposal 311
2.9A Product-wise water consumption and effluent discharge 316
2.9B Combined effluent characteristics 319
2.10 Solvent recovery 319
2.11 Measures to control evaporation losses and fugitive emissions for 327
few raw materials and solvents
2.12 Air pollution sources, fuel consumption and chimney height details 330
2.13 Solid waste generation & management 336
2.14 Summary of the total quantity of hazardous wastes 336
2.15 Storage and disposal of hazardous wastes 337
2.16 Quantity of by-products generated 339
2.17 Other products generated during manufacturing process 342
3.1 Meteorological data of Raichur for the year 2017 347
3.2 Predominant wind directions in different seasons 348
3.3 Sampling locations for environmental attributes 359
3.4 Ambient air quality data, analysis results 361
3.4A Ambient air quality – summary 366
3.5 Ambient air quality standards – MoEF as per the notification dated 367
16th November 2009 for industrial, residential & rural areas
3.6 A Noise level monitoring, data analysis results – March 2018 370
3.6 B Noise level monitoring, data analysis results –April 2018 371
3.6 C Noise level monitoring, data analysis results – May 2018 373
3.7 Equivalent noise levels 375
3.8 A Surface water analysis – March 2018 377
3.8 B Surface water analysis –April 2018 378
3.8 C Surface water analysis – May 2018 380
3.8 D Designated best use of surface water 382
3.8 E Class of surface water analysed – March 2018 383
3.8 F Class of surface water analysed – April 2018 383
3.8 G Class of surface water analysed – May 2018 384
viii
3.9 A Ground water analysis – March 2018 385
3.9 B Ground water analysis – April 2018 386
3.9 Ground water analysis – May 2018 388
3.10A Physico-chemical characteristics of soil –March 2018 390
3.10 B Physico-chemical characteristics of soil – April 2018 391
3.10 C Physico-chemical characteristics of soil –May 2018 392
3.10 D Soil classification 393
3.11 Flora in the study area 395
3.12 Fauna in the study area 396
3.13 Summary of demographic structure 397
3.14 List of infrastructural facilities in the surroundings 399
3.15 Connectivity from the project site 400
3.16 Surrounding industries 405
3.17 Existing land-use pattern 406
4.1 Air quality management during operation phase 425
4.2 Noise management during operation phase 426
4.3 Water quality management during operation phase 427
4.4 Land quality management during operation phase 428
4.5 Impact matrix 430
6.1 Monitoring schedule for environmental parameters 432
6.2 Financial allocation/budgetary provisions for environmental 433
management aspects
7.1 Probable hazards in the plant 438
7.2 Data considered for calculation of GLC 476
7.3 Predicted incremental short-term concentrations 477
7.4 Resultant Maximum 24 hourly concentrations 487
8.1 CSR activity - windmills 490
8.2 Other CSR activities 491
9.1 Production – consented vs actual (for last 3 consecutive years) 497
9.2 Water consumption - comparison between consented versus actual 499
water consumption (for last 2 consecutive years)
9.3 Hazardous waste generation - comparison between authorized 500
versus actual water consumption (for last 2 consecutive years)
9.4 Summary of CBA (Cost Benefit Analysis) 501
11.1 Measures adopted to mitigate the impacts 505
13.1 Land-use pattern 511
13.2 Immediate surroundings of project site 511
13.3 Groundwater quality in the immediate vicinity of the industry 516
13.4 Mitigation measures 519
13.5 Budgetary provisions for EMP 521
13.6 Assessment of environmental / ecological damage, remediation 522
measures & cost suggested
13.7 Economic benefits derived due to violation 546
13.8 Financial allocation for remediation 547
ix
List of figures
Fig. Description Pg. no
No.
2.1 General and specific location of industry 34
2.2 Google map with site boundary 35
2.3 Plant layout 36
2.4 Site Photographs 37
2.5 Photographs of raw materials storage area 56
2.6 Green chemistry – continuous flow reactors 308
2.7 Schematic representation of the overall feasibility and 309
environmental assessment process
2.8 Wastewater storage tanks at Unit I (20 KL capacity for each) 311
2.9 Effluent Treatment Plant at Unit II 312
2.10 Water balance chart 313
2.11 Solvent recovery system 324
2.12 Solvent storage area 325
2.13 Condenser system to reactors for solvent management 326
2.14 Centrifuge connected to scrubber 327
2.15 Rainwater harvesting tank and groundwater recharge pits 329
2.16 Photographs of air pollution sources and control equipments 331
2.17 Hazardous waste storage area 338
3.1 Topo map 345
3.2 Wind rose diagrams 349
3.3 A Hydrogeology of Raichur District 356
3.3 B Hydrogeology of Mahbubnagar District 357
3.4 Drainage pattern of Raichur District 358
3.5 Google map showing sampling locations for environmental 360
attributes
3.6 Wind rose diagram – March (sampling period) 368
3.7 Google map showing infrastructural facilities and connectivity 401
3.8 Google map 1 km radius 402
3.9 Google map 5 km radius 403
3.10 Google map 10 km radius 404
3.11 Google map showing surrounding industries 405
3.12 Existing land-use pattern 407
3.13 Google map showing surrounding water bodies 409
4.1 Personal with safety PPEs in work area 411
4.2 Eye and body showers 411
4.3 ISO 18001:2007 (Occupational Health and Safety Management 413
System) certification
4.4 Health and safety policy 414
4.5 Firefighting facilities 416
4.6 ISO 14001:2015 (Environmental Management System) 418
x
certification
4.7 Environment policy 419
4.8 A Spill control kits provided at various locations 421
4.8 B Green-belt 422
6.1 Continuous online monitoring system 433
7.1 Screenshot from KIADB website 435
7.2 Particulate matter (PM10) isotherms for proposed project 478
7.3 Sulfur di-oxide (SO2) isotherms for proposed project 481
7.4 Oxides of nitrogen (NOx) isotherms for proposed project 484
8.1 Photographs of CSR activities 493
10.1 Organization chart of Environment Cell 503
13.1 Google map showing sampling locations within and in the 515
immediate vicinity of the project site
13.2 Historical google maps 518
13.3 Photographs 544
List of enclosures
Enclosure Details Pg no.
no.
1 1. Borewell water analyzed at 550-554
Wells in Growth Centre (by KSPCB).
Yedlapur
2. Konan halla water at the outlet of surface water drain from
Deosugur industrial area
2 Dismissal order dated 05-10-2018 for complaint file case No: 33/2014- 555-557
15
3 1. Medical report regarding health status of people in the surrounding 558-563
areas obtained from the Department of Health and Family Welfare,
Government of Karnataka.
2. Sample health reports of workers at Shilpa Medicare Ltd. Unit I.
STAY ORDER 564-568
ANNEXURES (569-858)
xi
M/s. Shilpa Medicare Ltd. Unit I
EXECUTIVE SUMMARY
1. INTRODUCTION
COMPANY HISTORY
EIA
-1-
M/s. Shilpa Medicare Ltd. Unit I
PRODUCTION HISTORY
Prior to 2006, the then Shilpa Organics Pvt. Ltd. was manufacturing 4
products viz. Trimethoprim, Sulphmethoxazole, 1,3,5-Trimethoxy benzene
and Terfinadine of total capacity 9.4 MT per month. Prior to the merger of
Shilpa Organics Pvt. Ltd., the Company Shilpa Medicare Ltd. was also
manufacturing 4 products viz. Trimethoprim, Sulphamethoxazole, Nifedine
and Atenaol with a total production capacity of 20 MT per month.
After merger, Shilpa Medicare Ltd. had a Consent to Manufacture 6 products
of capacity 29.4 MT per month, viz., Trimethoprim, Sulphamethoxazole,
Nifedine, Atenalol, 1,3,5- Trimethoxy Benzene and Terfinadine.
During 2010, the industry conceptualized for change in product mix.
Karnataka State Pollution Control Board (KSPCB), after appraising the
project before the Technical Advisory Committee (TAC) has granted the
Consent to Establish (CTE) on 7-5-2011 for modification of existing products
without increase in pollution load. Subsequently Consent to Operate under
the Water and the Air Act was accorded by Karnataka State Pollution
Control Board for 30 products with a total capacity of 26.44 MT/month, in`
the process 5 of the old products were dropped and 25 new products w
ere added, without increase in the pollution load and quantity of
production.
This was renewed subsequently upto 30-06-2016. Consent application for
further period is made.
The Company was carrying on its activities and was operating by securing
necessary consent for operation from time to time ever since its
commencement from earlier to 1994 and lastly vide CTO issued by the
Board on 08-10-2015 which was valid till 30-06-2016.
The application made for consent renewal is held back by KSPCB. The
Company has been directed to obtain environmental clearance for the
change in product mix. Therefore, it is proposed to obtain Environment
Clearance for these 30 products with a total production capacity of 26.44
MT/month.
2. PURPOSE OF STUDY
EIA
-2-
M/s. Shilpa Medicare Ltd. Unit I
4. PROJECT AT A GLANCE
5. ENVIRONMENTAL EVALUATION
ENVIRONMENTAL STATUS
Three months data during the period of March to May 2018 has been collected
for environmental attributes like air, water, soil, noise etc., within a radius of
10 km to assess the environmental status around the industry area. Secondary
data from different government, semi-government and private agencies and
other sources are collected, interpreted, compiled and presented to
authenticate and draw conclusion/s regarding the status of the environment in
the study area.
PUBLIC AMENITIES
Water supply
Most of the villages in the study area are provided with basic civic amenities.
Water sources are Krishna river, open wells and bore wells.
EIA
-4-
M/s. Shilpa Medicare Ltd. Unit I
Electricity
Electricity is supplied from GESCOM for various needs such as domestic,
industrial and agricultural requirements in the study area.
AIR ENVIRONMENT
The ambient air quality status around the industry is characterized using the
following sources of data.
Ambient air quality monitoring data for selected locations within 10 km
radius of study area.
Meteorological data
Air quality
To evaluate the status of the ambient air quality, a short-term survey was
conducted at seven locations around the proposed project site for three
months during March to May 2018. Ambient air quality standards MoEF as per
the notification dated 16th November 2009 for industrial, residential and rural
areas were considered as the standard. During the study period, concentrations
of SPM (PM10 & PM2.5), SO2, NOx , CO were measured. From the observations, it
has been concluded that the concentration of pollutants under consideration
are within the specified limits of NAAQS for industrial and residential areas.
NOISE ENVIRONMENT
Noise level monitoring was conducted at seven locations within the study area
representing industrial and residential areas. The field observations during the
study period indicate that the ambient noise levels in both industrial and
residential areas are within the CPCB limits during most time of the day and
night. However on few days, at certain times the noise levels exceed the limits
stipulated due to truck/vehicular movement.
WATER ENVIRONMENT
Seven groundwater samples were collected in the study zone including project
site and surroundings and analyzed for their physico- chemical characteristics
to evaluate the existing status of water quality. The ground water analysis
results indicate that the parameters are within the permissible limits of the
Drinking Water Standards (IS: 10500-1991) except Muraharidoddi in Telangana.
Nitrates at Muraharidoddi in Telangana after crossing river Krishna are more
than the acceptable & permissible limit of 45 mg/L specified ranging from 96-
99 mg/L. This village is surrounded by agricultural fields where there is
extensive use of fertilizers.
EIA
-5-
M/s. Shilpa Medicare Ltd. Unit I
In addition, surface water sources analyzed for water quality are Krishna river
(both upstream & downstream), Rajasab Talav/ Merched Kere and Konad Halla
all located within 10 km distance form the industry. All the samples of surface
water analyzed come under class C (Drinking water source after conventional
treatment and disinfection) & D (Propagation of wildlife and fisheries).
The required water for this industry area is from KIADB (Krishna river).
SOIL ENVIRONMENT
There are naturally growing plants, vegetation and grass. Land within the study
zone is moderately dry, barren with few trees & bushes surrounding the rural
village settings. Tree species attaining moderate to considerable height are
found to be present in sparsely distributed area. The biodiversity of vegetation
in the area is not very high due to industries, brick industries and agro
ecosystem.
In the industry, an area of 33,591.25 SQM i.e. 35% of the total plot area is open
space and landscape/green-belt. About 50 native indigenous trees such as
Neem (Azadirachta indica) and Pongamia (Millettia pinnata) are present.
The fauna found in the region does not show much diversity since the forests in
the district are of mixed dry deciduous type consisting of open scrub jungles.
Plenty of snakes, scorpions and lizards are found. Few water birds such as
Indian pond heron, grey heron, river tern are found near the Krishna river.
SOCIO-ECONOMIC ENVIRONMENT
The industry has generated direct employment opportunities for 150 people out
of which 70% (105) are local people. The main occupation of the people in the
study area is agriculture. Paddy is extensively cultivated. As there was
apprehensions expressed by few participants during the public hearing on
13-11-2018 about the contamination of Konad/Konnan halla a natural stream,
monitoring was carried out. Inference that can be drawn from monitoring are
EIA
-6-
M/s. Shilpa Medicare Ltd. Unit I
AIR EMISSIONS
The sources of air pollution in the industry are
Process section provided with column scrubbers and stack of adequate
heights.
Two boilers of 4 TPH capacity each provided with multicyclones and
combined stack of 30 m height.
DG setsof 325 kVA capacity each provided with stacks of 5 m ARL height
and acoustic enclosures.
WATER POLLUTION
The sources of water pollution are domestic sewage and industrial effluent.
EIA
-7-
M/s. Shilpa Medicare Ltd. Unit I
NOISE
Sources of noise
DG sets are the major noise generating sources for which acoustic
enclosures are present.
Handling and conveying of raw materials and semi-finished
components to different operations can be a source of noise
pollution. This is controlled by regular maintenance.
SOLID WASTE
The solid waste generated from the industry is of 2 types non-hazardous solid
waste and hazardous solid waste. The total quantity of waste generated with
disposal & management options are detailed below.
EIA
-8-
M/s. Shilpa Medicare Ltd. Unit I
Boiler ash
Quantity of boiler ash generated 500 kg/day
Storage Stored in covered shed.
Disposal Handed over to local brick
manufacturers.
Hazardous wastes
Sl. Storage Name of disposal
Source Quantity Mode of disposal
No. container facility
Sent to KSPCB
Used oil from Leak proof authorized spent oil re-
1 0.2 KL/annum KM Oils Pvt. Ltd.
DG sets containers processors for
regeneration & re-use.
Handed over to KSPCB
Panchamukhi
Spent 39.6 Leak proof authorized
2 Pharma Chem,
solvents KL/annum containers recyclers/re-
Ramanagara
processors.
Distillation HDPE carboys E Nano Incitech,
3 2 MT/annum Sent for incineration.
residue / LDPE bags Ramanagara
Process HDPE carboys E Nano Incitech,
4 2 MT/annum Sent for incineration.
residue / LDPE bags Ramanagara
Discarded 200 Handed over to KSPCB Hajira Enterprises,
5 --
containers No.s/annum authorized recyclers. Ramanagara
E Nano Incitech,
6 Spent carbon 1 MT/annum Polybags Sent for incineration.
Ramanagara
EIA
-9-
M/s. Shilpa Medicare Ltd. Unit I
9. CONCLUSION
The overall impact of the project is beneficial as the impacts on air, noise,
water, soil and biological environment are not significant and socio-economic
impacts are predominantly positive. All the relevant safety norms &
precautionary measures are incorporated in the system, to ensure that the
project is environmentally viable.
EIA
- 10 -
M/s. Shilpa Medicare Ltd. Unit I
CHAPTER 1
INTRODUCTION
1.1 PURPOSE OF THE REPORT
M/s. Shilpa Medicare Limited, Unit I is located at Plot No. 1A, 1A"P", 1B, 2, 2A,
2B, 3A to 3E, 4A, 4B, 4C, 5A & 5B, Deosugar Industrial Area, Raichur,
Karnataka. The Company is manufacturing Active Pharmaceutical Ingredients
(APIs) and Intermediates. This activity is covered under schedule 5(f) of the EIA
notification S.O.1533(E) dated 14-09-2006.
The Company (Unit I) was carrying on its activities and was operating by
securing necessary consent for operation from time to time ever since its
commencement as issued by the Karnataka State Pollution Control Board
(KSPCB).
The Company is incorporated under the Indian Companies Act and has
undergone various changes in its constitution as follows:
Originally M/s. Green Leaves Organics Pvt. Ltd., which was a small scale
industry, was established prior to 1994.
M/s. Shilpa Antibiotics Private Limited which was also a small scale industry
was established in the year 1987 and commissioned during 1989. Later on
the said Shilpa Antibiotics Private Limited became Shilpa Antibiotics
Limited. Public issues were called and became a public limited company in
the year 1995.
The name of M/s. Shilpa Antibiotics Limited was later changed as Shilpa
Medicare Limited with effect from 13-12-2002.
As the said M/s. Green Leaves Organics Pvt. Ltd. was sick and was not in
operation the said company was taken over by one M/s. Shilpa Organics Pvt.
Ltd. on 28-06-2000 through the Karnataka State Finance Corporation and
the name of the said company was changed as M/s. Shilpa Organics Pvt. Ltd.
Subsequently both M/s. Shilpa Organics Pvt. Ltd. and Shilpa Medicare
Limited were merged and became M/s. Shilpa Medicare Limited on
01-04-2007.
The Company, Shilpa Organics Pvt. Ltd., prior to 2006 was manufacturing 4
products by name Trimethoprim, Sulphmethoxazole, 1,3,5-Trimethoxy
benzene & Terfinadine of total capacity 9.4 MT per month. Prior to the
EIA
- 11 -
M/s. Shilpa Medicare Ltd. Unit I
merger of Shilpa Organics Pvt. Ltd., the said Company was also
manufacturing 4 products by name Trimethoprim, Sulphamethoxazole,
Nifedine and Atenaol with a total production capacity of 20 MT per month.
The Company prior to the said merger had consent from the Karnataka State
Pollution Board to manufacture 6 products of capacity 29.4 MT per month.
On 07-05-2011 consent to establish for the change in product mix was issued
by the Board for 30 products with a total capacity of 26.44 MT per month.
During the issue of the said consent 25 new products were added by
dropping 5 old products without increasing the pollution load which fact is
disclosed in the consent to establish issued to the company. A true copy of
the said CTE is enclosed as Annexure A2.
Subsequently the Consent to Operate was issued on 30-03-2012 valid up to
30-06-2012, renewed subsequently upto 30-06-2016. Consent application is
made for further renewal.
The said Company also has another unit called as Unit No. II at Plot No. 33,
33A, 40 to 47, Industrial Growth Centre, Chicksugur Village, Raichur District.
The said Unit No. II was established in the year 2008. Unit II has obtained prior
EC and consent to establish in accordance with law. As permitted under the
consent conditions, the effluent from Unit I is taken to Unit II for necessary
treatment in accordance with law. The treated effluent is reused.
As regard to air pollution control, industry has complied with the regulatory
norms as per consent conditions.
Originally the activity of the Company was covered under the EIA Notification
No. S.O. 60(E) dated 27-01-1994 issued by the MOEF. As the Unit was
established prior to EIA notification 1994 and thereafter upto 2011 there was
no change in product, hence there was no requirement to obtain Environmental
Clearance (EC) from the Central Government or the State Government. In 2011
when the product mix was done it was within the earlier manufacturing
capacity and there was no increase in pollution load which was certified by
KSPCB and CTE and CTO was granted valid upto 30.6.2016. Thereafter, when
the application was made for renewal of consent under the Water and the Air
Act to KSPCB it was informed in letter dated 18th Jan 2017 to obtain
Environmental Clearance for the change in product mix.
EIA
- 12 -
M/s. Shilpa Medicare Ltd. Unit I
The Company has fully complied with all the previous consent conditions and
operated in accordance with law except that it has to secure EC from MOEFCC
which has been made mandatory by virtue of the 2006 notification and the
time is extended by virtue of the 14.3.2017 notification.
In the 2nd meeting of Expert Appraisal Committee (EAC) for the proposal
involving violation of EIA Notification, 2006, held on 16 th January, 2018 the
proposal was appraised.
The EIA report is prepared duly incorporating the terms of reference given by
the Ministry of Environment, Forest & Climate Change.
PROJECT
M/s. Shilpa Medicare Limited (SML)., Unit I, is located at Plot No. 1A, 1A"P", 1B,
2, 2A, 2B, 3A to 3E, 4A, 4B, 4C, 5A & 5B, Deosugar Industrial Area, Raichur,
Karnataka. The unit is in operation since 1989. Deosugar Industrial Area is a
designated industrial area established by Karnataka Industrial Area
Development Board (KIADB) on 27-04-1987.
PROJECT PROPONENT
M/s. Shilpa Medicare Limited (SML), No. 10/80, Rajendra Gunj, Raichur
584 102, Karnataka, a public limited company has two units at Raichur. Unit I is
Active Pharmaceutical Ingredients (APIs) & Intermediates manufacturing
industry with R & D activity at Plot No. 1A, 1A"P", 1B, 2, 2A, 2B, 3A to 3E, 4A,
4B, 4C, 5A & 5B, Deosugar Industrial Area, Raichur, Karnataka. Unit I initially
started producing Trimethoprim IP/BP with in-house developed technology.
The Company started manufacturing both for export and domestic markets in
the year 1992.
The Company was listed on Bombay Stock Exchange on Jun 19, 1995 and
National Stock Exchange (NSE) on Dec 03, 2009. Subsequently, Shilpa Medicare
has gained World Health Organization-Good Manufacturing Practices (GMP)
Certificate recognition. In the relentless efforts for growth-Shilpa Medicare
EIA
- 13 -
M/s. Shilpa Medicare Ltd. Unit I
-
Oncology APIs and intermediates. Further, to consolidate in field of generic
APIs and formulations, we are striving for achieving excellence by putting our
relentless efforts in field of Novel Drug Delivery Systems (NDDS) and peptides,
along with widening our focus to other therapy areas. Shilpa Medicare aims for
ensuring affordable healthcare without compromising quality standards.
Shilpa Medicare is an ISO 14001: 2015, ISO 18001:2007 certified organization
and committed to implement, maintain and improve the environmental
management system so as to assure its conformity with the stated
environmental policy. A broad and integrated portfolio of products and services
(CRAMS) are offered to the global pharmaceutical industry. In recognition of
the outstanding performance, Shilpa Medicare has received many awards &
recognitions
First Prize, National Energy Conservation award in Drugs & Pharmaceutical
Sector received from Shri. Pranav Mukharji President of India on
14-12-2012.
National Small scale Entrepreneurs Award in 1994, from the President of
India.
Consistently winning the best Exporter award from the Govt. of Karnataka
year on year since 1994.
Consistently earning Foreign Exchange for the country to the tune of
Rs.3,500 Crores so far.
Loba Finechem
Raichem Life Sciences
Nu Therapeutics
Reva Pharma
EIA
- 14 -
M/s. Shilpa Medicare Ltd. Unit I
The products of Shilpa Medicare are exported to USA, Canada, Australia, Japan
and European Countries viz., Germany, Switzerland, Netherlands, Belgium,
Spain, Greece, Cyprus, Italy, United Kingdom etc. and also to South American
Countries like Mexico, Brazil, and Columbia etc.; African Countries like Kenya,
Nigeria and West Indies etc. and Asian Countries like Singapore, Taiwan, China,
Malaysia, Thailand, etc.
Unit-II
Unit-II of Shilpa Medicare Ltd. is a 100% Export Oriented API Unit established
during 2008. This unit is at at a distance of 4.2 km from Unit I in the south east
direction. It is also well connected to state highway as being located just
adjacent to Hyderabad-Raichur state highway. This unit is certified by ISO
14001 and approved by WHO-GMP/EUGMP.
1.3 BRIEF DESCRIPTION OF NATURE, SIZE, LOCATION OF THE PROJECT AND ITS
IMPORTANCE TO THE COUNTRY, REGION
EIA
- 15 -
M/s. Shilpa Medicare Ltd. Unit I
Drugs have become a part of our life for sustaining many of our day-to-day
activities, preventing and controlling diseases. Bulk drugs manufacturing sector
in India is well established and has recorded a steady growth in the overall
Indian industrial scenario. The bulk drugs and allied industries have been
amongst the fastest growing segments of the Indian industry.
The Indian pharmaceuticals market is the third largest in terms of volume and
thirteenth largest in terms of value. It accounts for 20 percent in the volume
terms and 1.4 percent in value terms of the Global Pharmaceutical Industry as
per a report by Equity Master. India is the largest provider of generic drugs
globally with the Indian generics accounting for 20 percent of global exports in
terms of volume. Of late, consolidation has become an important characteristic
of the Indian pharmaceutical market as the industry is highly fragmented.
MARKET SIZE
GOVERNMENT INITIATIVES
EIA
- 16 -
M/s. Shilpa Medicare Ltd. Unit I
ROAD AHEAD
Going forward, better growth in domestic sales would also depend on the
ability of companies to align their product portfolio towards chronic therapies
for diseases such as such as cardiovascular, anti-diabetes, anti-depressants and
anti-cancers that are on the rise.
The Indian government has taken many steps to reduce costs and bring down
healthcare expenses. Speedy introduction of generic drugs into the market has
remained in focus and is expected to benefit the Indian pharmaceutical
companies. In addition, the thrust on rural health programs, lifesaving drugs
and preventive vaccines also augurs well for the pharmaceutical companies.
The state contributes about 10% to the pharmaceutical export revenues of the
country. At present Karnataka is home to more than 230 pharma and biotech
companies.
International pharma majors have preferred many companies from the State.
When large companies offer their services on contractual basis to global MNCs,
they want to outsource drug production for the domestic market from quality
small-medium manufacturers in State. Here the small-medium units ideally fit
into slot as third party manufacturers and serve as major hubs for
pharmaceutical outsourcing. In fact, two of Indian pharma sectors top five
brands, are already outsourced from Karnataka. The units have been
recognized for stringent regulatory enforcement and known to manufacture
quality products.
EIA
- 17 -
M/s. Shilpa Medicare Ltd. Unit I
PROJECT NEED
Cancer cases in India are on the rise with more than 3.5 million prevalent cases
& a million new cancer cases being diagnosed every year. Among men, the
cancer of the head and neck and in women cancer of cervix and breast are
leading forms of cancer. The oncology segment in India is now witnessing
increasing domestic presence with a large number of Indian companies entering
into the foray. Not only are these companies competing for the existing
portfolio but are also actively pursuing research for introduction of newer &
improved specialty products. The sale of cancer drugs is expected to grow at
nearly twice the rate of the rest of pharmaceuticals. With a large number of
patents for many oncology products due to expire shortly, there is a lot of
scope in oncology segment. Therefore, SML proposes to manufacture 22
oncology products to take advantage of the growing demand in this sector and
also to ensure availability of life saving drugs.
Environmental baseline monitoring has been carried out for three months i.e.
March to May 2018. Chapter 13 i.e. Assessment of ecological damage w.r.t.
various environmental attributes has been prepared in line with the ToR.
EIA
- 18 -
M/s. Shilpa Medicare Ltd. Unit I
The study area for the present EIA study is the area covered within the 10 km
radius from the plant boundary.
EIA
- 19 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 24 -
M/s. Shilpa Medicare Ltd. Unit I
specified to monitor at 5
locations.
Details are in Chapter 3,
Section 3.3.3.
viii Soil characteristic as per CPCB guidelines. Chapter 3, Section 3.3.5.
ix Traffic study of the area, type of vehicles, Chapter 4, Section 4.1.2.3,
frequency of vehicles for transportation of subsection III.
materials, additional traffic due to proposed
project, parking arrangement etc.
x Detailed description of flora and fauna (terrestrial Chapter 3, Section 3.3.6.
and aquatic) existing in the study area shall be
given with special reference to rare, endemic and
endangered species. If Schedule-I fauna are found
within the study area, a Wildlife Conservation
Plan shall be prepared and furnished.
xi Socio-economic status of the study area. Chapter 3, Section 3.3.7
7 Impact and Environment Management Plan. --
i Assessment of ground level concentration of Chapter 7, Section 7.3
pollutants from the stack emission based on site-
specific meteorological features. In case the
project is located on a hilly terrain, the AQIP
Modeling shall be done using inputs of the specific
terrain characteristics for determining the
potential impacts of the project on the AAQ.
Cumulative impact of all sources of emissions
(including transportation) on the AAQ of the area
shall be assessed. Details of the model used and
the input data used for modeling shall also be
provided. The air quality contours shall be plotted
on a location map showing the location of project
site, habitation nearby, sensitive receptors, if
any.
ii Water Quality modeling - in case of discharge in Not applicable as no
water body wastewater treated /
untreated is discharged
into any water body.
iii Impact of the transport of the raw materials and Chapter 2, Section 2.6.1 &
end products on the surrounding environment 2.6.2
shall be assessed and provided. In this regard,
options for transport of raw materials and
finished products and wastes (large quantities) by
rail or rail-cum road transport or conveyor cum
rail transport shall be examined.
iv A note on treatment of wastewater from different Chapter 2, Section 2.8.2
plant operations, extent recycled and reused for
different purposes shall be included. Complete
EIA
- 25 -
M/s. Shilpa Medicare Ltd. Unit I
Annexure A10.
8 Authorization/Membership for the disposal of Chapter 2, Section 2.8.2
liquid effluent in CETP and solid/hazardous waste Trade effluent is collected,
in TSDF, if any. neutralized and sent to
sister concerShilpa
Medicare Ltd. Unit II for
further treatment in ETP.
The treated effluent is
then reused.
9 Action plan for utilization of MEE/dryers salts. NA
10 Material Safety Data Sheet for all the Chemicals Annexure A12
are being used/will be used.
11 Authorization/Membership for the disposal of Annexure A10
solid/hazardous waste in TSDF.
12 Details of incinerator if to be installed. No incinerator is installed.
13 Risk assessment for storage and handling of Chapter 7, Section 7.2
hazardous chemicals/solvents. Action plan for
handling & safety system to be incorporated.
14 Arrangements for ensuring health and safety of Chapter 7, Section 7.2.17
workers engaged in handling of toxic materials.
EIA
- 29 -
M/s. Shilpa Medicare Ltd. Unit I
3 Submit the proposal for Environment Clearance EIA & EMP prepared as per
as per the ToRs to the concerned regulatory ToR granted.
authority, incorporating all the issues raised Public consultation report
during Public hearing/consultation. is included in Chapter 13,
Section 13.4.G.
ANNEXURE
4 Project description, its importance and benefits. Chapter 1, Section 1.2 &
1.3
5 Project site details (location, toposheet of the Chapter 2, Section 2.3
study area of 10 km, coordinates, google map, Annexure A11
layout map, land use, geological features and Chapter 3, Section 3.2.2,
geo-hydrological status of the study area, 3.2.3, 3.2.4
drainage).
6 Land acquisition status, R&R details. Annexure A10
7 Forest and Wildlife and eco-sensitive zones, if None within 10 km radius
any in the study area of 10 km - Clearances
required under the Forest (Conservation) Act,
1980, the Wildlife (Protection) Act, 1972 and/or
the Environment (Protection) Act, 1986.
8 Baseline environmental study for ambient air Chapter 3, Section 3.3.2
(PM10, PM2.5, SO2, NOx & CO), water (both surface
and ground), noise and soil for one season
(except monsoon period) as per MoEF&CC / CPCB
guidelines at minimum 5 locations in the study
area of 10 km.
EIA
- 30 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 31 -
M/s. Shilpa Medicare Ltd. Unit I
CHAPTER 2
PROJECT DESCRIPTION
M/s. Shilpa Medicare Limited, Unit I is located at Plot No. 1A, 1A"P", 1B, 2, 2A,
2B, 3A to 3E, 4A, 4B, 4C, 5A & 5B, Deosugar Industrial Area, Raichur,
Karnataka.
EIA
- 32 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 33 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 34 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 35 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 36 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 37 -
M/s. Shilpa Medicare Ltd. Unit I
M/s. Shilpa Medicare Ltd. Unit I has a total value of Rs. 13,038.51 Lakhs
(Rupees One Hundred and Thirty Crores Thirty Eight Lakhs Fifty One Thousand
Only) as on 31st March 2017. The total production capacity is 317.304 ton per
annum.
Now it is proposed to secure EC from MOEFCC which has been made mandatory
by virtue of the 2006 EIA notification for the change in product mix without
increasing the pollution load which has taken place during 2011.
EAC for projects related to violation of EIA notification was appraised. The
proposal and resolved to grant ToR vide proceedings dated 30-31st Jan 2018.
The impact assessment study is carried out as per the ToR mentioned above
along with the standard ToR for schedule 5(f) activity
under the said notification.
EIA
- 38 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 39 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.2 List of raw materials required and their source along with mode of
transportation
The raw materials required for the manufacture of APIs & intermediates are
appended in the table 2.6A below. Raw materials as listed will be procured as
per the production requirement.
The per month quantities tabulated in 2.6A are required for maximum
allowable production quantity as per CTO no. PCB/HPI/053/2015-16/1245
dated 8th October 2015 is achieved. However, this is seldom the case as seen
from the actual production records of the last 3 years. Details are in Chapter 9,
Section 9.1 of this EIA report.
Recent photographs of raw material storage area is show n in figure 2.5
EIA
- 41 -
M/s. Shilpa Medicare Ltd. Unit I
Aluminum chloride 8 48
Sodium bicarbonate 67 402
n-Hexane 670 4020
Water 5025 30150
IPA HCl 551 3306
Methanol 1820 21840
Pd. carbon 6.5 78
II Hydrogen 26 312
Liq. ammonia 700 8400
Water 2600 31200
Isopropyl alcohol (IPA) 672 4032
Tartaric acid 336 2016
Acetic anhydride 1545 9270
III
Liquor ammonia 772 4632
Sulfuric acid 90 540
Water 1682 10092
Methanol 670 4020
Carbon 3.5 21
IV
Acetone 840 5040
IPA HCl 200 1200
4-amino-1-methyl-3-n-
propylpyrazolo-5- 125 500
carboxamide
I
2-ethoxy benzoyl chloride 125 500
Methylene di-chloride (MDC) 500 2000
Sildenafil
6 Water 1250 4 5000
citrate
Chlorosulfonic acid 375 1500
II n-methyl piperazine 250 1000
Water 1250 5000
Acetone 1500 6000
III
Citric acid 75 300
Thiophene-2-ethanol 222.5 1780
Trimethyl amine 202.5 1620
I
Benzene sulfonyl chloride 345 2760
Toluene 650 5200
Ortho chloro benzylamine 375 3000
Hydrochloric acid 275 2200
II
7 Ticlopidine HCl Acetone 2475 8 19800
Methylene di-chloride (MDC) 700 5600
Water 250 2000
Formaldehyde 162.5 1300
III Toluene 600 4800
Isopropyl alcohol (IPA) HCl 200 1600
Methanol 155 1240
EIA
- 42 -
M/s. Shilpa Medicare Ltd. Unit I
Carbon 10 80
Cholic acid 590.835 21270.06
I Methanol 945.733 34046.388
Methane sulphonic acid 3.972 142.992
Ethyl acetate 1071.4 38570.4
II Sodium carbonate 238 8568
Acetic anhydride 357 12852
Sodium hypochloride 952.4 34286.4
III Acetic acid 76 2736
Water 600 21600
2-methoxy ethanol 3809 137124
Ursodeoxycholic
8 HzHz 500 36 18000
acid IV
KOH 357 12852
Water 250 9000
Sodium bromate 95 3420
V MDC 512 18432
Water 300 10800
Sodium metal 333.3 11998.8
Hydrochloric acid 130.95 4714.2
VI Butanol 4523.8 162856.8
Water
300 10800
a,a,a,a,-tetramethyl-5-
(methyl)-1,3- benzenedi- 8 16
acetonitrile
Acetonitrile 30 60
I
N- bromosuccianmide 6.6 13.2
Ethyl acetate 30 60
Water 10 20
Cyclohexane 5 10
1,2,4-triazole 2.5 5
9 Anastrozole 2
Potassium carbonate 5 10
Acetone 40 80
II
Water 4 8
Ethyl acetate 10 20
Hydrochloric acid 0.5 1
Water 10 20
Sodium carbonate 2 4
III
Ethyl acetate 10 20
Cyclohexane 5 10
Ethyl-4-(5-(bis(2-hydroxy
ethyl) amino)-1-methyl-1H-
Bendamustine 5 20
10 I benzoid) imidazol-2- 4
HCl
yl)butanoate
Thionyl chloride 20 80
EIA
- 43 -
M/s. Shilpa Medicare Ltd. Unit I
Water 40 160
N-[4-cyano-3-trifluoromethyl
phenyl]-3-[4-fluorophenyl
12 240
thio]-2-hydroxy-2-methyl
11 Bicalutamide I propanamide 20
Acetonitrile 100 2000
Potassium permanganate 5 100
Isopropyl alcohol 10 200
3- phenyl -2-[(pyrazine-2-
carbonyl)-amino] propionic 0.1 1.2
acid
R-borolex-(+)-pinanediol
0.115 1.38
trifluoro acetic acid
I n-hydroxy succinamide 0.09 1.08
MDC 0.27 3.24
Disopropyl amine 0.11 1.32
1N HCl 0.12 1.44
Saturated sodium bicarbonate 0.57 6.84
12 Bortezomib 12
Methanol 0.67 8.04
Methanol 0.17 2.04
Isobutyl boronic acid 0.085 1.02
n-Heptane 2.07 24.84
II 1N HCl 0.57 6.84
MDC 0.27 3.24
Ethyl acetate 0.57 6.84
Sat. sodium bicarbonate 0.57 6.84
Methanol 0.109 1.308
III
Water 0.109 1.308
5-methyl tetrahydrofuran-
150 1500
2,3,4-triyl triacetate
Toluene 300 3000
Hexa methyl disaline (HMDS) 150 1500
5-fluorocytosine 100 1000
Tetra methyl silyl chloride
I 5 50
(TMSC)
Methylene di-chloride (MDC) 500 5000
13 Capecitabine Sodium bicarbonate 150 10 1500
Water 300 3000
Stannic chloride 160 1600
Isopropyl alcohol 300 3000
Methylene di chloride (MDC) 250 2500
N-pentyl chloroformate 110 1100
II Pyridine 60 600
Heptane 500 5000
Water 300 3000
EIA
- 44 -
M/s. Shilpa Medicare Ltd. Unit I
Water 10 800
MDC 26.4 2112
Water 10 800
II
Sodium hydroxide 0.2 16
n-Hexane 6.54 523.2
Hydrobromic acid 1.5 120
Acetone 9.48 758.4
Sodium bicarbonate 0.1 8
Water 10 800
III
Methanol 7.9 632
Dioxane 7 560
MDC 26.4 2112
n-Hexane 9.8 784
7-methoxy-6-(3-morphalino
5 15
I propyl) quinazolin-4 (3H)-one
Thionyl chloride 10 30
18 Gefitinib 3
3-chloro-4-fluoroaniline 4.3 12.9
II Ethyl acetate 90 270
Potassium carbonate (K2CO3) 1.2 3.6
G Intermediate 330 3300
I Methanol 975 9750
Ammonia 25% 565 5650
Methanol 750 7500
Gemcitabine
19 II Carbon 10 10 100
HCl
HCl 40 400
Water 30 300
III Acetic acid 2000 20000
HCl 40 400
4-methyl-N3-(5-pyridin-3yl
pyrimidine-2-yl) benzene-1,3- 10 100
diamine
4-(4-methyl-piperazin-1-yl-
ethyl)benzoic acid 10 100
Imatinib dihydrochloride
20 I 10
mesylate Methylene dichloride (MDC) 100 1000
Triethyl amine 20 200
Hydroxy benzotriazole 6 60
Methanol 50 500
Methane sulphonic acid 2 20
Carbon 1 10
7-ethyl-10-hydroxy
2 10
camptothecin
Irinotecan HCl
21 I 1,chlorocarbonyl-4-piperidino 5
trihydrate 2.4 12
piperidine hydrochloride
Pyridine 80 400
EIA
- 46 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 47 -
M/s. Shilpa Medicare Ltd. Unit I
Water 12 120
MDC 4.85 48.5
IV Acetone 1.38 13.8
Petroleum ether 7.7 77
L-glutamic acid diethyl ester
1.14 11.4
HCl
4-[2-(2-amino-4,7-dihydro-4-
oxo-1H-pyrrolo[2,3-
1.56 15.6
d]pyrimidin-5-
yl)ethyl)benzolic acid
I
N-methyl morphalane 1.16 11.6
DMF 10.2 102
MDC 38.5 385
26 Pemetrexed Water 38.5 10 385
2-chloro-4,6-dimethoxy-
1 10
1,3,5-triazine
Hydrochloric acid 1 10
II Sodium hydroxide 1 10
Water 25 250
Acetone 30.78 307.8
Hydrochloric acid 1 10
III
Sodium hydroxide 1 10
Water 25 250
5-amino-1-(n-methyl
carbomyl) imidazole-4- 100 400
carboxamide
I
Water 600 2400
27 Temozolomide Sodium nitrite 40 4 160
Tartaric acid 80 320
Acetone 400 1600
II Water 150 600
Carbon 5 20
Phthalic anhydride 10 50
L-glutamine 10 50
Dimethyl sulphoxide (DMSO) 50 250
28 Thalidomide I 5
N,N-carbomyl diimidazole 15 75
Carbon 1 5
Water 100 500
10-hydroxy camptothecin 1 10
Dimethyl amine 0.5 5
I Formaldehyde 0.67 6.7
29 Topotecan HCl Acetic acid 10 10 100
Water 10 100
Water 10 100
II
Hydrochloric acid 0.3 3
EIA
- 48 -
M/s. Shilpa Medicare Ltd. Unit I
Carbon 0.1 1
Imidazole 10 10
Toluene 50 50
Potassium carbonate 15 15
I Methyl chloroacetate 22 22
Isopropyl alcohol
30 30
hydrochloride
30 Zoledronic acid 1
Water 25 25
Phosphoric acid 14 14
Chlorobezene 40 40
II Phosphorous trichloride 20 20
Water 20 20
Carbon 1 1
The raw materials are either obtained from the local suppliers or imported
transportation mode is by road & sea. List of raw materials, their sources and
mode of transportation are given in table 2.6 B below.
EIA
- 49 -
M/s. Shilpa Medicare Ltd. Unit I
Table 2.6 B: List of raw materials, their sources and mode of transportation
Sl.
List of raw materials Vendor Name Place Mode of Transportation
No.
1 1,1-cyclobutane dicarboxylic acid HEFEI Home Sunshine Pharmaceutical China By sea/ By road
2 1,2,4-triazole Riddhi Pharma Ankleshwar By road through transport by sharing
3 1,3,5-trimethoxy benzene Inogent Laboratories Pvt. Ltd. Hyderabad By road through transport by sharing
1,chlorocarbonyl-4-piperidino
4 Vasuha Pharma Chem Vizag By road through transport by sharing
piperidine hydrochloride
5 10-hydroxy camptothecin Avra Labs Hyderabad By road through transport by sharing
6 1N HCl TGV Sraa Ltd. Kurnool By road through transport by sharing
2 amino 3,5-dibromo
7 Riddhi Pharma Ankleshwar By road through transport by sharing
benzaldehyde
2-chloro-4,6-dimethoxy-1,3,5-
8 Eastar Technology Development Co. L Hong Kong By road through transport by sharing
triazine
9 2-ethoxy benzoyl chloride Urmi Chemicals Mumbai By road through transport by sharing
10 2M enol Dynamic (Hong Kong) Ind Co. Ltd. Hong Kong By road through transport by sharing
3- phenyl -2-[(pyrazine-2-carbonyl)-
11 Brilliant Top Corporation Limited China By sea / By road
amino] propionic acid
12 3-chloro-4-fluoroaniline Spectrochem Pvt. Ltd. Mumbai By road through transport by sharing
4-(4-methyl-piperazin-1-yl-
13 HEFEI Home Sunshine Pharmaceutical China By sea / By road
ethyl)benzoic acid dihydrochloride
4-[2-(2-amino-4,7-dihydro-4-oxo-
14 1H-pyrrolo[2,3-d]pyrimidin-5- HEFEI Home Sunshine Pharmaceutical China By sea / By road
yl)ethyl)benzolic acid
4-amino-1-methyl-3-n-
15 HEFEI Home Sunshine Pharmaceutical China By sea / By road
propylpyrazolo-5-carboxamide
16 4-chloro butyryl chloride Transpek Industry Vadodara By road through transport by sharing
4-methyl-N3-(5-pyridin-3yl
17 pyrimidine-2-yl) benzene-1,3- HEFEI Home Sunshine Pharmaceutical China By sea / By road
diamine
EIA
- 50 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 51 -
M/s. Shilpa Medicare Ltd. Unit I
42 Citric acid Mahalaxmi Dyes And Chemicals Ltd. Mumbai By road through transport by sharing
43 CN1 Spectrochem Pvt. Ltd. Mumbai By road through transport by sharing
44 Cyclohexane R R Innovative Pvt. Ltd. Mumbai By road through transport by sharing
45 Dimethyl amine Sanjay Chemicals (India) Pvt. Ltd. Mumbai By road through transport by sharing
46 Dimethyl formamide (DMF) Lok Chemicals Mumbai By road
47 Dimethyl sulphoxide (DMSO) Mahalaxmi Dyes And Chemicals Ltd. Mumbai By road through transport by sharing
48 Dioxane Urmi Chemicals Mumbai By road through transport by sharing
49 Disopropyl amine Urmi Chemicals Mumbai By road through transport by sharing
50 EPI-i NA
51 Ethanol Shree Venkatesh Scientific Systems Gulbarga By road through transport by sharing
52 Ethyl acetate Laxmi Organics Mahad By road
Ethyl-4-(5-(bis(2-hydroxy ethyl)
53 amino)-1-methyl-1H-benzoid) Brilliant Top Corporation Limited China By sea / By road
imidazol-2-yl)butanoate
54 Formaldehyde Urmi Chemicals Mumbai By road through transport by sharing
55 G Intermediate By road through transport by sharing
56 HCl Durga Industries Hyderabad By road through transport by sharing
57 Heptane Vipul Life Science Ltd. Mumbai By road
58 Hexa methyl disaline (HMDS) Xinyaqiang silicon chemistry co., L China By sea/ By road
Pon Pure Chemical India Private
59 Hexane Hyderabad By road through transport by sharing
Limited
60 Hydrobromic acid Mody Chem Mumbai By road through transport by sharing
Sree Rayalaseema Hi Strength Hypo
61 Hydrogen Kurnool By road through transport by sharing
Ltd.
Sree Rayalaseema Hi Strength Hypo
62 Hydrogen gas Kurnool By road
Ltd.
63 Hydroxy benzotriazole Snap Intermediates Mumbai By road through transport by sharing
64 HzHz Chori Co. Ltd. Japan By sea / By road
65 Imidazole Spectrochem Pvt. Ltd. Mumbai By road through transport by sharing
66 IPA R R Innovative Pvt. Ltd. Mumbai By road through transport by sharing
EIA
- 52 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 53 -
M/s. Shilpa Medicare Ltd. Unit I
94 N-methyl morphalane Spectrochem Pvt. Ltd. Bangalore By road through transport by sharing
95 n-methyl piperazine Spectrochem Pvt. Ltd. Bangalore By road through transport by sharing
96 N-pentyl chloroformate M/s Vandemark Chemcials Inc. New York, USA By sea / By road
97 Ortho chloro benzylamine Sanjay Chemicals (India) Pvt. Ltd. Mumbai By road through transport by sharing
98 Ortho nitrobenzaldehyde Hangzhou longshan Chemical Co. Ltd. China By sea / By road
99 Oxalic acid Jaya Scientific Enterprises Raichur By road through transport by sharing
100 Pd. carbon Evonik Catalyst Mumbai By road through transport by sharing
101 Petroleum ether Sanjay Chemicals (India) Pvt. Ltd. Mumbai By road
Panchiao,
102 Phosphoric acid Hiforce Chemical Co Limited By sea / By road
Taiwan
103 Phosphorous trichloride Sandhya Groups Mumbai By road through transport by sharing
104 Phthalic anhydride Sonkamal Enterprises Pvt. Ltd. Mumbai By road through transport by sharing
105 Piperidine catalyst Sanjay Chemicals (India) Pvt. Ltd. Mumbai By road through transport by sharing
106 Potassium carbonate (K2CO3) Unid Korea Korea By sea / By road
107 Potassium chloride Jaya Scientific Enterprises Raichur By road
108 Potassium iodide Avra Synthesis Pvt. Ltd. Hyderabad By sea / By road
109 Potassium permanganate Piyush Chemicals Mumbai By sea / By road
110 Potassium tetrachloroplatinate Ravindra Heraeus Pvt. Ltd. Udaipur By road through transport by sharing
111 p-tolunitrile Naveep Chemicals Gujrat By road through transport by sharing
112 Pyridine Arthasri Impex Hyderabad By road
113 Pyrrolidine Spectrochem Pvt. Ltd. Bangalore By road through transport by sharing
114 Raney nickel catalyst Namokar Specialty Chemicals Indore By road through transport by sharing
R-borolex-(+)-pinanediol trifluoro
115 Suzhou Lixin Pharmaceutical Co. Ltd. China By sea / By road
acetic acid
116 Saturated sodium bicarbonate TATA Chemicals Mithapur By road through transport by sharing
Saturated sodium bicarbonate
117 solution in water 10 kg in 12 L Spectrochem Pvt. Ltd. Mumbai By road
water
118 Silver nitrate Silver White Chemicals Ahmedabad By road through transport by sharing
119 Silver oxide Hindustan Platinum Pvt. Ltd. Mumbai By road through transport by sharing
EIA
- 54 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 55 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 56 -
M/s. Shilpa Medicare Ltd. Unit I
Details of all reactors used in the manufacturing process are listed in the
following table
Table 2.7: Reactor details
Sl. Capacity of the Stainless Glass Lined All Glass (Round
no. reactors Steel (SS) (GL) Reactor Bottom - RB flask)
Reactor (No.s) (No.s)
(No.s)
1 1L 0 0 1
2 2L 0 0 1
3 3L 0 0 1
4 8L 0 0 1
5 10 L 0 0 1
6 20 L 0 0 1
7 63 L 0 2 0
8 100 L 0 5 0
9 160 L 0 5 0
10 250 L 0 2 0
11 500 L 2 7 0
12 1.0 KL 1 1 0
13 1.6 KL 2 5 0
14 2.0 KL 5 2 0
15 2.5 KL 7 5 0
16 3.0 KL 4 2 0
17 4.0 KL 12 4 0
18 6.3 KL 0 3 0
19 8.0 KL 4 5 0
Total 36 48 6
EIA
- 57 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.1 Acebrophylline
REACTION SCHEME
EIA
- 58 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
EIA
- 59 -
M/s. Shilpa Medicare Ltd. Unit I
SS Reactor
Methanol
Water 24 hrs reflux recovered
100 kg 895 kg
Sodium borohydride SS Reactor Distillation loss
22.5 kg 15 kg
Water Process
Centrifuge
600 kg wastewater
735 kg
Ambroxol base
200 kg
SS Reactor
Ethyl acetate
Filter Ambroxol base
5350 kg
78 kg DMF
recovered
Centrifuge Distillation 1050 kg
loss
15 kg
Ethyl acetate
Drier Recovered
5310 kg
Loss
40 kg
Acebrophylline
250 kg
EIA
- 60 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty./batch
Output (kg)
Input Qty./batch Reactor Output from 200
(kg) 1st stage
2 amino 3,5 dibromo
benzaldehyde 150
Water 700
Wastewater 735
EIA
- 61 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Output (kg)
Qty./batch Reactor Acebrophylline 250
Input
(kg)
Output from 1st
stage 200
By product
DMF 1065 Ambroxol base 78
2) Ethyl acetate
recovered from 5310
reaction
loss 40
EIA
- 62 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
CYCLE TIME
Time (hrs)
Particulars
1 stage 2nd stage
st
Reaction 24 - 26 12 - 14
Isolation & centrifugation 4-6 8 - 10
Solvent recovery 8 - 10 5-6
Total process time 36 - 42 25 - 30
APPLICATIONS
EIA
- 63 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
EIA
- 64 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
EIA
- 65 -
M/s. Shilpa Medicare Ltd. Unit I
Acetone Carbon
2nd stage 2780 kg 50 kg
SS Reactor
By product: carbon
Filter 50 kg
Hydrochloric acid
150 kg
GL Reactor
Solvent acetone
recovered from
reaction
Centrifuge Mother liquor 2700 kg
recovered from
Water
scrubber
25 kg 70 kg
Drier loss
Slurry
10 kg
1st stage
Qty./batch
Output (kg)
Qty./batch
Input Reactor Output from 535
(kg)
1st stage
2 amino 3,5 dibromo
benzaldehyde 400
Solvent methanol
Trans -4- amino 250
cyclohexanol recovered from 2920
reaction
Sodium 75 recovered from 70
borohydride scrubber
loss 10
Methanol 3000
EIA
- 67 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Output (kg)
Qty./batch Reactor
Input Ambroxol HCl 585
(kg)
Output from 1st
stage 535
Carbon 50
Acetone 2780
Solvent acetone
Hydrochloric 150 recovery from 2700
acid
reaction
50 recovered from 70
Carbon
scrubber
Water 25 10
loss
Wastewater 125
EIA
- 68 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
Ambroxol base is converted into crude ambroxol HCl in the presence of acetone
and carbon which is then purified to get ambroxol HCl pharma grade. HCl is
used for pH adjustment.
CYCLE TIME
EIA
- 69 -
M/s. Shilpa Medicare Ltd. Unit I
APPLICATIONS
Ambroxol is a very potent inhibitor of the neuronal Na+ channels. This property
led to the development of a lozenge containing 20 mg of ambroxol. Many state-
of-the-art clinical studies have demonstrated the efficacy of Ambroxol in
relieving pain in acute sore throat, with a fast onset of action and a long
duration of effect of at least 3 hours. Additional anti-inflammatory properties
of Ambroxol are of clinical relevance since treatment lead to a marked
EIA
- 70 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
EIA
- 71 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sl. Raw material used Qty./batch
No. (kg)
1 4-chloro butyryl chloride 177
2 Aluminium chloride 183
3 1,3,5-trimethoxy benzene 111
4 Methylene di-chloride (MDC) 500
5 Hydrochloric acid 250
6 Water 2000
2nd stage
Sl. Raw material used Qty./batch
No. (kg)
1 Ethyl acetate 300
2 Pyrrolidine 125
3 Iso propyl alcohol (IPA) HCl 257
3rd stage
Production yield per batch 130 kg
Sl. Raw material used Qty./batch
No. (kg)
1 IPA 600
2 C.S. lye 100
3 Carbon 11
4 Toluene 300
5 IPA HCl 180
6 Water 500
EIA
- 72 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
GL Reactor
Hydrochloric acid
250 kg Process wastewater
Water GL Reactor 2571 kg
2000 kg
Crystallizer Distillation
Methylene dichloride
Recovered
Output from 1st stage 490 kg
Loss
150 kg 10 kg
EIA
- 73 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Reactor
Ethyl acetate
IPA HCl recovered
257 kg Reactor 290 kg
loss
10 kg Process
ML residue
Centrifuge Distillation
3 kg
EIA
- 74 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
C.S. lye
Reactor
100 kg
Toluene
Reactor Process wastewater
300 kg 555.3 kg
Carbon Organic layer
11 kg
Spent carbon
Filter 11 kg
IPA IPA
600 kg Reactor recovered 635 kg
loss 13.14 kg
Process
Centrifuge Distillation residue
2.7 kg
Drier
Buflomedil HCl
130 kg
EIA
- 75 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty./batch
Input Reactor Qty./batch
(kg) Output
4-chloro butyryl (kg)
chloride 177
Output from 150
1st stage
Aluminum 183
chloride
EIA
- 76 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Output
(kg)
Qty./batch
Input Reactor Output from 198
(kg)
2nd stage
Output from 1st
150
stage
300 By product pyrrolidine 100
Ethyl acetate
Pyrrolidine 125
Solvent ethyl acetate
IPA HCl 257 recovered from 290
reaction
loss 10
IPA recovery 231
Process residue 3
EIA
- 77 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
2) Toluene
recovered from 295
reaction
loss 5
PROCEDURE
1st stage
2nd stage
The output from 1st stage is condensed with pyrrolidine in the presence of ethyl
acetate at 800C to 850C and subsequently with isopropyl alcohol/HCl to produce
buflomedil hydrochloride (crude output from 2nd stage).
3rd stage
CYCLE TIME
APPLICATIONS
It is used for the treatment of disease of peripheral blood vessel and symptom
which is caused by chronic brain blood vessel offering blood not enough.
EIA
- 79 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.4 Nifedipine
REACTION SCHEME
H H H H2N CH3
+H2O
H C C C C O C H NH3 Mol. Wt. 18
O
Ammonia CH3
H O H O H Mol. Wt. 17.03
Methyl acetoacetate O
C5H8O3
Methyl 3-aminobut-2-enoate
Mol. Wt.: 116.12
C5H9NO2
Mol. Wt.: 115.13
H3C O
+H2O
O Mol. Wt. 18
H3C
NO2
H H H O NO2
CHOH H C C C C O C H
H O H O H
H3C O
H2N CH3 OCH3
O CH3
O
H3C O
CH3 NH
O NO2
O NO2 O CH3
Methyl 3-aminobut-2-enoate OCH3
C5H9NO2 +H2O
Mol. Wt.: 115.13
Mol. Wt. 18
Nifedipine
methyl 2-(2-nitrobenzylidene)-3-oxobutanoate C17H18N2O6
C12H11NO5 Mol. Wt.:346.33
Mol. Wt.: 249.22
EIA
- 80 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
3rd stage
EIA
- 81 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
SS Reactor
Drier
EIA
- 82 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
EIA
- 83 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
SS Reactor
Filter
Methanol
Centrifuge recovered &
Distillation
recycled
2680 kg
Drier Hazardous
waste (process
Centrifuge residue)
5 kg
Sifter
Nifedipine
450 kg
EIA
- 84 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty/batch Qty/batch
Input Reactor Output
(kg) (kg)
Methyl aceto acetate 435 Output from 1st stage 375
SS
Methanol 435 Process wastewater 930
Reactor
Ammonia (25%
435 (SSR) -
solution)
2 KL
Total input 1305 Total output 1305
Qty./batch
Qty./batch Output (kg)
Input
(kg)
Reactor Output from 375
Methyl aceto 1st stage
acetate 435
Methanol 435
Ammonia 435
Process wastewater 930
EIA
- 85 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty/batch Qty/batch
Input Reactor Output
(kg) (kg)
Ortho Output from 2nd stage 375
250
nitrobenzaldehyde By product:
Methyl aceto acetate 99.5
Isopropyl alcohol 1500
(recovered)
SS Piperidine catalyst
Piperidine catalyst 4.5 4.5
Reactor (recovered)
Methyl aceto 3 KL Solvent IPA
217.5
acetate recovered & 1485
recycled
Acetic acid 7
loss 15
Total input 1979 Total output 1979
Output Qty./batch
(kg)
Output from 375
Input Qty./batch
Reactor 2nd stage
(kg)
Ortho
nitrobenzaldehyde 250 By-product
1500 Methyl aceto acetate 99.5
Isopropyl alcohol
(recovered)
Piperidine 4.5
catalyst
Piperidine catalyst
4.5
(recovered)
Methyl aceto 217.5
acetate
Solvent IPA
Acetic acid 7
recovered 1485
loss 15
EIA
- 86 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty/batch Qty/batch
Input Reactor Output
(kg) (kg)
Methanol 2700 Nifedipine 450
Output from 1st Nitro phenyl pyridine 105
185
stage Solvent methanol
Output from 2nd 375 SS recovered & 2680
stage Reactor recycled
4 KL 2 loss 20
no.s Hazardous waste
5
(process residue)
Total input 3260 Total output 3260
Qty./batch
Input Qty./batch Reactor Output (kg)
(kg)
Nifedipine 450
Methanol 2700
Hazardous waste 5
Output from
2nd stage 375
Solvent methanol
recovered 2680
loss 20
EIA
- 87 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
Methyl aceto acetate is treated with ammonia solution and methanol to form
an intermediate compound (A).
2nd stage
3rd stage
CYCLE TIME
APPLICATIONS
EIA
- 88 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
EIA
- 89 -
M/s. Shilpa Medicare Ltd. Unit I
Stage-III
HO CH3 HO CH3
H2 H2
H C C NH.HCl H C C NH2
IPA
OH OH
DL-Phenyl ephrine HCl DL-Phenyl ephrine HCl
C9H14ClNO2 C9H14NO2
Mol. Wt.: 203.67 Mol. Wt.: 168.21
Stage-IV
HO CH3 HO CH3
H2 H2
H C C NH2 H C C NH2
Methanol
OH OH
DL-Phenyl ephrine HCl Phenyl ephrine HCl
C9H14NO2 C9H15ClNO2
Mol. Wt.: 168.21 Mol. Wt.: 204.67
EIA
- 90 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sl. Raw materials used Qty./batch
No. (kg)
1 Metahydroxy acetophenone 337
2 Toluene 2847
3 Ethyl acetate 1005
4 Liq. bromine 442
5 Liq. ammonia 442
6 N-methyl benzyl amine 543
7 Aluminium chloride 8
8 Sodium bicarbonate 67
9 n-Hexane 670
10 Water 5025
11 IPA (isopropyl alcohol) HCl 551
2nd stage
Sl. Raw materials used Qty./batch
No. (kg)
1 Methanol 1820
2 Pd. carbon 6.5
3 Hydrogen 26
4 Liq. ammonia 700
5 Water 2600
3rd stage
Sl. Raw materials used Qty./batch
No. (kg)
1 Isopropyl alcohol (IPA) 672
2 Tartaric acid 336
3 Acetic anhydride 1545
4 Liquor ammonia 772
5 Sulfuric acid 90
6 Water 1682
4th stage
Production yield/batch 250 kg
Sl. Raw materials used Qty./batch
No. (kg)
1 Methanol 670
2 Carbon 3.5
3 Acetone 840
4 IPA HCl 200
EIA
- 91 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Reactor
Water Liq. ammonia
1436 kg 442 kg
Sodium bicarbonate Sodium carbonate solution
Reaction mass 2677 kg
67 kg
Solvent toluene
recovered 2820 kg Distillation Organic layer
spent 17 kg
loss 10 kg
IPA HCl
Organic layer
551 kg
Solvent ethyl acetate
recovered 950 kg
loss 55 kg
Spent IPA+hexane
110 kg
EIA
- 92 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
SS Reactor
EIA
- 93 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
SS Reactor
Isopropyl alcohol
224 kg
Centrifuge
Liquor ammonia Water
604 kg 168 kg
Salt
SS Reactor (MLR) Process wastewater
274 kg
Water Centrifuge
471 kg
Solvent IPA
Process recovered 330 kg
Centrifuge Cake spent 336 kg
wastewater
1646 kg loss 6 kg
Drier Drier
EIA
- 94 -
M/s. Shilpa Medicare Ltd. Unit I
4th stage
Methanol Acetone
670 kg 756 kg
Carbon
3.5 kg
SS Reactor
Spent carbon
Filter 6.5 kg
Methanol recovery
IPA HCl 500 kg
200 kg SS Reactor
Methanol ML
Acetone
Centrifuge
84 kg
Acetone ML
Acetone recovery
180 kg
Spent solvent mixture
991 kg
Phenyl ephrine isomer
Drier salt
21 kg
EIA
- 95 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty/batch Qty/batch
Input Reactor Output
(kg) (kg)
Metahydroxy Output from 1st stage 280
337
acetophenone By product: n-methyl
540
Toluene 2847 benzyl amine
GL
Ethyl acetate 1005 Sodium carbonate
Reactor 2677
Liq. bromine 442 3 KL
solution
Liq. ammonia 442 Solvent
N-methyl benzyl 1. Toluene
543 2820
amine recovery
17
Aluminium chloride 8 spent (from
SS scrubber)
Sodium bicarbonate 67
Reactor loss 10
n-Hexane 670
3 KL
Water 5025 2. Ethyl acetate
IPA HCl 551 recovery 950
loss 55
3. n- Hexane
recovery
loss 645
SS 15
4. IPA
Reactor
Recovered 425
6.3 KL
5. Spent IPA + hexane 110
Hazardous waste
12
(process residue)
Process wastewater 3381
Total input 11937 Total output 11937
EIA
- 96 -
M/s. Shilpa Medicare Ltd. Unit I
Output Qty./batch
(kg)
Output from 280
1st stage
By-product
Input Qty./batch
(kg) Reactor n-methyl benzyl 540
amine
Metahydroxy
acetophenone 337
Sodium carbonate 2677
Toluene 2847 solution
Sodium 67
bicarbonate Spent IPA +
110
hexane
n-Hexane 670
Hazardous waste 12
5025 (process residue)
Water
EIA
- 97 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty/batch Qty/batch
Input Reactor Output
(kg) (kg)
Output from 1st SS
280 Output from 2nd stage 168
stage Rector
Methanol 1820 4 KL 1 Pd. carbon 6.5
Pd. carbon 6.5 no. Solvent methanol
Hydrogen 26 recovery
1750
spent (methanol+
150
SS toluene comes from
Liq. ammonia 700
Rector process)
9
6.3 KL loss
1 no. Process wastewater
Water 2600 3349
(neutral pH)
Total input 5432.5 Total output 5432.5
Output Qty./batch
Qty./batch (kg)
Input
(kg) Output from 168
Reactor
st 2nd stage
Output from 1
stage 280
EIA
- 98 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty/batch Qty/batch
Input Reactor Output
(kg) (kg)
Output from 2nd SS Output from 3rd stage 235
stage (2 times x 336 Reactor
output) 2 KL
Solvent IPA
SS
Isopropyl alcohol recovery 330
672 Reactor
(IPA) spent 336
3 KL
loss 6
Tartaric acid 336 SS
Acetic anhydride 1545 Reactor
Liquor ammonia 772 1 KL Acetic anhydride recovered 1450
+ ammonia liquid + tartaric
Sulfuric acid 90 SS acid
Reactor
Water 1682 Process wastewater 3076
2.5 KL
Total input 5433 Total output 5433
Output Qty./batch
Qty./batch (kg)
Input Reactor
(kg) Output from 235
3rd stage
Output from 336
2nd stage
Process
3076
wastewater
EIA
- 99 -
M/s. Shilpa Medicare Ltd. Unit I
4th stage
Qty/batch Qty/batch
Input Reactor Output
(kg) (kg)
Output from 3rd Phenyl ephrine HCl 250
235
stage Phenyl ephrine isomer
21
Methanol 670 salt
Carbon 3.5 Carbon (wet) 6.5
Acetone 840 SS Solvent
IPA HCl 200 Reactor 1. Methanol
500
2 KL 2 recovery
no.s 2. Acetone
recovery 180
3. Spent acetone,
methanol & IPA 991
mixture
Total input 1948.5 Total output 1948.5
EIA
- 100 -
M/s. Shilpa Medicare Ltd. Unit I
Output Qty./batch
(kg)
Phenyl
250
ephrine HCl
Methanol 670
3.5 6.5
Carbon Carbon
Acetone 840
EIA
- 101 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
Meta hydroxyl aceto phenone reacts with bromine in the presence of toluene to
form bromo aceto phenone. The reaction mass is then treated with liquor
ammonia, sodium bi-carbonate & water. This further reacts with n-methyl
benzyl amine and aluminium chloride in presence of solvent ethyl acetate. The
reaction mass is then treated with IPA HCl & n-hexane to form 3-hydroxy
methyl benzyl amine aceto phenone HCl.
2nd stage
The output from 1st stage is hydrogenated using palladium carbon in presence
of solvent methanol, liquor ammonia and water. The resultant reaction mass
forms DL-phenyl ephirine HCl obtained after isolation.
3rd stage
The output from 2nd stage on racemization with tartaric acid and acetic
anhydride and in the presence of solvent isopropyl alcohol and water forms L(-
_) phenyl ephirine.
4th stage
The output from 3rd stage is purified in methanol by addition of carbon. The
reaction mass is then filtered, isolated and crystallized with acetone in the
presence of solvent IPA to form pure phenyl ephirine HCl.
CYCLE TIME
EIA
- 102 -
M/s. Shilpa Medicare Ltd. Unit I
APPLICATIONS
EIA
- 103 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
EIA
- 104 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
3rd stage
EIA
- 105 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
4-amino-1-methyl-3-n-
propylpyrazolo-5-carboxamide Methylene di-chloride
125 kg 500 kg
2-ethoxy benzoyl
chloride Water
125 kg 1250 kg
GL Reactor
MDC
Recovered
Centrifuge Distillation 400 kg
loss
100 kg
Process wastewater
1325 kg
Drier
EIA
- 106 -
M/s. Shilpa Medicare Ltd. Unit I
Reactor
Process wastewater
Centrifuge 1857.5 kg
Drier
Multimill
Sifter
Sildenafil citrate
250 kg
EIA
- 107 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Input Qty./batch
(kg) Reactor
4-amino-1- Qty./batch
125 Output
methyl-3-n- (kg)
propylpyrazolo- Output from
5-carboxamide 175
1st stage
EIA
- 108 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Chlorosulfonic 375
acid
n-methyl
piperazine 250 1857.5
Wastewater
Water 1250
EIA
- 109 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty./batch
Output (kg)
Solvent acetone
Citric acid 75
recovery 1480
loss 20
EIA
- 110 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
The output from 1st stage is converted into sildenafil base [5-[2-ethoxy-5-(4-
methylpiperazinyl sulfonyl) phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-
pyrazolo[4,3-d]pyrimidin-7-one] by reacting with chlorosulfonic acid n-methyl
piperazine & water and the resultant intermediate is condescend with n-methyl
piperazine.
3rd stage
Sildenafil base is treated with citric acid in the presence of acetone to get
sildenafil citrate.
CYCLE TIME
EIA
- 111 -
M/s. Shilpa Medicare Ltd. Unit I
APPLICATIONS
Sildenafil citrate is sold as Viagra, Revatio and under various other trade
names. It was developed and is being marketed by the pharmaceutical
company Pfizer. Since becoming available in 1998, sildenafil has been the
prime treatment for erectile dysfunction.
3. Altitude sickness: Sildenafil has been shown to be useful for the prevention
and treatment of high-altitude pulmonary edema associated with altitude
sickness such as that suffered by mountain climbers.
4. Use in sports: Professional sports players have been documented using drugs
such as Viagra, with the thinking that the opening of their blood vessels will
enrich their muscles. In turn, they believe that it will enhance their
performance.
EIA
- 112 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
EIA
- 113 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sl. Raw material used Qty./batch
No. (kg)
1 Thiophene-2-ethanol 222.5
2 Trimethyl amine 202.5
3 Benzene sulfonyl chloride 345
4 Toluene 650
2nd stage
Sl. Raw material used Qty./batch
No. (kg)
1 Ortho chloro benzylamine 375
2 Hydrochloric acid 275
3 Acetone 2475
4 Methylene di-chloride (MDC) 700
3rd stage
Production yield per batch 250 kg
Sl. Raw material used Qty./batch
No. (kg)
1 Water 250
2 Formaldehyde 162.5
3 Toluene 600
4 Isopropyl alcohol (IPA) HCl 200
5 Methanol 155
6 Carbon 10
EIA
- 114 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
GL Reactor
Toluene
Mother Liquor (ML) recovered
640 kg
loss
10 kg
Output from 1st stage
225 kg
EIA
- 115 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Reactor
Drying
EIA
- 116 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Toluene Water
600 kg 250 kg
Reactor
Process wastewater
Layer separation
510 kg
Carbon
Organic layer
10 kg
Spent carbon
Filtration
10 kg
IPA HCl
Filtrate
200 kg
IPA recovered 160.5 kg
Toluene
recovered 595 kg
Centrifuge loss 5 kg
Process residue
1.5 kg
Methanol
Cake
155 kg
Methanol
recovered 152 kg
Centrifuge
loss 3 kg
Process residue
0.5 kg
Drier
Ticlopidine HCl
250 kg
EIA
- 117 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
EIA
- 118 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Output Qty./batch
(kg)
Qty./batch
Input Reactor Output from 310
(kg)
st 2nd stage
Output from 1 225
stage By product
Ortho chloro Benzene sulphonic acid 565
375
benzylamine
Hydrochloric 275 Solvent
acid 1) Acetone
recovered from 2450
Acetone 2475
reaction
loss 25
MDC 700
2) MDC
recovered from 685
reaction
loss 15
EIA
- 119 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty./batch
Output
(kg)
Qty./batch
Input Reactor Ticlopidine HCl 250
(kg)
Output from
2nd stage 310
By product
Carbon 10
Water 250
Formaldehyde 162.5 Solvent
1) Toluene
Toluene 600 recovered from 595
reaction
IPA HCl 200
loss 5
Methanol 155
2) Methanol
Carbon recovered from 152
10
reaction
loss 3
Process residue 2
PROCEDURE
1st stage
2nd stage
3rd stage
CYCLE TIME
EIA
- 121 -
M/s. Shilpa Medicare Ltd. Unit I
APPLICATIONS
Action
Inhibits platelet aggregation by altering the function of platelet membranes
by blocking ADP receptors. This prevents the conformational change of
glycoprotein IIb/IIIa which allows platelet binding to fibrinogen.
Prolongs bleeding time.
Decreased incidence of stroke in high-risk patients.
EIA
- 122 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
COOH
OH OH
STEP 1 STEP 2
95% 74%
Practical yield Practical yield
HO OH HO OH
Cholic acid M. Wt. 408 Cholic acid methyl ester M. Wt. 422 COOH
CH3
COOCH3 COOCH3 CH3
OH O
STEP 4
CH3
STEP 3
75%
70% Practical
Practical yield yield
HO OH
OOCCH3 H3 CCOO OOCCH3
H3 CCOO
CH3 COOH
CH3 COOH
CH3
STEP 5 CH3
STEP 6
CH3
80% 75% CH3
HO O
HO
3 , hydroxy-7-keto-Cholanic acid OH
M. Wt. 390.6
Ursodeoxycholic acid
M. Wt. 392.6
EIA
- 124 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
3rd stage
4th stage
EIA
- 125 -
M/s. Shilpa Medicare Ltd. Unit I
5th stage
6th stage
EIA
- 126 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Cholic acid Methanol
595 kg 952.4 kg
Methanol recovered
935 kg
Centrifuge Distillation
Methanol spent
17.4 kg
Drier
Methylcholonate
545 kg
Sodium carbonate
238 kg
Diacetyl compound
Reused methyle cholonate 50 kg
50 kg SS Reactor
Ethyl acetate
recovered
Process wastewater 1065.5 kg
Centrifuge
containing acetic acid Distillation
415 kg Ethyl acetate
loss
5.9 kg
Sodium acetate
180 kg
- - hydroxy- methyl cholanate
(Diacetylate intermediate) 545 kg
EIA
- 127 -
M/s. Shilpa Medicare Ltd. Unit I
Process wastewater
Centrifuge
1628.4 kg
Drier
- - cholanic acid
429 kg
EIA
- 128 -
M/s. Shilpa Medicare Ltd. Unit I
5th stage
- - cholanic acid
429 kg
MDC recovered
495 kg
Distillation MDC loss
17 kg
Process wastewater
395 kg
hydroxyl-7-keto-cholanic acid
6th stage 333.3 kg
HCl Water
130.95 kg 300 kg
Dihydroxy
cholanic acid
SS Reactor 83.3 kg
Cautic soda lye
595 kg
Butanol recovered
4476.6 kg
Butanol loss
Distillation
47.6 kg
Process wastewater
169.25 kg
Ursodeoxycholic acid
250 kg
EIA
- 129 -
M/s. Shilpa Medicare Ltd. Unit I
First purification
Reactor
Centrifuge
Purification
done
Drying at
ICE S.r.l., Italy
Ursodeoxycholic acid
Second purification
Reactor
EIA
- 130 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty/batch Qty/batch
Input Reactor Output
(kg) (kg)
Cholic acid 595 Methylcholonate 545
Reused methyl
SS 54
cholonate
Methanol 952.4 Reactor Solvent methanol
2 KL 4 recovery 935
Methane sulphonic 4 no.s
acid spent 17.4
Total input 1551.4 Total output 1551.4
Qty./batch
Output (kg)
Qty./batch Reactor
Input
(kg) Methylcholonate 545
Solvent methanol
Methane 4
recovery 935
sulphonic acid
loss 17.4
EIA
- 131 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty/batch Qty/batch
Input Reactor Output
(kg) (kg)
Methylcholonate 595 Diacetylate 545
(including reused) intermediate
Diacetylate compound 50
Ethyl acetate 1071.4 By-product: 180
SS Sodium acetate
Rector Process wastewater 415
4 KL containing acetic acid
Sodium carbonate 238 Solvent ethyl acetate
Acetic anhydride 357 recovery 1065.5
loss 5.9
Total input 2261.4 Total output 2261.4
Qty./batch
Output (kg)
Diacetylate 545
Qty./batch intermediate
Input Reactor
(kg)
Diacetylate 50
Methylcholonate 595 compound
Ethyl acetate 1071.4 By-product
Sodium acetate 180
Sodium carbonate 238
Process wastewater
Acetic 357 containing acetic 415
anhydride acid
EIA
- 132 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty/batch Qty/batch
Inputs Reactor Output
(kg) (kg)
Output from 2nd GL Output from 3rd stage 523
stage (including 595 Reactor
By product: Cholic acid 72
compound) 4 KL
Sodium hypochloride 952.4 1 no.
Acetic acid 76 SS
Process wastewater 1628.4
Reactor
Water 600
2 KL 1
Total input 2223.4 no. Total output 2223.4
Qty./batch Qty./batch
Input Reactor Output (kg)
(kg)
Output from 523
Output from 595 3rd stage
2nd stage
Acetic acid 76
Process 1628.4
wastewater
Water 600
EIA
- 133 -
M/s. Shilpa Medicare Ltd. Unit I
4th stage
Qty/batch Qty/batch
Input Reactor Output
(kg) (kg)
Output from 3rd 523 Output from 4th stage 429
stage By product:
2-methoxy ethanol 3809 Dihydroxy cholanic 94
SS acid
Reactor caustic potash lye 606
HzHz 500 6 KL 2 Solvent
KOH 357 no.s 2-methoxy ethanol +
Water 250 water + HzHz 4298
recovered 12
Loss
Total input 5439 Total output 5439
Qty./batch
Output (kg)
Input Qty./batch
(kg)
Reactor Output from 429
Output from 3rd 523.8 4th stage
stage
2-methoxy 3809
ethanol By product
500 Dihydroxy cholanic 94
HzHz
acid
caustic potash lye 606
KOH 357
Solvent
Water 250 2-methoxy
ethanol + water
+ Hz Hz 4298
recovery 12
loss
EIA
- 134 -
M/s. Shilpa Medicare Ltd. Unit I
5th stage
Qty/batch Qty/batch
Input Reactor Output
(kg) (kg)
Output from 4th 429 GL Output from 5th stage 333.3
stage Reactor By product: hydroxy keto 95.3
3 KL 2 cholonic acid
Sodium bromate 95 no.s Solvent MDC
MDC 512 recovery 495
SS loss 17
Water 300
Reactor
Process wastewater 395
2 no.s
Total input 1335.6 Total output 1335.6
Output Qty./batch
(kg)
Output from
Input Qty./batch 333.3
(kg) Reactor 5th stage
EIA
- 135 -
M/s. Shilpa Medicare Ltd. Unit I
6th stage
Qty/batch Qty/batch
Input Reactor Output
(kg) (kg)
Output from 5th 333.3 Ursodeoxycholic acid 250
stage (UDCA)
By product:
Sodium metal 333.3 SS Dihydroxy cholanic 83.3
Reactor acid
8 KL 2 Caustic soda lye 595
Hydrochloric acid 130.95 no.s Solvent butanol
Butanol 4523.8 recovery 4476.2
Water 300 loss 47.6
Process wastewater 169.25
Total input 5621.35 Total output 5621.35
Output Qty./batch
(kg)
Input Qty./batch Reactor Ursodeoxycholic
(kg) 250
acid (UDCA)
Output from 5th 333.3
stage
By product
Sodium metal 333.3 Dihydroxy 83.3
cholanic acid
Hydrochloric Caustic soda lye 595
130.95
acid
Solvent butanol
Butanol 4523.8 recovery 4476.2
loss 47.6
Water 300
Process 169.25
wastewater
EIA
- 136 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
3rd stage
4th stage
5th stage
6th stage
EIA
- 137 -
M/s. Shilpa Medicare Ltd. Unit I
CYCLE TIME
APPLICATIONS
Ursodiol, also known as ursodeoxycholic acid and the abbreviation UDCA, is one
of the secondary bile acids, which are metabolic by-products of intestinal
bacteria.
Ursodeoxycholic acid goes by the trade names Actigall, Ursosan, Ursofalk, Urso,
and Urso Forte.
It can be chemically synthesized and was brought to market by the Montreal-
based Axcan Pharma in 1998, which continues to market the drug.
The drug reduces cholesterol absorption and is used to dissolve
(cholesterol) gallstones in patients who want an alternative to surgery.
The drug is very expensive, however, and if the patient stops taking it,
the gallstones tend to recur if the condition that gave rise to their
formation does not change. For these reasons, it has not supplanted
surgical treatment by cholecystectomy.
It is the only FDA approved drug to treat primary biliary cirrhosis.
A Cochrane review to evaluate if ursodeoxycholic acid has any beneficial
effect in primary biliary cirrhosis patients included 16 randomized clinical
trials with a total of 1447 patients. The primary outcome measures were
mortality and mortality or liver transplantation. Although treatment with
ursodeoxycholic acid showed a reduction in liver biochemistry, jaundice,
and ascites, it did not decrease mortality or liver transplantation.
In children, its use is not licensed, as its safety and effectiveness are not
established.
In double the recommended daily dose ursodeoxycholic acid reduces
elevated liver enzyme levels in patients with primary sclerosing
cholangitis, but its use was associated with an increased risk of serious
adverse events (the development of cirrhosis, varices, death or liver
transplantation) in patients who received ursodeoxycholic acid compared
with those who received placebo). After adjustment for baseline
stratification characteristics, the risk was 2.1 times greater for death,
transplantation, or minimal listing criteria in patients on ursodeoxycholic
acid than for those on placebo (P = 0.038). Serious adverse events were
more common in the ursodeoxycholic acid group than the placebo group
(63% versus 37% [P < 0.01])).
EIA
- 138 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.9 Anastrozole
REACTION SCHEME
EIA
- 139 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sl. Raw material used Qty./batch
No. (kg)
1 , , , ,-tetramethyl-5- 8
(methyl)-1,3- benzenedi-
acetonitrile
2 Acetonitrile 30
3 N- bromosuccianmide 6.6
4 Ethyl acetate 30
5 Water 10
6 Cyclohexane 5
2nd stage
Sl. Raw material used Qty./batch
No. (kg)
1 1,2,4-triazole 2.5
2 Potassium carbonate 5
3 Acetone 40
4 Ethyl acetate 10
5 Hydrochloric acid 0.5
6 Water 4
3rd stage
Production yield per batch 2 kg
Sl. Raw material used Qty./batch
No. (kg)
1 Water 10
2 Sodium carbonate 2
3 Ethyl acetate 10
4 Cyclohexane 5
EIA
- 140 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
, , , ,-tetramethyl-5-(methyl)-
1,3- benzenedi- acetonitrile N- bromosuccianmide
8 kg 6.6 kg
Acetonitrile Ethyl acetate
30 kg 30 kg
Water
10 kg GL Reactor
Hydrobromic acid -
succinamide 4.6 kg
Process wastewater
Layer separation 12 kg
Organic layer
Acetonitrile
Distillation recovered 28 kg
loss 2 kg
Cyclohexane Cyclohexane
Reaction mass
5 kg recovered 4.5 kg
loss 0.5 kg
Centrifuge Distillation
Ethyl acetate
recovered 28 kg
Drying
loss 2 kg
EIA
- 141 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
GL Reactor
, , , ,-tetramethyl-
5-(methyl)-1,3-
benzenedi- acetonitrile
2.5 kg
Filter Potassium bromide
1 kg
Acetone
recovered 34 kg
Ethyl acetate loss 6 kg
10 kg
HCl
Distillation
0.5 kg GL Reactor
Ethyl acetate
recovered 8 kg
loss 2 kg
Drying
EIA
- 142 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
GL Reactor
Sodium chloride
2.5 kg
Process wastewater
Layer separation
12 kg
Centrifuge Distillation
Cyclohexane
Drying recovered 4.5 kg
loss 0.5 kg
Anastrozole
2 kg
EIA
- 143 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Output Qty./batch
(kg)
Input Qty./batch Reactor Output from
(kg) 1st stage 8
, , , ,-
tetramethyl-5- 8 4.6
By product
(methyl)-1,3-
Hydrobromic acid -
benzenedi-
succinamide
acetonitrile
Acetonitrile 30 Solvent
1) Ethyl acetate
N- recovered 28
bromosuccianmide 6.6 loss 2
Wastewater 12
EIA
- 144 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Output Qty./batch
Qty./batch (kg)
Input (kg) Reactor Output from
4.5
2nd stage
Output from 1st
stage 8
, , , ,-tetramethyl- 2.5
1,2,4-triazole 2.5 5-(methyl)-1,3-
benzenedi- acetonitrile
Potassium carbonate 5
potassium bromide 1
Acetone 40
Solvent
Water 4 1) Acetone
recovered from 34
Ethyl acetate 10 reaction
loss 6
Hydrochloric 0.5
acid 2) Ethyl acetate
recovered from 8
reaction
loss 2
Process wastewater 12
EIA
- 145 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty./batch
Output (kg)
Anastrozole 2
Input Qty./batch Reactor
(kg)
Output from By product 2.5
2nd stage 4.5
sodium chloride
Water 10
Solvent
Sodium 2 1) Ethyl acetate
carbonate recovered from 9
reaction
Ethyl 10 loss 1
acetate
2) Cyclohexane
Cyclohexane 5
recovered from 4.5
reaction
loss 0.5
Wastewater 12
EIA
- 146 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
The output from 1st stage is dissolved in acetone to which potassium carbonate
and 1,2,4 triazole are added at 40 500 C for 2 hrs to complete the reaction.
Potassium bromide salt formed is filtered; acetone is distilled to get the
residue. Ethyl acetate is added to dissolve completely. Anastrozole
hydrochloride is formed by adding hydrochloric acid which is cooled and
filtered to get HCl salt of anastrozole.
3rd stage
CYCLE TIME
Time (hrs)
Particulars
1st stage 2nd stage 3rd stage
Reaction 8 - 10 6 8 6 8
Isolation & centrifugation 8 - 12 6 8 8 - 12
Solvent recovery 1-2 2-3 1-2
Total process time 17 - 24 14 - 19 15 - 22
EIA
- 147 -
M/s. Shilpa Medicare Ltd. Unit I
APPLICATIONS
EIA
- 148 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
EIA
- 149 -
M/s. Shilpa Medicare Ltd. Unit I
GL Reactor
Process residue
0.1 kg
Centrifuge Distillation
Process wastewater
63.7 kg
Bendamustine HCl
1.2 kg
EIA
- 150 -
M/s. Shilpa Medicare Ltd. Unit I
Qty./batch Qty./batch
Input Reactor
(kg) Output (kg)
Ethyl-4-(5-(bis(2-
hydroxy ethyl) Bendamustine 1.2
5 HCl
amino)-1-methyl-
1H-benzoid)
imidazol-2-
yl)butanoate Process residue 0.1
Thionyl chloride 20
Wastewater 63.7
Water 40
EIA
- 151 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
CYCLE TIME
Time
Particulars
(hrs)
Reaction 8 - 10
Isolation & centrifugation 2 2.5
Total process time 10 12.5
APPLICATIONS
EIA
- 152 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.11 Bicalutamide
REACTION SCHEME
EIA
- 153 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 154 -
M/s. Shilpa Medicare Ltd. Unit I
N-[4-cyano-3-trifluoromethyl Acetonitrile
phenyl]-3-[4-fluorophenyl thio]-2- 100 kg
hydroxy-2-methyl propanamide
Potassium permanganate
12 kg 5 kg
GL Reactor
Manganese dioxide
Filtration 5 kg
Acetonitrile
recovered 97 kg
loss 3 kg
Impurity-A (2,3-epoxy-2-methyl-N-[4-cyano-
3-trifluoromethyl)phenyl] propanamide
2 kg
Centrifuge Distillation
IPA
recovered 8 kg
loss 2 kg
Bicalutamide
10 kg
EIA
- 155 -
M/s. Shilpa Medicare Ltd. Unit I
Qty./batch
Input (kg) Reactor Qty./batch
Output (kg)
N-[4-cyano-3-
trifluoromethyl Bicalutamide 10
12
phenyl]-3-[4-
fluorophenyl thio]-
2-hydroxy-2- By-product
methyl Manganese dioxide 5
propanamide
100 Solvent
Acetonitrile
1) Acetonitrile
recovered 97
Potassium 5 loss 3
permanganate
2) IPA
Isopropyl 10 recovered 8
alcohol loss 2
Impurity-A (2,3-
epoxy-2-methyl-N- 2
[4-cyano-3-
trifluoromethyl)phe
nyl] propanamide
EIA
- 156 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
CYCLE TIME
Time
Particulars
(hrs)
Reaction 6 8
Isolation & centrifugation 10 12
Solvent recovery 1 2
Total process time 17 22
APPLICATIONS
EIA
- 157 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.12 Bortezomib
REACTION SCHEME
EIA
- 158 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sl. Raw material used Qty./batch
No. (kg)
1 3- phenyl -2-[(pyrazine-2- 0.1
carbonyl)-amino] propionic
acid
2 R-borolex-(+)-pinanediol 0.115
trifluoro acetic acid
3 n-hydroxy succinamide 0.09
4 MDC 0.27
5 Disopropyl amine 0.11
6 1N HCl 0.12
7 Saturated sodium bicarbonate 0.57
8 Methanol 0.67
2nd stage
Sl. Raw material used Qty./batch
No. (kg)
1 Methanol 0.17
2 Isobutyl boronic acid 0.085
3 n-Heptane 2.07
4 1N HCl 0.57
5 MDC 0.27
6 Ethyl acetate 0.57
7 Saturated sodium bicarbonate 0.57
3rd stage
Production yield per batch 0.08 kg
Sl. Raw material used Qty./batch
No. (kg)
1 Methanol 0.109
2 Water 0.109
EIA
- 159 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Filter
MDC recovered
0.22 kg
Process residue
Filtration
0.07 kg
EIA
- 160 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Process wastewater
Layer separation 1.542 kg
Ethyl acetate
Recovered n-heptane
0.57 kg Residue 1.57 kg
Methanol
0.17 kg
MDC Process
Filter Distillation
residue
0.27 kg
0.27 kg
Output from 2nd stage Recovered heptane,
MDC, methanol
0.083 kg
0.97 kg
EIA
- 161 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Filter Distillation
Recovered methanol
0.109 kg
Drying
Bortezomib
0.08 kg
EIA
- 162 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty./batch Reactor
Input
(kg) Qty./batch
3- phenyl -2-[(pyrazine-2- Output (kg)
carbonyl)-amino] 0.1 Output from
propionic acid 0.13
1st stage
R-borolex-(+)-pinanediol
0.115 MDC recovered 0.22
trifluoro acetic acid
MDC 0.27
Wastewater 1.625
Disopropyl amine 0.11
1N HCl 0.12
Methanol 0.67
EIA
- 163 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch Qty./batch
Input (kg) Reactor Output
(kg)
Output from 1st Output from 0.083
stage 0.13
2nd stage
Methanol 0.17
MDC 0.27
Process residue 0.27
Ethyl acetate 0.57
EIA
- 164 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty./batch
Qty./batch Output (kg)
Input Reactor
(kg)
Output from Bortezomib 0.08
2nd stage 0.083
Water 0.109
Wastewater 0.112
EIA
- 165 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
Methanol, N-heptane, isobutyl boromic acid & 1N HCL are charged into a clean
dry reactor and stirred for 2 hrs. Organic layer is separated. HCl layer is taken
& product is extracted in MDC & washed. Saturated sodium bicarbonate
solution & MDC are added & the reaction mass is distilled to which ethyl
acetate is added to crystallize the output from 2nd stage, which is filtered &
dried to get crude bortezomib.
3rd stage
Crude product from 2nd stage is dissolved in methanol & water is added to
crystallize the final product. The final product is filtered & dried to get pure
bortezomib.
CYCLE TIME
Time (hrs)
Particulars st
1 stage 2nd stage 3rd stage
Reaction 6-8 6-8 4-6
Isolation & centrifugation 2-3 6-8 10 - 14
Total process time 8 - 11 12 - 16 14 - 20
EIA
- 166 -
M/s. Shilpa Medicare Ltd. Unit I
APPLICATIONS
EIA
- 167 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.13 Capecitabine
REACTION SCHEME
EIA
- 168 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sl. Raw material used Qty./batch
No. (kg)
1 5-methyl tetrahydrofuran-
150
2,3,4-triyl triacetate
2 Toluene 300
3 Hexa methyl disaline
150
(HMDS)
4 5-fluorocytosine 100
5 Tetra methyl silyl
5
chloride (TMSC)
6 MDC 500
7 Sodium bicarbonate 150
8 Water 300
9 Stannic chloride 160
10 Isopropyl alcohol 300
2nd stage
Sl. Raw material used Qty./batch
No. (kg)
1 Methylene di chloride (MDC) 250
2 N-pentyl chloroformate 110
3 Pyridine 60
4 Heptane 500
5 Water 300
3rd stage
Production yield per batch 100 kg
Sl. Raw material used Qty./batch
No. (kg)
1 Methanol 350
2 MDC 250
3 Toluene 900
4 Hydrochloric acid 50
5 Sodium hydroxide 20
6 Water 300
EIA
- 169 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sodium bicarbonate
150 kg
5-methyl tetrahydrofuran-2,3,4-
triyl triacetate TMSC
150 kg 5 kg
Toluene MDC
300 kg 500 kg
HMDS
150 kg Stannic chloride
5-fluorocytosine GL Reactor 160 kg
100 kg Trimethyl silane
15 kg
Sodium bicarbonate
Filtration
+stannous chloride
+ silyl chloride
350 kg
Water Process wastewater
MDC layer
300 kg 496 kg
Toluene
recovered 290 kg
loss 10 kg
MDC
recovered 470 kg
Isopropyl alcohol loss 30 kg
Organic layer
300 kg
Process residue
4 kg
Centrifuge Distillation
IPA
recovered 280 kg
Output from 1st stage loss 20 kg
150 kg
EIA
- 170 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
GL Reactor
Pyridine HCl
Filter
64 kg
Water
300 kg Process wastewater
Layer separation
375 kg
Heptane
Organic layer Distillation
500 kg
MDC
recovered 200 kg
loss 50 kg
Process residue
1 kg
Centrifuge Distillation
Heptane
recovered 470 kg
Drying
loss 30 kg
EIA
- 171 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
GL Reactor
Sodium acetate
Layer separation
78 kg
Water
Organic layer
300 kg
Process wastewater
Layer separation
370 kg
MDC
recovered 220 kg
loss 30 kg
Methanol
recovered 330 kg
Toluene loss 20 kg
Reaction mass
900 kg
Process residue
2 kg
Centrifuge Distillation
Toluene
Drying recovered 870 kg
loss 30 kg
Capecitabine
100 kg
EIA
- 172 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
EIA
- 173 -
M/s. Shilpa Medicare Ltd. Unit I
Qty./batch
Output (kg)
Qty./batch Output from 150
Input Reactor
(kg)
1st stage
5-methyl
tetrahydrofuran- 150
2,3,4-triyl By product
trimethyl silane 15
triacetate
Sodium bicarbonate 350
Toluene 300 + stannous chloride
+ silyl chloride
HMDS 150
100 Solvent
5-fluorocytosine
1) MDC
TMSC recovered 470
5
loss 30
MDC 500
2) Toluene
Sodium 150 290
recovered
bicarbonate 10
loss
EIA
- 174 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Output (kg)
Qty./batch
Input (kg) Reactor Output from 180
Output from 1st 2nd stage
150
stage
By product
MDC 250 Pyridine HCl 64
N-pentyl
110 Solvent
chloroformate
1) MDC
recovered from 200
Pyridine 60
reaction
Heptane 500 loss 50
Process residue 1
EIA
- 175 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
3) Methanol
SS recovered from reaction 330
Water 300
Reactor loss 20
3 KL Process residue 2
Process wastewater 370
Total input 2,050 Total output 2,050
Qty./batch
Output (kg)
Capecitabine 100
Input Qty./batch
Reactor
(kg)
Output from By product:
180
2nd stage 78
Sodium acetate
Methanol 350
Solvent
MDC 250 1) Toluene
recovered 870
Toluene 900 loss 30
Hydrochloric 50
2) MDC
acid
recovered 220
Sodium 20 loss 30
hydroxide
3) Methanol
Water 300 recovered 330
loss 20
Process residue 2
Wastewater 370
EIA
- 176 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
Toluene, hexa methyl disaline, 5-fluorocytosine and tetra methyl silyl chloride
are added and heated to reflux at 128°C for 2 hrs to dissolve completely. Then
toluene is distilled and cooled. 5-methyl tetrahydrofuran-2,3,4-triyl triacetate,
MDC and stannic chloride are added to the reaction mixture and maintained for
2 hrs. Then sodium bicarbonate is added and maintained 1 hr and filtered.
Filtrate MDC is collected and given water wash. MDC layer is separated and
distilled and crystallized in IPA, centrifuged and dried to get 1st stage output.
2nd stage
1st stage output is dissolved in MDC to which pyridine is added. Then added n-
pentyl chloroformate is added slowly to the reaction mixture which is
maintained as such for 2 hrs to complete the reaction. Then MDC layer is
washed with water, separated, distilled and isolated in heptane, centrifuged
and dried to get 2nd stage output.
3rd stage
The output from 3rd stage is dissolved in methanol and cooled to 0-5°C. 1N
NaOH solution is then slowly added to the reaction mixture in 1-2 hrs and
maintained for 2 hrs to complete the reaction. Reaction mass is adjusted to pH
range 4.5 to 5.5 with HCl 30% and product is extracted in MDC. MDC layer is
water washed and distilled and crystallized in toluene, centrifuged and dried to
get capecitabine.
CYCLE TIME
Time (hrs)
Particulars
1st stage 2nd stage 3rd stage
Reaction 25 - 30 15 - 20 15 - 20
Isolation & centrifugation 10 - 14 10 - 14 12 - 16
Solvent recovery 3-4 2-3 4-5
Total process time 38 - 48 27 - 37 31 - 41
EIA
- 177 -
M/s. Shilpa Medicare Ltd. Unit I
APPLICATIONS
Alone to prevent the return of colon cancer (that had spread to at least one
lymph node) after surgery has removed the tumour.
Alone to treat metastatic colorectal cancer (cancer that spread to other
parts of the body).
In combination with docetaxel (Taxotere®) to treat metastatic breast
cancer in people whose tumours are resistant to anthracycline
chemotherapy medications.
Alone to treat metastatic breast cancer in people whose tumours are
resistant to both paclitaxel (Onxol®, Taxol®) and anthracycline
chemotherapy medications (or cannot take any more anthracycline
medications).
EIA
- 178 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.14 Carboplatin
REACTION SCHEME
EIA
- 179 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
EIA
- 180 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Potassium iodide
40 kg
GL Reactor
Potassium chloride
Filtration
41.5 kg
Drying
EIA
- 181 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
GL Reactor
Silver iodide
Filter
22.84 kg
Filtrate Distillation
Water
750 kg
Process residue
0.16 kg
Centrifuge Distillation
Water
250 kg
Drier
Carboplatin
10 kg
EIA
- 182 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty./batch
Input Qty./batch Reactor Output (kg)
(kg)
Water 50 Output from 18
1st stage
Potassium 17
tetrachloroplatinate 41.5
Potassium chloride
Potassium 40
iodide
Wastewater 57.5
Ammonium 10
hydroxide (25%)
EIA
- 183 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Input Qty./batch Reactor Output (kg)
(kg)
Output from 1st Carboplatin 10
stage 18
EIA
- 184 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
CYCLE TIME
APPLICATIONS
EIA
- 185 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.15 Cisplatin
REACTION SCHEME
EIA
- 186 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
EIA
- 187 -
M/s. Shilpa Medicare Ltd. Unit I
Potassium tetrachloroplatinate
17 kg
Potassium iodide Ammonium hydroxide (25%)
40 kg 10 kg
GL Reactor
Crystallization
Drying
GL Reactor
Silver iodide
Filter
24 kg
Potassium chloride
Filtrate
7 kg
Process wastewater
Centrifuge
50 kg
Drying
Cisplatin
10 kg
EIA
- 188 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty./batch
Output (kg)
Input Qty./batch Reactor
(kg) Output from 18
Potassium 1st stage
17
tetrachloroplatinate
Ammonium 10
hydroxide (25%) Wastewater 57.5
EIA
- 189 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Water 50
Silver iodide 24
Silver nitrate 9
Wastewater 50
Potassium 7
chloride
EIA
- 190 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
Silver nitrate is dissolved in water to which the output from 1st stage is added
and the mixture is maintained for 30 min at 50 600C. Silver iodide formed
during the reaction is isolated by filtration. The filtrate is collected and
potassium chloride is added to crystallize cisplatin. The material is filtered and
dried to get cisplatin.
CYCLE TIME
Time (hrs)
Particulars st
1 stage 2nd stage
Reaction 6 8 6 8
Isolation & centrifugation 8 10 8 12
Total process time 14 18 14 20
APPLICATIONS
Cisplatin is a chemotherapy drug. It targets fast dividing cells, like cancer cells,
and causes these cells to die.
EIA
- 191 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
EIA
- 192 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sl. Raw material used Qty./batch
No. (kg)
1 CN1 20
2 Acetonitrile 200
3 6N HCl 8.4
4 Saturated sodium 440
bicarbonate solution in
water 10 kg in 12 L water
5 Ethyl acetate 300
6 Sodium chloride 6
7 Sodium sulfate 20
2nd stage
Sl. Raw material used Qty./batch
No. (kg)
1 MDC 240
2 Acetone 240
3 Petroleum ether 600
3rd stage
Production yield per batch 10 kg
Sl. Raw material used Qty./batch
No. (kg)
1 Methanol 240
2 Water 240
EIA
- 193 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
CN1
20 kg
Saturated sodium bicarbonate
solution in water Ethyl acetate
440 kg 240 kg
Acetonitrile 6N HCl
200 kg 8.4 kg
GL Reactor
Filter
Process wastewater
Filtrate
440 kg
Ethyl acetate
Layer separation 60 kg
Distillation Sodium chloride
6 kg
Filter
Sodium sulfate
Filter
20 kg
Aceto nitrile
recovered 140 kg
loss 60 kg
Ethyl acetate
st recovered 260 kg
Output from 1 stage
loss 40 kg
16 kg
EIA
- 194 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
GL Reactor MDC
recovered 200 kg
loss 40 kg
Acetone
ML Distillation recovered
Centrifuge
170 kg
loss 10 kg
Petroleum ether
Acetone Residue recovered 560 kg
60 kg loss 40 kg
Drying
EIA
- 195 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
GL Reactor
Filter
Water
Filtrate
240 kg
Process wastewater
242 kg
Centrifuge Distillation
Methanol
Drying recovered 200 kg
loss 40 kg
Docetaxel trihydrate
10 kg
EIA
- 196 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
EIA
- 197 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
3) Petroleum ether
recovered from reaction 560
loss 40
Process residue 4
Total input 1096 Total output 1096
Qty./batch
Output
(kg)
Input Qty./batch (kg) Reactor Output from 12
2nd stage
Output from 1st
16
stage
Solvent
MDC 240
1) MDC
Acetone 240 recovered 200
loss 40
Petroleum 600
ether 2) Acetone
recovered 220
loss 20
3) Petroleum ether
recovered 560
loss 40
Process residue 4
EIA
- 198 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty./batch
Output (kg)
Docetaxel trihydrate 10
Input Qty./batch
Reactor
(kg)
Output from Solvent methanol
12
2nd stage recovered 200
loss 40
Methanol 240
Water 240
Wastewater 242
EIA
- 199 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
The output from 1st stage is dissolved in MDC and acetone. Petroleum ether is then
added slowly in 1 to 2 hrs at room temperature. After complete addition, the
reaction mixture is maintained for 1 hr at room temperature, filtered and dried to
get crude docetaxel (output from 2nd stage).
3rd stage
CYCLE TIME
Time (hrs)
Particulars
1st stage 2nd stage 3rd stage
Reaction 6-8 4-6 4-6
Isolation & centrifugation 4-6 4-6 12 - 16
Solvent recovery 2-3 1-2 2-3
Total process time 12 - 17 9 - 14 18 - 25
APPLICATIONS
REACTION SCHEME
EIA
- 201 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sl. Raw material used Qty./batch
No. (kg)
1 EPI-i 2
2 Ethanol 7.89
3 MDC 26.4
4 Acetone 3.95
5 Sodium hydroxide 0.5
6 Hydrochloric acid 2.36
7 Sodium borohydride 0.1
8 Water 10
2nd stage
Sl. Raw material used Qty./batch
No. (kg)
1 MDC 26.4
2 Water 10
3 Sodium hydroxide 0.2
4 n-Hexane 6.54
3rd stage
Production yield per batch 0.25 kg
Sl. Raw material used Qty./batch
No. (kg)
1 Hydrobromic acid 1.5
2 Acetone 9.48
3 Sodium bicarbonate 0.1
4 Water 10
5 Methanol 7.9
6 Dioxane 7
7 MDC 26.4
8 n-Hexane 9.8
EIA
- 202 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sodium hydroxide
0.5 kg
RBF
MDC
Reaction mass
26.4 kg
Sodium acetate
Layer separation
1 kg
MDC + ethanol +
acetone recovered
36 kg
Acetone Distillation
Reaction mass
3.95 kg
EIA
- 203 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
RBF
MDC
recovered 24 kg
loss 2.4 kg
Process residue
10.1 kg
Centrifuge Distillation
n-Hexane
Drying recovered 5 kg
loss 1.54 kg
EIA
- 204 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
GL Reactor
Process wastewater
Layer separation
11.1 kg
Methanol
7.9 kg
Dioxane
7 kg
Water Spent recovered acetone
Organic layer
10 kg + methanol + dioxane +
n-hexane + MDC
58 kg
n-Hexane
Centrifuge Distillation
9.8 kg
Process residue
3.83 kg
Drying
Epirubicin HCl
0.25 kg
EIA
- 205 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sodium 0.1
borohydride
Water 10
EIA
- 206 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Output (kg)
Qty./batch Reactor
Input Output from 1
(kg)
2nd stage
Output from 1st
stage 1.1
Solvent
MDC 26.4 1) MDC
recovered 24
Water 10 loss 2.4
0.2 2) n-Hexane
Sodium hydroxide
recovered 5
n-Hexane 6.54 loss 1.54
EIA
- 207 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty./batch
Input Reactor
(kg)
Output from
1
2nd stage
Sodium
Spent recovered
bicarbonate 0.1
acetone + methanol + 58
10 dioxane + n-hexane +
Water
MDC
MDC 26.4
n-Hexane 9.8
EIA
- 208 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
N-((2R,3R,4R,6R)-6-(((1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-
1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl)oxy)-3-hydroxy-2-methyltetrahydro-
2H-pyran-4-yl)-2,2,2-trifluoroacetamide reacts with sodium borohydride in
ethanol, in the presence of HCl & NaOH to form the 1st stage output.
2nd stage
N-((2R,3S,4R)-6-(((1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-
1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl)oxy)-3-hydroxy-2-methyltetrahydro-
2H-pyran-4-yl)-2,2,2-trifluoroacetamide reacts with aqueous sodium hydroxide in
the presence of dichloromethane to form the 2nd stage output.
3rd stage
8S,10S)-8-acetyl-10-(((4R,5S,6R)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-
2-yl)oxy)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-
5,12(5aH,11aH)-dione reacts with hydrobromic acid and MDC in methanol and
dioxane in presence of sodium bicarbonate in water and acetone to get the
required product.
CYCLE TIME
Time (hrs)
Particulars
1st stage 2nd stage 3rd stage
Reaction 4-6 4 6 4-6
Isolation & centrifugation 5-8 8 - 12 6-8
Solvent recovery 2-3 2-3 2-3
Total process time 11 - 17 14 - 21 12 - 17
APPLICATIONS
2.6.4.18 Gefitinib
REACTION SCHEME
EIA
- 210 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
EIA
- 211 -
M/s. Shilpa Medicare Ltd. Unit I
GL Reactor
Scrubbed water
HCl Scrubber
consisting of HCl
5 kg
Thionyl chloride
recovered 4 kg
Centrifuge Distillation
Process residue
1 kg
Output from 1st stage
5 kg
GL Reactor
Potassium chloride
Filtration 1.2 kg
Ethyl acetate
recovered 88 kg
loss 2 kg
HCl
Centrifuge Distillation 5.9 kg
Process residue
0.4 kg
Gefitinib
3 kg
EIA
- 212 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty./batch
Output (kg)
Input Qty./batch Reactor
(kg) Output from 5
7-methoxy-6-(3- 1st stage
morphalino propyl) 5
quinazolin-4 (3H)-
one Thionyl chloride 4
10 recovered
Thionyl chloride
Process residue 1
EIA
- 213 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Output (kg)
Qty./batch Gefitinib 3
Input (kg) Reactor
EIA
- 214 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
The solid mass from the centrifuge is taken in GL reactor and treated with 3-
chloro-4-fluoroaniline and K2CO3 in solvent ethyl acetate, under heating centrifuge
at 55-60°C for 3 hrs. The reaction mass is then filtered and dissolved K2CO3 is
removed. The filtrate is cooled in the same reactor at 5-10°C for 2 hrs. The
material is then centrifuged and dried. The mother liquor is transferred for
recovery of solvent.
Solvent recovery
The mother liquor in GLR reactor is distilled to recover ethyl acetate which is
recycled.
CYCLE TIME
1st stage
Particulars Time (hrs)
Reaction 10 15
Centrifugation 2 3
Solvent recovery 2
Total process time 14 20
2nd stage
Particulars Time (hrs)
Reaction 3 4
Filtration 4 5
Centrifugation 1 1.5
Solvent recovery 1 1.5
Total process time 9 12
EIA
- 215 -
M/s. Shilpa Medicare Ltd. Unit I
APPLICATIONS
EIA
- 216 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
EIA
- 217 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sl. Raw material used Qty./batch
No. (kg)
1 G Intermediate 330
2 Methanol 975
3 Ammonia 25% 565
2nd stage
Sl. Raw material used Qty./batch
No. (kg)
1 Methanol 750
2 Carbon 10
3 Hydrochloric acid (HCl) 40
3rd stage
Production yield per batch 25 kg
Sl. Raw material used Qty./batch
No. (kg)
1 Water 30
2 Acetic acid 2000
3 HCl 40
EIA
- 218 -
M/s. Shilpa Medicare Ltd. Unit I
Methanol Carbon
750 kg 10 kg
Reactor
HCl Carbon
Filter
40 kg 10 kg
Filtrate
Methanol
recovered 700 kg
Centrifuge loss 50 kg
Wastewater
177.5 kg
Drying
EIA
- 219 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
GL Reactor
Crystallization
Acetic acid recovered
1975 kg
ANFD
(Filtration & Drying)
Wastewater
107.5 kg
Gemcitabine HCl
25 kg
EIA
- 220 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Output
Qty./batch (kg)
Output from 175
1st stage
Methanol 975
Solvent methanol
Ammonia 25% 565 recovered 925
loss 50
Wastewater 420
EIA
- 221 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Output (kg)
Qty./batch
Input Reactor Output from 37.5
(kg)
2nd stage
Output from 1st 175
stage
Carbon 10
40 Solvent methanol
HCl
recovered 700
loss 50
EIA
- 222 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty./batch
Qty./batch (kg)
Output
Input (kg) Reactor
Output from Gemcitabine 25
2nd stage 37.5 HCl
EIA
- 223 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
Output from 1st stage is dissolved in methanol. Carbon is then added to the
reaction mixture, maintained for 30 minutes and filtered. Filtrate is collected in
GLR to which HCl is added at room temperature. The reaction mixture is
maintained at 20-25°C for 24 hours, centrifuged and dried to obtain output.
3rd stage
Output from 2nd stage is dissolved in water at 50-55°C and filtered. The filtrate is
quenched in acetic acid and maintained for 2 hours at room temperature and for
20 hr at 15-25°C to crystallize the product. The product is then filtered and dried
in ANFD to get gemcitabine HCl.
CYCLE TIME
Time (hrs)
Particulars
1st stage 2nd stage 3rd stage
Reaction 20 30 30 32 28 32
Isolation & centrifugation 8 10 10 12 16 18
Solvent recovery 6 8 6 8 8 10
Total process time 34 48 46 52 52 60
EIA
- 224 -
M/s. Shilpa Medicare Ltd. Unit I
APPLICATIONS
Ovarian cancer that is advanced and has not gotten better with other
chemotherapy.
Breast cancer that has metastasized (spread to other parts of the body) and has
not gotten better with other chemotherapy.
Non-small cell lung cancer (NSCLC) that is advanced, cannot be treated with
surgery, or has metastasized (spread to other parts the body).
Gemcitabine hydrochloride is also being studied in the treatment of other types
of cancer.
EIA
- 225 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
EIA
- 226 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 227 -
M/s. Shilpa Medicare Ltd. Unit I
4-methyl-N3-(5-pyridin-3yl pyrimidine-
2-yl) benzene-1,3-diamine
10 kg
4-(4-methyl-piperazin-1-yl-
ethyl)benzoic acid dihydrochloride Triethyl amine
10 kg 20 kg
MDC Hydroxy benzotriazole
100 kg 6 kg
GL Reactor
Crystallization MDC
recovered 95 kg
loss 5 kg
Hydroxy
Centrifuge Distillation benzotriazole
Methanol 13 kg
recovered 47 kg
Drier loss 3 kg
Imatinib mesylate
10 kg
EIA
- 228 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 229 -
M/s. Shilpa Medicare Ltd. Unit I
Qty./batch Reactor
Input
(kg)
4-methyl-N3-(5- Qty./batch
10 Output (kg)
pyridin-3yl
pyrimidine-2-yl) Imatinib mesylate 10
benzene-1,3-
diamine
By product
4-(4-methyl- Triethylamine 25
piperazin-1-yl- HCl salt
ethyl)benzoic acid 10 Hydroxy 13
dihydrochloride benzotriazole
Methanol 50
Spent carbon 1
Methane 2
sulphonic acid
Carbon 1
EIA
- 230 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
CYCLE TIME
APPLICATIONS
EIA
- 231 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
EIA
- 232 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sl. Raw material used Qty./batch
No. (kg)
1 7-ethyl-10-hydroxy
2
camptothecin
2 1,Chlorocarbonyl-4-piperidino
2.4
piperidine hydrochloride
3 Pyridine 80
4 Chloroform 140
5 Water 20
6 Hexane 20
2nd stage
Sl. Raw material used Qty./batch
No. (kg)
1 Ethanol 2
2 Dimethyl formamide (DMF) 2
3 Water 8
3rd stage
Production yield per batch 2 kg
Sl. Raw material used Qty./batch
No. (kg)
1 Water 18
2 Carbon 0.2
EIA
- 233 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
1,chlorocarbonyl-4-piperidino
piperidine hydrochloride 7-ethyl-10-hydroxy camptothecin
2.4 kg 2 kg
Pyridine Pyridine recovered
80 kg 78 kg
Distillation
GL Reactor
Chloroform
140 kg Pyridine
Water hydrochloride
Reaction mass
20 kg 3.6 kg
Process wastewater
20 kg
Chloroform
Hexane recovered 136 kg
Residue
20 kg loss 4 kg
Hexane
Centrifuge recovered 19 kg
loss 1 kg
EIA
- 234 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
GL Reactor
Process wastewater
8 kg
Ethanol & DMF
Water recovered 3.6 kg
Centrifuge Distillation
8 kg Ethanol loss
0.4 kg
Process residue
Drying 0.4 kg
EIA
- 235 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Carbon Water
0.2 kg 17 kg
GL Reactor
Carbon
Filter
0.2 kg
- 236 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Wastewater 20
- 237 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Output (kg)
Qty./batch
Input (kg) Reactor Output from 2.4
Output from 1st 2nd stage
2.8
stage
2 Ethanol & DMF 3.6
Ethanol
2 recovered
DMF
Ethanol loss 0.4
Water 8
Process wastewater 8
including DMF
- 238 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty./batch
Output (kg)
Irinotecan HCl 2
Qty./batch trihydrate
Input Reactor
(kg)
Output from
2nd stage 2.4 Spent carbon 0.2
Water 18
Pure water recovered 9.8
Carbon 0.2
Wastewater 7.8
- 239 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
The crude irinotecan base is purified in ethanol and dimethyl formamide to get
irinotecan base of 99.0% HPLC purity.
3rd stage
Irinotecan base from 3rd stage is purified in water in the presence of carbon to get
irinotecan HCl. Further it is crystallized in water to get irinotecan HCl trihydrate
of 99.5% HPLC purity.
CYCLE TIME
Time (hrs)
Particulars
1st stage 2nd stage 3rd stage
Reaction 30 - 32 28 - 32 12 - 20
Isolation & centrifugation 10 - 12 16 - 18 12 - 16
Solvent recovery 6-8 8 - 10 -
Total process time 46 - 52 52 - 60 24 36
APPLICATIONS
- 240 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.22 Lenalidomide
REACTION SCHEME
- 241 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
- 242 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Methanol
4 kg
RB Flask Methanol
recovered 3 kg
loss 1 kg
Centrifuge Distillation
Process residue
st 0.1 kg
Output from 1 stage
0.9 kg
- 243 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
GL Reactor
Spent carbon
Filter
0.1 kg
Filtrate
Cooling (100 C)
Process residue
Filter 2 kg
Water
25 kg Filtrate
DMSO
recovered 4.9 kg
loss 0.1 kg
Centrifuge Distillation
Process wastewater
26.9 kg
Lenalidomide
1 kg
- 244 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty./batch
Output (kg)
4 Methanol
Methanol
recovered 3
loss 1
4-nitropthalide 1
EIA
- 245 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Dimethyl 5 DMSO
sulphoxide recovery 4.9
loss 0.1
L-glutamine 1
N,N, carbomyl 3
diimidazole Process residue 2
Water 25
Wastewater 26.9
Carbon 0.1
EIA
- 246 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
Methanol, 4-nitrophthalide and raney nickel catalyst are charged into a clean 5 L
hydrogenator and the manhole is tightened. The hydrogenator is first flushed with
nitrogen and then with hydrogen (not shown in material balance). Hydrogen
pressure is maintained at 4.0 kg and at a temperature of 40 to 50°C for 4 hrs. TLC
is checked for completion of reaction. The catalyst is filtered and methanol is
distilled out to get the output from 1st stage.
2nd stage
The output from 1st stage is charged along with dimethysulphoxide, L-glutamine
and N,N, carbomyl diimidazole and maintained for 4 hrs at a temperature of 25 to
30°C for completion of reaction, monitored by TLC. Carbon is then added and
filtered. The filtrate is quenched in water to crystallize the product which is
centrifuged and dried to get the final product lenalidomide.
CYCLE TIME
Time (hrs)
Particulars
1st stage 2nd stage
Reaction 4-6 4-6
Isolation & centrifugation 2-3 12 - 16
Solvent recovery 0.5 - 1 2-3
Total process time 6.5 - 10 18 - 25
APPLICATIONS
EIA
- 247 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.23 Letrozole
REACTION SCHEME
EIA
- 248 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
EIA
- 249 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
p-tolunitrile Hexane
3 kg 3 kg
GL Reactor
Succinamide
Filter
2.5 kg
Aceto nitrile
recovered 14.5 kg
loss 0.5 kg
Process residue
Centrifuge Distillation
0.2 kg
Hexane
Output from 1st stage recovered 2.5 kg
3 kg loss 0.3 kg
EIA
- 250 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Process wastewater
Layer separation 12 kg
Ethyl acetate
recovered 9.5 kg
loss 0.5 kg
Potassium bromide
Filter 3.2 kg
Dimethyl formamide
recovered 2.7 kg
loss 0.3 kg
Centrifuge Distillation
Process residue
0.1 kg
Letrozole
1 kg
EIA
- 251 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty./batch
Output
(kg)
Output from 3
1st stage
Input Qty./batch Reactor
(kg)
3 By product
p-tolunitrile
succinamide 2.5
n-
bromosuccinamide 2.5
Solvent
1) Aceto nitrile
Aceto nitrile 15 recovered 14.5
loss 0.5
Hexane 3 2) Hexane
recovered 2.5
loss 0.3
EIA
- 252 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Output (kg)
Qty./batch
Input Reactor Letrozole 1
(kg)
st
Output from 1
stage 3 By product:
Hydrobromic acid 0.7
1,2,4-triazole 1 Potassium bromide 3.2
Dimethyl 3 Solvent
formamide 1) Ethyl acetate
recovered 9.5
Potassium 3 loss 0.5
carbonate
2) Dimethyl formamide
10 recovered 2.7
Ethyl acetate
loss 0.3
Water 10
Process residue 0.1
Wastewater 12
EIA
- 253 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
CYCLE TIME
Time (hrs)
Particulars st
1 stage 2nd stage
Reaction 6-8 10 - 12
Isolation & centrifugation 8 - 12 10 - 12
Solvent recovery 0.5 - 1 0.5 - 1
Total process time 14.5 - 21 20.5 - 25
EIA
- 254 -
M/s. Shilpa Medicare Ltd. Unit I
APPLICATIONS
Letrozole is approved by the Food and Drug Administration (FDA) to be used alone
to treat postmenopausal women who have any of the following types of breast
cancer:
Early-stage, hormone receptor positive (HR+) breast cancer in women who have
already received other treatment.
Early-stage breast cancer that has been treated with tamoxifen for at least five
years.
Breast cancer that is locally advanced or has metastasized (spread to other
parts of the body) and is hormone receptor positive (HR+).
Breast cancer that is locally advanced or has metastasized and it is not known
whether the cancer is HR+ or hormone receptor negative (HR-).
Advanced breast cancer that has gotten worse after anti-estrogen therapy.
Letrozole is also used with a drug called lapatinib to treat postmenopausal women
who need hormonal therapy to treat metastatic breast cancer that is:
EIA
- 255 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.24 Oxaliplatin
REACTION SCHEME
EIA
- 256 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
EIA
- 257 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Trans-1,2-diamino cyclohexane
0.51 kg
GL Reactor
Process wastewater
5.01 kg
Centrifuge Distillation
Potassium chloride
Drying 0.8 kg
EIA
- 258 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Silver oxide
Oxalic acid
0.93 kg
0.47 kg
Water
75 kg
Reactor
Silver oxide
Carbon Spent carbon
Reactor
0.14 kg 0.14 kg
Distillation
Filtrate (water)
Process wastewater
Centrifuge Distillation 65 kg
Silver chloride
Filtration 1.73 kg
Mother liquor
Drier
Process residue
Distillation 0.07 kg
EIA
- 259 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty./batch
Qty./batch Output
(kg)
Input (kg) Reactor
Output from 1.4
Potassium 1st stage
tetrachloroplatinate 1.7
Water 5
Wastewater 5.01
EIA
- 260 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Output (kg)
Water 75
Spent carbon 0.14
Silver oxide 0.93
Carbon 0.14
Wastewater 75
EIA
- 261 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
Silver oxide and oxalic acid are added to water and maintained at 50-60°C for 15
min to form silver oxalate. This is then reacted with the output from 1st stage at
50-60°C for 6 hrs. Silver chloride is formed which is filtered and collected. The
water layer is treated with carbon, concentrated and filtered to get the product
which is washed with water to get pure oxaliplatin.
CYCLE TIME
APPLICATIONS
EIA
- 262 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.25 Paclitaxel
REACTION SCHEME
EIA
- 263 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sl. Raw material used Qty./batch
No. (kg)
1 TxL RM 2
2 Zinc 3.75
3 Methanol 15.6
4 Acetic acid 20
5 Ethyl acetate 22.5
2nd stage
Sl. Raw material used Qty./batch
No. (kg)
1 MDC 17.45
2 Acetone 5.27
3 Petroleum ether 32.7
3rd stage
Sl. Raw material used Qty./batch
No. (kg)
1 Methanol 9.36
2 Water 12
4th stage
Production yield per batch 1 kg
Sl. Raw material used Qty./batch
No. (kg)
1 MDC 4.85
2 Acetone 1.38
3 Petroleum ether 7.7
EIA
- 264 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
TxL RM Methanol
2 kg 15.6 kg
Zinc Acetic acid
3.75 kg 20 kg
GL Reactor
Ethyl acetate
Filtrate Distillation
22.5 kg
Methanol
recovered 15 kg
loss 0.6 kg
Process residue
0.3 kg
Filter Distillation
Ethyl acetate
Drier recovered 22 kg
loss 0.5 kg
EIA
- 265 -
M/s. Shilpa Medicare Ltd. Unit I
Filter ML
Drying
Methanol Water
9.36 kg 12 kg
GL Reactor
Methanol
recovered 8 kg
loss 1.36 kg
Process wastewater
Filter
12.1 kg
Drying
4th stage
Glass vessel
L- isomer of paclitaxel
Filter 0.1 kg
Petroleum ether
Filtrate
7.7 kg
MDC
recovered 4.5 kg
loss 0.35 kg
Filter ML Distillation
Paclitaxel
1 kg
EIA
- 267 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Output
Qty./batch (kg)
Output from 2
1st stage
TxL RM 2
Solvent
3.75 1) Methanol
Zinc recovered 15
loss 0.6
Methanol 15.6
2) Ethyl acetate
Acetic acid 20 recovered 22
loss 0.5
Ethyl 22.5
acetate
Acetic acid recovered 19.7
EIA
- 268 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
EIA
- 269 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty./batch
Qty./batch Output (kg)
Input Reactor
(kg)
Output from Output from 1.1
2nd stage 1.2 3rd stage
Wastewater 12.1
EIA
- 270 -
M/s. Shilpa Medicare Ltd. Unit I
4th stage
Qty./batch
Output (kg)
Qty./batch
Input (kg) Reactor Paclitaxel 1
Output from 3rd
1.1
stage
By products: L- 0.1
4.85
MDC isomer of paclitaxel
Acetone 1.38
2) Acetone +
petroleum ether
recovered 8.9
loss 0.18
EIA
- 271 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
TxL RM is dissolved in methanol to which acetic acid & zinc powder are added &
heated to 40-50°C for 2 hrs. The reaction is monitored by TLC. The reaction
mixture is then filtered & methanol, acetic acid is evaporated until residue
formed. The residue is crystallized in ethyl acetate, filtered and dried to get 1st
stage output.
2nd stage
The output from 1st stage is dissolved in MDC & acetone, which is then re-
crystallized in petroleum ether. The resultant mass is filtered and dried to get the
output from 3rd stage.
3rd stage
The output from 2nd stage is dissolved in methanol and re-crystallized, filtered and
dried to get the output from 3rd stage.
4th stage
The output from 3rd stage is dissolved in MDC and acetone and re-crystallized in
petroleum ether. The reaction mass is then filtered and dried to get pure
paclitaxel.
CYCLE TIME
Time (hrs)
Particulars st nd
1 stage 2 stage 3rd stage 4th stage
Reaction 8-9 6-8 8 - 10 6-8
Isolation & centrifugation 6-7 6-8 10 - 12 6-8
Solvent recovery 1-2 Nil 0.5 - 1 1-2
Total process time 15 - 18 12 - 16 18.5 - 23 13 - 18
APPLICATIONS
Paclitaxel is approved by the Food and Drug Administration (FDA) to treat ovarian
and breast cancer, and AIDS-related Kaposi sarcoma. It is also approved to be used
together with a drug called cisplatin to treat advanced ovarian cancer and non-
small cell lung cancer (NSCLC).
2.6.4.26 Pemetrexed
REACTION SCHEME
EIA
- 273 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Sl. Raw material used Qty./batch
No. (kg)
1 L-glutamic acid diethyl ester HCl 1.14
2 4-[2-(2-amino-4,7-dihydro-4-oxo- 1.56
1H-pyrrolo[2,3-d]pyrimidin-5-
yl)ethyl)benzolic acid
3 N-methyl morphalane 1.16
4 DMF 10.2
5 MDC 38.5
6 Water 38.5
7 2-chloro-4,6-dimethoxy-1,3,5- 1
triazine
2nd stage
Sl. Raw material used Qty./batch
No. (kg)
1 Hydrochloric acid 1
2 Sodium hydroxide 1
3 Water 25
3rd stage
Production yield per batch 1 kg
Sl. Raw material used Qty./batch
No. (kg)
1 Acetone 30.78
2 Hydrochloric acid 1
3 Sodium hydroxide 1
4 Water 25
EIA
- 274 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
DMF
10.2 kg 4-[2-(2-amino-4,7-dihydro-4-oxo-1H-
pyrrolo[2,3-d]pyrimidin-5-
L-glutamic acid diethyl ester HCl yl)ethyl)benzolic acid
1.14 kg 1.56 kg MDC
recovered 30.8 kg
N-methyl morphalane MDC loss 7.7 kg
1.16 kg 38.5 kg
2-chloro-4,6-dimethoxy- Distillation
1,3,5-triazine 1 kg GL Reactor
DMF
recovered 9.5 kg
loss 0.7 kg
EIA
- 275 -
M/s. Shilpa Medicare Ltd. Unit I
GL Reactor
Distillation
GL Reactor
Acetone
recovered 30 kg
loss 0.78 kg
Pemetrexed
Centrifuge
1 kg
Process residue
0.4 kg
EIA
- 276 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty./batch
Input Reactor
(kg) Qty./batch
L-glutamic acid Output (kg)
diethyl ester HCl 1.14
Output from 1.87
4-[2-(2-amino-4,7- 1st stage
dihydro-4-oxo-1H-
pyrrolo[2,3- 1.56
d]pyrimidin-5- Solvent
yl)ethyl)benzolic 1) MDC
acid recovered 30.8
loss 7.7
N-methyl
1.16 2) DMF
morphalane
recovered 9.5
DMF 10.2 0.7
loss
MDC 38.5
Water 38.5
Wastewater 41.49
2-chloro-4,6- 1
dimethoxy-
1,3,5-triazine
EIA
- 277 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Input (kg) Reactor
Qty./batch
Output from 1st Output (kg)
1.87
stage
Output from 1.4
Hydrochloric 1 2nd stage
acid
Sodium 1
hydroxide Process wastewater 27.47
including DMF
Water 25
EIA
- 278 -
M/s. Shilpa Medicare Ltd. Unit I
3rd stage
Qty./batch
Output (kg)
Input Qty./batch Reactor
(kg) Pemetrexed 1
Output from
2nd stage 1.4
25 Wastewater 27
Water
EIA
- 279 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
The output from 1st stage is dissolved in coater to which sodium hydroxide is added
and stirred at 25-30°C for 2 hrs. To this reaction mixture hydrochloric acid is
added and the material is centrifuged.
3rd stage
The output from 2nd stage is dissolved in acetone and water to which sodium
hydroxide is added and stirred at a temperature of 25-30°C. To this reaction
mixture hydrochloric acid is added. After the reaction is complete, the product is
centrifuged.
CYCLE TIME
Time (hrs)
Particulars
1st stage 2nd stage 3rd stage
Reaction 5-7 5 - 5.5 4 - 4.5
Isolation & centrifugation 3 - 3.5 2 - 2.5 2-3
Total process time 8 - 10.5 7-8 6 - 7.5
Solvent recovery 2-3 - 2-3
EIA
- 280 -
M/s. Shilpa Medicare Ltd. Unit I
APPLICATIONS
EIA
- 281 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.27 Temozolomide
REACTION SCHEME
EIA
- 282 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
EIA
- 283 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
SS Reactor
Process wastewater
Centrifuge Distillation
646 kg
Filtration Distillation
Drying
Sodium tartrate Process residue
120 kg 4 kg
EIA
- 284 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Acetone
Carbon
400 kg
5 kg
Water
150 kg
Reactor
Spent carbon
Filter
8 kg
Solvent acetone
recovered 385 kg
Filtrate Distillation
loss 15 kg
0 50 C for 2 hrs
Process wastewater
Centrifuge ML Distillation
147 kg
1st stage
Qty./batch
Output (kg)
Qty./batch
Input Reactor
(kg) Output from 50
5-amino-1-(n-methyl 1st stage
carbomyl) 100
imidazole-4-
carboxamide By product: 120
sodium tartrate
Water 600
40
Sodium nitrite Wastewater 646
Tartaric acid 80
Process residue 4
EIA
- 286 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Output
(kg)
Temozolomide 25
Qty./batch By product:
Input Reactor
(kg) azahypoxanthine
Output from 1st & 5- 25
stage 50 aminoimidazole-4-
carboxamide
Acetone 400
Carbon 5
Solvent acetone
recovered 385
from reaction
loss 15
EIA
- 287 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
Acetone & water are charged into the reactor. Then the output from 1st stage is
charged into the reactor and heated to 35 - 450C. Carbon is then charged & after
complete dissolution carbon is filtered and the reaction mass is cooled to 0 - 50 C
for 2 hrs and centrifuged and dried to get temozolomide.
CYCLE TIME
APPLICATIONS
Temozolomide is approved by the Food and Drug Administration (FDA) to treat two
different types of brain tumour in adults: anaplastic astrocytoma and glioblastoma
multiforme (GBM).
EIA
- 288 -
M/s. Shilpa Medicare Ltd. Unit I
2.6.4.28 Thalidomide
REACTION SCHEME
EIA
- 289 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 290 -
M/s. Shilpa Medicare Ltd. Unit I
Carbon
1 kg
Phthalic anhydride DMSO
10 kg 50 kg
L-glutamine N,N-carbomyl diimidazole
10 kg 15 kg
GL Reactor
Spent carbon
Filter
1 kg
Water
Filtrate
100 kg
Cooling & chilling
Phthalic acid &
Filter imidazole
24.92 kg
Filtrate Distillation
DMSO
recovered 40 kg
loss 10 kg
Process
residue
Centrifuge Distillation
0.08 kg
Process wastewater
100 kg
Drier
Thalidomide
10 kg
EIA
- 291 -
M/s. Shilpa Medicare Ltd. Unit I
Qty./batch
Qty./batch Output (kg)
Input Reactor
(kg)
Thalidomide 10
Phthalic anhydride 10
By products: 24.92
L-glutamine 10
phthalic acid &
imidazole
Dimethyl 50
sulphoxide Spent carbon 1
Solvent DMSO
N,N-carbomyl 15 recovered 40
diimidazole from reaction
loss 10
Carbon 1
Process residue 0.08
Water 100
Process wastewater 100
EIA
- 292 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
CYCLE TIME
APPLICATIONS
EIA
- 293 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
EIA
- 294 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
EIA
- 295 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
GL Reactor
Formic acid
0.63 kg
Filter Distillation
Process wastewater
10.24 kg
Acetic acid
10 kg GL Reactor
Acetic acid
recovered 8 kg
loss 2 kg
Filter Distillation
Process wastewater
0.3 kg
Drying
EIA
- 296 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Water
10 kg Carbon
0.1 kg
Hydrochloric acid
0.3 kg
GL Reactor
Spent carbon
Filter 0.1 kg
Filtrate
Centrifuge ML
Chill to 00 C Isomer of topotean
& 10-hydroxy
camptothecin
Drier Filtration 0.2 kg
Process wastewater
Topotecan HCl 10.6 kg
0.5 kg
EIA
- 297 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty./batch
Qty./batch Output
(kg)
Input (kg) Reactor
Output from 1
10-hydroxy 1st stage
camptothecin 1
10 Solvent acetic
Acetic acid
acid
10 recovered 8
Water
loss 2
Wastewater 10.54
EIA
- 298 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Output (kg)
Qty./batch
Input (kg) Reactor Topotecan HCl 0.5
Output from 1st
stage 1
By product: isomer
of topotean & 10- 0.2
Water 10 hydroxy
camptothecin
Hydrochloric 0.3
acid
Spent carbon 0.1
Carbon 0.1
Wastewater 10.6
EIA
- 299 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
1st stage
2nd stage
The output from 1st stage is dissolved in water and hydrochloric acid at 60-70°C, to
which carbon is added & filtered. The filtrate is cooled to 5-10°C for 12 hrs and
filtered, dried to get topotecan hydrochloride.
CYCLE TIME
APPLICATIONS
EIA
- 300 -
M/s. Shilpa Medicare Ltd. Unit I
REACTION SCHEME
EIA
- 301 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
2nd stage
EIA
- 302 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Methyl chloroacetate
22 kg
Toluene Water
50 kg 25 kg
Imidazole
10 kg GL Reactor
Potassium acetate
Layer separation
21 kg
Organic layer
Chill to 00 C Process wastewater
51 kg
Toluene
ML recovered 48 kg
Centrifuge Distillation
loss 2 kg
Process residue Isopropyl alcohol
Drying 0.1 kg recovered 21.9 kg
2nd stage
Phosphoric acid
Chlorobezene
14 kg
40 kg
Water
20 kg
GL Reactor
Carbon
Water layer
1 kg
Spent carbon
Filter 1 kg
Phosphorous
Filtrate (cooling)
trichloride 20 kg
Solvent chlorobenzene
Centrifuge Distillation recovered 38 kg
loss 2 kg
Process wastewater
Drier 57 kg
Zoledronic acid
5 kg
EIA
- 304 -
M/s. Shilpa Medicare Ltd. Unit I
1st stage
Qty./batch
Output (kg)
Qty./batch
Input Reactor
(kg) Output from 8
1st stage
Imidazole 10
50 By product: 21
Toluene
potassium acetate
Potassium carbonate 15
Solvent:
1) Toluene
Methyl 22 recovered 48
chloroacetate loss 2
Isopropyl alcohol 30 2) isopropyl 21.9
hydrochloride
alcohol recovered
Water 25
Process residue 0.1
Process 51
wastewater
EIA
- 305 -
M/s. Shilpa Medicare Ltd. Unit I
2nd stage
Qty./batch
Qty./batch Output (kg)
Input Reactor
(kg)
Zoledronic acid 5
Output from 1st
stage 8
Solvent
Phosphoric acid 14 chlorobenzene
recovered 38
Chlorobezene 40 from reaction
loss 2
Phosphorous 20
trichloride
Spent carbon 1
Water 20
Carbon 1 Wastewater 57
EIA
- 306 -
M/s. Shilpa Medicare Ltd. Unit I
PROCEDURE
The process involves 2 steps.
1st stage
Toluene, imidazole & potassium carbonate are charged into the reactor and
cooled to 10 to 15°C. Methyl chloroacetate is then added to the reaction
mixture at 10 to 15°C & maintained for 3 hrs. The reaction completion is
monitored by TLC. Water and isopropyl chloride are then added to the
reaction mixture at a temperature of 10 to 15°C and filtered to get 1st stage
output.
2nd stage
Chlorobenzene, output from 1st stage, phosphorus trichloride &
orthophosphoric acid are heated to 80 to 90°C for 8 hrs. The reaction
completion is monitored by TLC. Water is then added and water layer is
separated. Carbon is added to the water layer and filtered in hot condition.
The reaction mixture is then cooled to 0-5°C and filtered to get zoledronic
acid.
CYCLE TIME
Particulars Time (hrs)
st
1 stage 2nd stage
Reaction 6-8 12 - 14
Isolation & centrifugation 8 - 12 10 - 12
Solvent recovery 1-2 3-4
Total process time 15 - 22 25 - 30
APPLICATIONS
EIA
- 307 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 308 -
M/s. Shilpa Medicare Ltd. Unit I
Public consultation
Addressing all environmental concerns raised during public consultation in EIA report
EIA
- 309 -
M/s. Shilpa Medicare Ltd. Unit I
The treatment methods and the final disposal of each type of wastewater
generated is appended in the table 2.8 below
EIA
- 310 -
M/s. Shilpa Medicare Ltd. Unit I
Fig 2.8: Wastewater storage tanks at Unit I (20 KL capacity for each)
EIA
- 311 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 312 -
M/s. Shilpa Medicare Ltd. Unit I
WATER CONSUMPTION
55945 LPD
Process DM/
Washing QC, R&D Boiler blow Scrubber Domestic
effluent Softener Cooling Tower
effluent Wastes down effluent wastewater
11255 rejects bleed off
8000 LPD 700 LPD 1500 LPD 2000 LPD 1500 LPD 6,000 LPD
LPD 1000 LPD
Septic
tank &
25,955 LPD sent to Effluent Treatment Plant of Unit II soak pit
PSF tank
Biological Treatment
EIA
- 314 -
M/s. Shilpa Medicare Ltd. Unit I
Anaerobic digester
Salt send to TSDF
Sludge
Domestic Effluent Aeration tank -1
25 ,000 LPD ATFD
Clarifier -1 Feed to Boiler
MEE plant
Poly Dosing
EIA
- 315 -
M/s. Shilpa Medicare Ltd. Unit I
The quantity of water required and wastewater discharged during the process of manufacture of each of the products
is tabulated below.
Table 2.9 A: Product-wise water consumption and effluent discharge
No. of WASTEWATER
WATER CONSUMPTION
Sl. batches DISCHARGE
Product Stage
No. per
kg/batch kg/month kg/batch kg/month
month
1 Acebrophylline I 700 8400 12 735 8820
I 2000 20000 2190 21900
2 Ambroxol HCl 10
II 25 250 125 1250
I 2000 14000 2571 17997
3 Buflomedil HCl 7
III 500 3500 555.3 3887.1
4 Nifedipine I 0 0 2 458.49 916.98
I 5025 30150 3381 20286
5 Phenyl ephrine HCl II 5200 31200 6 6698 40188
III 1682 10092 3076 18456
I 1250 5000 1325 5300
6 Sildenafil citrate 4
II 1250 5000 1857.5 7430
7 Ticlopidine HCl III 250 2000 8 510 4080
II 0 0 415 14940
III 600 21600 1628.4 58622.4
8 Ursodeoxycholic acid IV 250 9000 36 0 0
V 300 10800 395 14220
VI 300 10800 169.25 6093
I 10 20 12 24
9 Anastrozole II 4 8 2 12 24
III 10 20 12 24
EIA
- 316 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 317 -
M/s. Shilpa Medicare Ltd. Unit I
Note:
Considering no. of working days/month = 25
1. Daily process water consumption = 2,06,106.308/25 = 8,244.25 LPD Or say 8,245 LPD
2. Daily process effluent discharge = 2,81,297.6/25 = 11,251.904 Or say 11,255 LPD.
EIA
- 318 -
M/s. Shilpa Medicare Ltd. Unit I
Various solvents are used during the process of manufacture of APIs &
Intermediates. Details of solvents recovered and recycled are in the 2.10 table.
EIA
- 319 -
M/s. Shilpa Medicare Ltd. Unit I
Iso propyl
1260 0 0 0
alcohol HCl
Toluene 2100 2065 35 0
Isopropyl
II 3000 2970 30 0
4 Nifedipine alcohol
III Methanol 5400 5360 40 0
Toluene 17082 16920 60 102
Ethyl acetate 6030 5700 330 0
n-Hexane 4020 3870 90 0
Iso propyl
I
alcohol HCl
(recovered 3306 2550 0 660
IPA; spent
IPA+hexane)
Methanol
(spent
II methanol + 10920 10500 54 900
toluene comes
from process)
Phenyl ephrine Isopropyl
5 4032 1980 36 2016
HCl alcohol
Acetic
anhydride
(recovered
III
acetic
9270 8700 0 0
anhydride +
ammonia
liquid +
tartaric acid)
Methanol 4020 3000 0 5946
Acetone 5040 1080 0 0
IV Iso propyl
alcohol (IPA) 1200 0 0 0
HCl
Methylene di-
Sildenafil I 2000 1600 400 0
6 chloride
citrate
III Acetone 6000 5920 80 0
I Toluene 5200 5120 80 0
Acetone 19800 19600 200 0
II Methylene di-
5600 5480 120 0
chloride
7 Ticlopidine HCl
Toluene 4800 4760 40 0
Methanol 1240 1216 24 0
III
Iso propyl
1600 1284 0 0
alcohol HCl
EIA
- 320 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 321 -
M/s. Shilpa Medicare Ltd. Unit I
Methylene di-
chloride 2500 2200 300 0
(MDC)
Methanol 3500 3300 200 0
Acetonitrile 1000 700 300 0
I
Ethyl acetate 1500 1300 200 0
Methylene di
chloride 1200 1000 200 0
Docetaxel
13 (MDC)
trihydrate II
Acetone 1200 1100 100 0
Petroleum
3000 2800 200 0
ether
III Methanol 1200 1000 200 0
Methylene di
chloride 2112 2880 0 0
I (MDC)
Ethanol 631.2 0 0 0
Acetone 316 0 0 0
Methylene di
chloride 2112 1920 192 0
II
(MDC)
14 Epirubicin HCl
n-Hexane 523.2 400 123.2 0
Acetone 758.4 4640 0 0
Methanol 632 0 0 0
Dioxane 560 0 0 0
III n-Hexane 784 0 0 0
Methylene di
chloride 2112 0 0 0
(MDC)
Thionyl
I 30 12 0 0
15 Gefitinib chloride
II Ethyl acetate 270 264 6 0
I Methanol 9750 9250 500 0
Gemcitabine
16 II Methanol 7500 7000 500 0
HCl
III Acetic acid 20000 19750 0 0
Methylene
Imatinib dichloride 1000 950 50 0
17 I
mesylate (MDC)
Methanol 500 470 30 0
Chloroform 700 680 20 0
I
Hexane 100 95 5 0
Irinotecan HCl Ethanol 10 18 2 0
18
trihydrate Dimethyl
II
formamide 10 0 0 0
(DMF)
EIA
- 322 -
M/s. Shilpa Medicare Ltd. Unit I
I Methanol 4 3 1 0
Dimethyl
19 Lenalidomide
II sulphoxide 5 4.9 0.1 0
(DMSO)
Aceto nitrile 75 72.5 2.5 0
I
Hexane 15 12.5 1.5 0
20 Letrozole Ethyl acetate 50 47.5 2.5 0
II Dimethyl
15 13.5 1.5 0
formamide
Methanol 156 150 6 0
I
Ethyl acetate 225 220 5 0
Methylene
dichloride 174.5 540 0 0
(MDC)
II
Acetone 52.7 0 0 0
21 Paclitaxel Petroleum
327 0 0 0
ether
III Methanol 93.6 80 13.6 0
MDC 48.5 45 3.5 0
Acetone 13.8 89 1.8 0
IV
Petroleum
77 0 0 0
ether
Methylene
dichloride 385 308 77 0
(MDC)
I
22 Pemetrexed Dimethyl
formamide 102 95 7 0
(DMF)
III Acetone 307.8 300 7.8 0
23 Temozolomide II Acetone 1600 1540 60 0
Dimethyl
24 Thalidomide I sulphoxide 250 200 50 0
(DMSO)
25 Topotecan HCl I Acetic acid 100 80 20 0
Toluene 50 48 2 0
Isopropyl
26 Zoledronic acid I
alcohol 30 21.9 0 0
hydrochloride
TOTAL 789151 920690 11525 10250
EIA
- 323 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 324 -
M/s. Shilpa Medicare Ltd. Unit I
There are three solvent storage tanks one above the ground to store
butanol, toluene, isopropyl alcohol etc. & two below the ground level
acetone, ethyl acetate & methanol etc.
The above ground solvent storage tank farm is of 49.3 x 38.25 m. This area
has six tanks of 30 KL storage capacity each and is provided with protective
dyke wall of 18.46 X 13.26 X 1.3 m (all-around to contain leakages or
spillages if any within the designated area.
Below ground solvent storage tank farms are of 13.65 m X 14.5 m and
14.56 X 11.3 m area.
License has been obtained from PESO (Petroleum and Explosives Safety
Organization).
The spilt solvents are collected and pumped back into the tanks.
Cooling
tower of
Raichur
Thermal
Power
Plant
EIA
- 325 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 326 -
M/s. Shilpa Medicare Ltd. Unit I
All centrifuge vents are connected to the scrubber for controlling of fugitive
emissions. In addition, measures taken to control fugitive emissions for raw
materials & solvents are tabulated below.
Table 2.11: Measures to control evaporation losses and fugitive emissions for
raw materials and solvents
Sl. Mode of Safety systems Measures to avoid loss and
no. storage control of evaporation
1 Above Breather valve followed by Enclosed dispensing system.
ground flame arrester. Pumps with double mechanical
Non-contact level indicator. seal.
2 Drums No dispensing in storage area. No dispensing of solvent is
Secondary containment carried out in storage area.
Spill and leak control kit Required quantities are issued
Organic vapour detectors in sealed drums.
Stored at required
temperature as per MSDS
EIA
- 327 -
M/s. Shilpa Medicare Ltd. Unit I
The rainwater is diverted into infiltration pits, specially prepared for the
purpose of groundwater recharge at various locations within the campus.
The total amount/quantity of water i.e. received in the form of rainfall over an
area is called the rain water endowment of that area, out of which the amount
of water that can be effectively harvested is called the rain water harvesting
potential.
Rain water harvesting potential = rainfall (mm) x collection efficiency
The collection efficiency accounts for the fact that all the rain water falling
over an area cannot be effectively harvested due to losses on account of
evaporation, spillage or runoff etc.
According to the data available from the Indian Meteorological Department,
the average annual rainfall around month of September for the year 2017 = 264
mm
Assuming that about 85% rainfall can be effectively used for recharging
Number of rainy days = 9.3
Therefore the I.R = 264/9.3 = 24.1 mm/day or 0.0241 m/day or 0.024 m/day
The amount of storm water that the landscaped area will produce can be
determined by considering the impermeability factor to be 0.3.
Q = 0.024 x 33,591.25 m2 x 0.3
= 242 m3/day
The amount of storm water that the paved area will produce can be
determined by considering the impermeability factor to be 0.9.
Q = 0.024 x 11,706.26 m2 x 0.9
= 253 m3/day
Groundwater recharge pits of 2.5 m deep filled with graded media comprising
of boulder at bottom and with coarse aggregates to facilitate percolation to
recharge ground water table are provided at different locations within the
premises.
EIA
- 328 -
M/s. Shilpa Medicare Ltd. Unit I
The major air pollution sources from the industry are DG sets and boilers apart
from the process sections. These sources are provided with suitable air
pollution control equipments and stacks of adequate height so as to disperse
the emanating flue gases without affecting the ground level concentrations.
EIA
- 329 -
M/s. Shilpa Medicare Ltd. Unit I
Table 2.12: Air pollution sources, fuel consumption and chimney height details
SI. Stack attached to Fuel Fuel consumption Number Stack/s height Air pollution Predicted
no. used of control unit emissions
stacks
1 Process section - - 4 3 m ARL for each Packed Acid
column mist/
scrubbers VOCs
4 no.s
2 Steam boilers 4 TPH 2 no.s Coal/ 900 kg/hr coal 1 30 m AGL combined Multicyclone SO2, NOx ,
Briquette or stack - 2 no.s SPM
1050 kg/hr briquette
for each boiler
3 D.G. sets - 325 kVA 2 no.s HSD 76 L/hr for each DG set 2 5 m ARL for each Stack SO2, NOx ,
DG set SPM
Note:
HSD High Speed Diesel
The stack heights are provided as stipulated in the Consent to Operate (CTO) no. PCB/HPI/053/2015-16/1245 dated
8th October 2015.
EIA
- 330 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 331 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 332 -
M/s. Shilpa Medicare Ltd. Unit I
4) Accoustics - DG
Adequate port holes with access platform are provided as per KSPCB guidelines
for flue gas analysis. The same is shown in fig 2.16.
Also all stacks are analysed monthly for the parameters stipulated in CTO no.
PCB/HPI/053/2015-16/1245 dated 8th October 2015. Sample analysis reports
are enclosed as Annexure A3.
Scrubber
a) Scrubber details:
EIA
- 333 -
M/s. Shilpa Medicare Ltd. Unit I
b) Blower:
Type : Backward curve SISW
Casing : PP/FRP with isopthalic resin
Impeller : MS/FRP with bisphenol resin
Capacity : 18000 CMH
Stat. Pressure : 150 mmwg
Motor : 20 HP FLP 1440 RPM
Make : Kirloskar or CG
Drive : Belt
c) Ducting details:
MOC : PP/FRP
Sizes : 250, 350, 450 & 700 mm dia
Ducting includes straight lengths, elbows, T-sections & reducers
e) Pump:
Make : Antico
Model : 130 CT
Drive Motor : 3 HP 2900 RPM FLP
EIA
- 334 -
M/s. Shilpa Medicare Ltd. Unit I
DG sets are the major noise generating sources for which acoustic enclosures
are present.
Handling and conveying of raw materials and semi-finished components
to different operations can be a source of noise pollution. This is
controlled by regular maintenance.
Also ambient noise levels will be ensured within the ambient standards by
inbuilt design of mechanical equipment viz. dampners, periodic maintenance,
accoustic buildings apart from vegetation (tree plantations) along the periphery
and at various locations within the industry premises.
The details of the quantity of solid waste generated from the industry and
disposal options are shown in the following table.
EIA
- 335 -
M/s. Shilpa Medicare Ltd. Unit I
The quantities of hazardous waste generated from various processes are shown
in the table 2.14.
Note:
EIA
- 336 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 337 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 338 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 339 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 340 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 341 -
M/s. Shilpa Medicare Ltd. Unit I
Apart from products, by-products and used solvents few other materials are also generated during manufacturing
process. They are segregated and stored in a designated area for further disposal/management. Details are tabulated
below.
Sl.
Product Stage Other output kg/month Mode of storage Disposal
No.
1 Buflomedil HCl III Caustic lye 700 HDPE drums Used for neutralization
2 Nifedipine III Nitro phenyl pyridine 210 HDPE carboys Recycled (in-house)
Sodium carbonate
I 16062 Storage tank Used for neutralization
Phenyl ephrine solution
3
HCl Phenyl ephrine isomer
IV 126 HDPE carboys Recycled (in-house)
salt
Hydrobromic acid -
4 Anastrozole I 9.2 HDPE carboys Recycled (in-house)
succinamide
Impurity-A (2,3-epoxy-
2-methyl-N-[4-cyano-3- Cement industry for
5 Bicalutamide I 40 HDPE bags
trifluoromethyl)phenyl] co-processing in kiln
propanamide
Disposed to recyclers
I Potassium chloride 207.5 HDPE sacs for making fertilizers
containing potassium
6 Carboplatin Sent for recovery of
Silver iodide 114.2 HDPE carboys
silver
II Recycled to boiler/
Water 5000 Storage tank Chilling plant brine
makeup
EIA
- 342 -
M/s. Shilpa Medicare Ltd. Unit I
Disposed to recyclers
I Potassium chloride 4 HDPE bags for making fertilizers
11 Oxaliplatin containing potassium
Sent for recovery of
II Silver chloride 8.65 HDPE carboys
silver
2.9 ASSESSMENT OF NEW AND UNTESTED TECHNOLOGY FOR THE RISK OF TECHNOLOGICAL FAILURE
The industry is involved in the manufacture of APIs and intermediates. The manufacturing process for these products is
a tried and tested method. Therefore, there is no risk of technological failure. In addition to this, the facility is being
backed up by the R & D centre where there are continuous efforts for optimization of the process to take care of
technological failures if any.
EIA
- 343 -
M/s. Shilpa Medicare Ltd. Unit I
CHAPTER 3
STUDY AREA: An area, covering 10 km radial distance with the project site at the
centre is considered for study. Topo map showing study area is enclosed as
Annexure A11.
METHODOLOGY:
Studies were conducted to know the status of various environmental attributes, viz.
climatic and atmospheric conditions, air, water, noise, soil, land use pattern,
ecological, socio-economic environment. It involved conducting field studies, socio-
economic survey among the people. Secondary data was collected from
State/Central Government, semi-Government and public-sector organizations and
verified for correctioness.
EIA
- 344 -
M/s. Shilpa Medicare Ltd. Unit I
Project Site
EIA
- 345 -
M/s. Shilpa Medicare Ltd. Unit I
Assessment of the micro and macro meteorology is important from the standpoint
of understanding the nature and extent of air pollution in the study area. Climate
has an important role in the build-up of pollution levels. The climatic condition of
the area may be classified as moderately or seasonally dry, tropical or temperate
savannah climate with four seasons in a year. Winter is critical for air pollution
build-up because of frequent calm conditions with temperature inversions
resulting in poor atmospheric mixing, natural ventilation and high emission loads.
The classification of months according to the seasons is given in the following table.
Season Period
Summer/Pre-monsoon March to May
Monsoon June to September
Post monsoon October to December
Winter January to February
EIA
- 346 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 347 -
M/s. Shilpa Medicare Ltd. Unit I
3.2.1.1 TEMPERATURE
The mean maximum temperature is observed at 40.9°C in the month of April
and the mean minimum temperature at 16.2°C is observed in the month of
December. In the summer season the mean minimum temperature is observed
during the month of March (22.7°C). During the monsoon the mean maximum
temperature is observed to be 34.8°C in the month of June with the mean
minimum temperature at 23.3°C during September. By the end of September
with the onset of post monsoon season (October - December), day
temperatures drop slightly with the mean maximum temperature at 30.8°C in
November and mean minimum temperature at 16.2°C in December. The values
are presented in table 3.1.
3.2.1.3 RAINFALL
The maximum annual rate of precipitation over this region ranges between 0 to
248.3 mm.
3.2.1.5 WIND
The data on wind patterns are pictorially represented by means of wind rose
diagrams for the entire year and for different seasons in fig 3.2. Predominant
wind directions in different seasons are shown in table 3.2.
EIA
- 348 -
M/s. Shilpa Medicare Ltd. Unit I
NORTH
15%
12%
9%
6%
3%
WEST EAST
WIND SPEED
(m/s)
>= 11.1
8.8 - 11.1
5.7 - 8.8
SOUTH
3.6 - 5.7
2.1 - 3.6
0.5 - 2.1
Calms: 11.51%
Samrakshan
EIA
- 349 -
M/s. Shilpa Medicare Ltd. Unit I
NORTH
20%
16%
12%
8%
4%
WEST EAST
WIND SPEED
(m/s)
>= 11.1
8.8 - 11.1
5.7 - 8.8
SOUTH
3.6 - 5.7
2.1 - 3.6
0.5 - 2.1
Calms: 14.09%
Samrakshan
EIA
- 350 -
M/s. Shilpa Medicare Ltd. Unit I
NORTH
30%
24%
18%
12%
6%
WEST EAST
WIND SPEED
(m/s)
>= 11.1
8.8 - 11.1
5.7 - 8.8
SOUTH
3.6 - 5.7
2.1 - 3.6
0.5 - 2.1
Calms: 2.22%
Samrakshan
EIA
- 351 -
M/s. Shilpa Medicare Ltd. Unit I
NORTH
25%
20%
15%
10%
5%
WEST EAST
WIND SPEED
(m/s)
>= 11.1
8.8 - 11.1
5.7 - 8.8
SOUTH
3.6 - 5.7
2.1 - 3.6
0.5 - 2.1
Calms: 10.10%
Samrakshan
EIA
- 352 -
M/s. Shilpa Medicare Ltd. Unit I
NORTH
20%
16%
12%
8%
4%
WEST EAST
WIND SPEED
(m/s)
>= 11.1
8.8 - 11.1
5.7 - 8.8
SOUTH
3.6 - 5.7
2.1 - 3.6
0.5 - 2.1
Calms: 28.88%
Samrakshan
EIA
- 353 -
M/s. Shilpa Medicare Ltd. Unit I
Raichur district. These formations are grouped under hard rock, as they do not
have any primary porosity. However, secondary porosity is developed due to
faults, fractures, joints, and due to weathering, which has improved
permeability and water yielding capacity of these rocks. Ground water occurs
under water table conditions in the weathered and jointed hard rock, and
under confined to semi confined conditions in the fractured rock. Since the
district is covered predominantly by black cotton soils, which inhibit
percolation and circulation of water, there are pockets of poor quality ground
water in the area. The hydrogeology of the district is shown in the figure 3.3.
The depth to water level in general varies from 0.65-m BGL to 10.70 m BGL in
the area during the pre-monsoon period (May) and from 0.05 m BGL to 11.00 m
BGL during the post monsoon (Nov) period.
Aquifers, the water bearing formations, in the district have been classified into
two types
EIA
- 354 -
M/s. Shilpa Medicare Ltd. Unit I
The drainage pattern is highly dendritic in nature (as shown in fig 3.4) and has
been altered due to the irrigation practices in the area.
EIA
- 355 -
M/s. Shilpa Medicare Ltd. Unit I
PROJECT SITE
EIA
- 356 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 357 -
M/s. Shilpa Medicare Ltd. Unit I
PROJECT SITE
EIA
- 358 -
M/s. Shilpa Medicare Ltd. Unit I
Fig 3.5 shows google map with all the sampling locations.
Details of sampling locations are tabulated in Table 3.3
EIA
- 359 -
M/s. Shilpa Medicare Ltd. Unit I
Fig 3.5: Google map showing sampling locations for environmental attributes
EIA
- 360 -
M/s. Shilpa Medicare Ltd. Unit I
Summary of the average concentrations of pollutants at seven locations within 10 km of the project site are given in
the table 3.4. Ambient air quality standards stipulated by MoEF as per the notification dated 16th November 2009 for
industrial, residential and rural areas is shown table 3.5.
EIA
- 361 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 362 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 363 -
M/s. Shilpa Medicare Ltd. Unit I
5 Carbon Week 1 (1st to 0.18 0.15 0.3 0.1 0.19 0.14 0.2
monoxide 10th March 2018) 0.2 0.17 0.18 0.19 0.17 0.16 0.18
(CO), mg/m 3 Week 2 (11th to 0.18 0.18 0.18 0.16 0.19 0.16 0.12
17th March 2018) 0.21 0.17 0.15 0.15 0.19 0.12 0.14
Week 3 (18th to 0.2 0.16 0.22 0.16 0.14 0.14 0.15
24th March 2018) 0.21 0.16 0.17 0.15 0.13 0.15 0.15
Week 4 (25th to 0.16 0.16 0.19 0.14 0.16 0.1 0.12
31st March 2018) 0.14 0.17 0.18 0.2 0.17 0.13 0.15
Week 1 (1st to 0.16 0.18 0.12 0.22 0.2 0.18 0.14
7th April 2018) 0.22 0.18 0.19 0.21 0.19 0.16 0.15
Week 2 (8th to 0.21 0.18 0.22 0.17 0.15 0.16 0.12
14th April 2018) 0.22 0.16 0.18 0.14 0.14 0.15 0.14
Week 3 (15th to 0.23 0.19 0.2 0.18 0.17 0.19 0.16
21st April 2018) 0.2 0.18 0.15 0.16 0.15 0.14 0.15
EIA
- 364 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 365 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 366 -
M/s. Shilpa Medicare Ltd. Unit I
Table 3.5: Ambient air quality standards MoEF as per the notification dated
16th November 2009 for industrial, residential & rural areas
Air quality parameter Concentration
24 hrs Annual
1 Particulate matter (size less than 10 µm), 100 60
(PM10), µg/m3
2 Particulate matter (size less than 2.5 µm), 60 40
(PM2.5),µg/m3
3 Sulfur-di-oxide (SO2), µg/m3 80 50
4 Nitrogen dioxide (NO x ), µg/m3 80 40
3
5 Carbon monoxide (CO), mg/m 4 1 hr 2 8 hrs
Note:
24 hourly or 08 hourly or 01 hourly monitored values, as applicable, shall be
complied with 98% of the time in a year. 2% of the time, they may exceed the
limits but not on two consecutive days of monitoring.
Whenever and wherever monitoring results on two constitutive days of
monitoring exceed the limits specified above for the respective category, it
shall be considered adequate reason to institute regular or continuous
monitoring and further investigation.
OBSERVATIONS
The monitored values are within the limits specified by MoEF (as per the
notification dated 16th November 2009 for industrial, residential and rural
areas) at all the sampling locations.
EIA
- 367 -
M/s. Shilpa Medicare Ltd. Unit I
NORTH
20%
16%
12%
8%
4%
WEST EAST
2017
WIND SPEED
(m/s)
>= 11.1
8.8 - 11.1
5.7 - 8.8
SOUTH
3.6 - 5.7
2.1 - 3.6
0.5 - 2.1
Calms: 14.09%
Samrakshan
EIA
- 368 -
M/s. Shilpa Medicare Ltd. Unit I
Hourly noise levels are shown in table 3.6 A, B & C and day equivalent of noise
levels and CPCB standards are shown in table 3.7.
EIA
- 369 -
M/s. Shilpa Medicare Ltd. Unit I
Table 3.6 A: Noise level monitoring, data analysis results March 2018
Sl. Location Time of Time (in hrs) Noise Time (in Noise Time (in Noise Time (in hrs) Noise Std.
No. the day level hrs) level hrs) level level
in in in in
dB(A) dB(A) dB(A) dB(A)
Leq Leq Leq Leq
5-3-2018 13-3-2018 19-3-2018 24-3-2018
1 Project site Morning 9.30-9.45 72 8.15-8.30 69 8.30-8.45 74 9.45-10.00 74 75
Afternoon 13.45-14.00 70 13.00-13.15 72 13.15-13.30 72 14.30-14.45 72
Evening 17.30-17.45 73 17.15-17.30 72 17.00-17.15 70 17.45-18.00 70
Night 3.15-3.30 67 2.00-2.15 68 2.15-2.30 67 1.30-1.45 67 70
2 Hegsanhalli Morning 8.45-9.00 59 8.00-8.15 58 8.15-8.30 58 9.30-9.45 60 55
Afternoon 14.00-14.15 54 14.15-14.30 59 14.45-15.00 59 14.00-14.15 58
Evening 17.15-17.30 56 17.30-17.45 54 17.00-17.15 54 17.15-17.30 59
Night 1.30-1.45 58 1.45-2.00 59 1.30-1.45 55 1.45-2.00 55 50
3 Deosugur Morning 9.30-9.45 58 9.30-9.45 61 9.30-9.45 57 9.00-9.15 59 55
Afternoon 14.00-14.15 62 14.30-14.45 58 14.00-14.15 60 14.30-14.45 58
Evening 17.45-18.00 54 17.15-17.30 57 17.00-17.15 56 17.15-17.30 61
Night 1.45-2.00 60 1.15-1.30 59 1.45-2.00 59 1.30-1.45 54 50
4 Chicksugur Morning 9.30-9.45 61 9.30-9.45 57 8.30-8.45 59 8.00-8.15 58 55
Afternoon 14.00-14.15 58 14.00-14.15 61 14.15-14.30 57 14.45-15.00 56
Evening 17.00-17.15 54 17.30-17.45 56 17.00-17.15 58 17.15-17.30 54
Night 2.15-2.30 55 2.00-2.15 54 1.15-1.30 53 1.45-2.00 59 50
5 Kadlur Morning 8.30-8.45 57 9.30-9.45 59 9.30-9.45 63 9.30-9.45 58 55
Afternoon 14.00-14.15 56 14.15-14.30 56 14.00-14.15 53 14.45-15.00 54
Evening 17.45-18.00 54 17.00-17.15 53 16.30-16.45 54 17.15-17.30 57
Night 1.45-2.00 53 1.45-2.00 54 1.45-2.00 51 1.30-1.45 59 50
EIA
- 370 -
M/s. Shilpa Medicare Ltd. Unit I
Table 3.6 B: Noise level monitoring, data analysis results April 2018
Sl. Location Time of Time (in hrs) Noise Time (in Noise Time (in Noise Time (in hrs) Noise Std.
No. the day level hrs) level hrs) level level
in in in in
dB(A) dB(A) dB(A) dB(A)
Leq Leq Leq Leq
2-4-2018 9-4-2018 16-4-2018 24-4-2018
1 Project site Morning 8.30-8.45 69 8.15-8.30 69 8.30-8.45 74 9.45-10.00 74 75
Afternoon 13.15-13.30 72 13.00-13.15 72 13.15-13.30 72 14.30-14.45 72
Evening 17.00-17.15 71 17.15-17.30 72 17.00-17.15 70 17.45-18.00 70
Night 2.15-2.30 68 2.00-2.15 68 2.15-2.30 67 1.30-1.145 67 70
2 Hegsanhalli Morning 8.15-8.30 57 8.00-8.15 58 8.15-8.30 58 9.30-9.45 60 55
Afternoon 14.30-14.45 53 14.15-14.30 59 14.45-15.00 59 14.00-14.15 58
Evening 17.00-17.15 54 17.30-17.45 54 17.00-17.15 54 17.15-17.30 59
Night 1.15-1.30 59 1.45-2.00 59 1.30-1.45 55 1.45-2.00 55 50
EIA
- 371 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 372 -
M/s. Shilpa Medicare Ltd. Unit I
Table 3.6 C: Noise level monitoring, data analysis results May 2018
Sl. Location Time of Time (in hrs) Noise Time (in Noise Time (in Noise Time (in hrs) Noise Std.
No. the day level hrs) level hrs) level level
in in in in
dB(A) dB(A) dB(A) dB(A)
Leq Leq Leq Leq
3-5-2018 12-5-2018 21-5-2018 27-5-2018
1 Project site Morning 08.15-08.30 68 08.15-08.30 68 08.30-08.45 73 09.00-09.15 72 75
Afternoon 13.00-3.15 71 13.00-13.15 71 13.15-13.30 72 13.30-13.45 70
Evening 17.15-17.30 69 17.15-17.30 69 17.00-17.15 70 17.30-17.45 69
Night 02.00-02.15 67 02.00-02.15 67 02.15-02.30 69 02.30-02.45 68 70
2 Hegsanhalli Morning 08.30-08.45 56 08.30-8.45 56 08.00-08.15 61 09.15-09.30 62 55
Afternoon 14.45-15.00 62 14.45-15.00 62 14.15-14.30 66 14.15-14.30 68
Evening 17.15-17.30 52 17.15-17.30 52 17.30-17.45 52 17.30-17.45 65
Night 01.30-01.45 59 01.30-01.45 69 01.15-01.30 54 01.15-01.30 55 50
3 Deosugur Morning 09.00-09.15 59 9.00-09.15 59 09.15-09.30 59 09.30-09.45 62 55
Afternoon 14.45-15.00 61 14.45-15.00 61 14.30-14.45 61 14.15-14.30 66
Evening 17.00-17.15 55 17.00-17.15 55 17.15-17.30 54 17.30-17.45 67
Night 1.45-2.00 61 01.45-02.00 61 1.00-01.15 61 01.15-01.30 63 50
4 Chicksugur Morning 9.15-09.30 58 09.15-09.30 58 8.15-8.30 59 08.30-08.45 54 55
Afternoon 14.15-14.30 64 14.15-14.30 64 14.00-14.15 57 14.15-14.30 56
Evening 17.30-17.45 54 17.30-17.45 54 17.15-17.30 61 17.30-17.45 53
Night 1.15-1.30 66 1.15-01.30 66 1.00-1.15 58 1.15-1.30 60 50
5 Kadlur Morning 09.45 - 56 9.45-10.00 56 9.15-9.30 61 9.00-9.15 58 55
10.00
Afternoon 14.00 - 54 14.00-14.15 52 14.30-14.45 54 14.30-14.45 54
14.15
EIA
- 373 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 374 -
M/s. Shilpa Medicare Ltd. Unit I
OBSERVATIONS
The field observations during the study period indicate that the ambient noise
levels in both industrial and residential areas are within the CPCB limits during
most time of the day and night. However on few days, at certain times the
noise levels exceed the limits stipulated, the reason for exceedance is
vehicular/truck movements.
The range of noise levels observed during the monitoring period are tabulated
below
Range of
Sl. Environment Time of noise Limit
Location
No. setting day levels dB(A) Leq
dB(A) Leq
Project site Industrial Morning 68-74
Afternoon 70-72 75
1
Evening 69-73
Night 67-69 70
Hegsanhalli Morning 56-62
Afternoon 53-68 55
2
Evening 52-65
Night 54-69 50
Deosugur Morning 57-62
Afternoon 58-66 55
3
Evening 54-67
Night 54-63 50
Chicksugur Morning 54-62
Afternoon 56-64 55
4
Evening 53-61
Night 53-66 50
Residential
Kadlur Morning 56-63
Afternoon 52-56 55
5
Evening 52-57
Night 51-59 50
Krishana Morning 55-58
Village Afternoon 54-56 55
6
Evening 54-58
Night 50-52 50
Muraharidoddi Morning 54-58
Afternoon 54-58 55
7
Evening 53-57
Night 50-52 50
EIA
- 375 -
M/s. Shilpa Medicare Ltd. Unit I
The major river of Raichur district is the Krishna. This is located within the
study area. To assess the prevailing status of surface water quality, samples
from Krishna river upstream & downstream, Rajasab Talav/ Merched Kere and
Konad Halla were collected and analysed. The same is presented in tables 3.8
A, B & C.
EIA
- 376 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 377 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 378 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 379 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 380 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 381 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 382 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 383 -
M/s. Shilpa Medicare Ltd. Unit I
OBSERVATIONS
The designated best use of surface water samples analysed are tabulated below
Sl. Class of Designated best use
Surface water
No. water
1 Krishna river upstream of industry C - Drinking water source after conventional treatment and
2 Krishna river downstream of industry disinfection.
C-D
3 Rajasab Talav/ Merched Kere
4 Konad Halla D - Propogation of wildlife and fisheries
EIA
- 384 -
M/s. Shilpa Medicare Ltd. Unit I
Ground water is the major source of water in the study area, occurring under water table conditions in the weathered
mantle of granite gneisses and in the joints, cracks and crevices of the basement rock. The depth of water is also
dependent on topography and varies depending on the depth of weathering.
The results of the ground water analysis collected from the project site and other locations within the study area are
appended in tables 3.9 A, B & C.
10 Sulphate as mg/L 200 400 370 350.6 300 354 250.4 67 144
SO4
11 Iron as Fe mg/L 0.3 No <0.01 <0.01 <0.01 <0.01 <0.01 <0.02 <0.02
Relaxation
12 Nitrate as mg/L 45 No 0.4 ND ND 1.5 ND 37 99
NO3 Relaxation
13 Sulphide mg/L 1.2 1.1 1.5 1 1 BDL BDL
14 Zinc mg/L 5 15 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
15 Magnesium as mg/L 30 100 44.7 25.4 6.2 20.6 46 7.29 38.2
Mg
16 Lead mg/L 0.05 No BDL(<0.01) BDL(<0.01) BDL(<0.01 BDL(<0.01) BDL(<0.01) <0.01 <0.01
Relaxation )
17 Aluminium mg/L <0.01 <0.01 <0.01 <0.01 <0.01 0.01 0.01
18 Sodium as Na mg/L 10.2 11.8 8.8 12 11 265 90
19 Potassium as mg/L 5 4.8 4.2 5.2 4.6 10.7 34
K
EIA
- 386 -
M/s. Shilpa Medicare Ltd. Unit I
relaxation
3 Turbidity NTU 1 5 2.6 3.7 2.5 0.46 2.1 <1 <1
CHEMICAL PARAMETERS
4 Calcium as Ca mg/L 75 200 42.6 149.6 168.2 40.6 83 62 60
5 Chloride as Cl mg/L 250 1000 440.2 277.9 360.8 360.4 248.9 206 279
6 Total mg/L 200 600 302 475.3 455 172.2 336.3 180 310
Hardness as
CaCO3
7 Alkalinity mg/L 200 600 470.3 219.2 340.9 528.6 310.6 435 449
8 Dissolved mg/L 500 2000 1680 1750 1820 1660 1750 1200 1230
Solids
9 Fluoride as F mg/L 1.0 1.5 1.2 0.7 0.5 0.6 0.52 0.9 0.01
10 Sulphate as mg/L 200 400 372.8 358 319.2 341.2 258.6 68 148
SO4
11 Iron as Fe mg/L 0.3 No <0.01 <0.01 <0.01 <0.01 <0.01 <0.02 <0.02
Relaxation
EIA
- 387 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 388 -
M/s. Shilpa Medicare Ltd. Unit I
OBSERVATIONS
All the parameters of the groundwater samples analysed are within the permissible limit specified under IS
10500:2012 even though few parameters such as turbidity, alkalinity, dissolved solids, total hardness, calcium,
magnesium, sulfates are more than the acceptable limits.
Fluoride at the project site is slightly higher than the acceptable limits ranging from 1.2-1.3 mg/L though less
than the permissible limit of 1.5 mg/L.
Nitrates at Muraharidoddi in Telangana after crossing river Krishna is more than the acceptable & permissible
limit of 45 mg/L specified ranging from 96-99 mg/L. Also, magnesium ranges from 37.6 38.8 mg/L which is
more than the acceptable limit of 30 mg/L though less than permissible limit of 100 mg/L. This village is
surrounded by agricultural fields where there is extensive use of fertilizers.
EIA
- 389 -
M/s. Shilpa Medicare Ltd. Unit I
The soil of Raichur district can be classified broadly into the following four types namely: mixed red and black soils,
medium black soils, deep black soils and red sandy soils.
EIA
- 390 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 391 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 392 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 393 -
M/s. Shilpa Medicare Ltd. Unit I
OBSERVATIONS
3.3.6 Ecology
Ecology is a branch of biology that deals with the relations of organisms with one
another and to their physical surroundings. Natural flora and fauna are important
features of the environment. They are organized into natural communities with
mutual dependencies among their members and show various responses and
sensitivities to physical environment. The integrated ecological thinking and planning
process is an urgent need in the context of natural environment's deterioration which
has a direct bearing on socio-economic development.
Ecological survey of the study area was carried out by actual field visits to observe
the various species of flora and fauna. Personal enquiries/discussion with local people
and forest department officials was also conducted to get a fair idea of the existing
ecological status.
The industry is located in designated industrial area of KIADB, Raichur. The impact
can be considered insignificant as the region consists of only skeletal vegetation like
grass and thorny shrubs with no rare and endangered species. The industrial activity is
limited only to the core zone and mitigative measures are implemented to contain
water, air and noise pollution. Hence, there shall be no damage to the flora and fauna
of the buffer zone.
When compared to the mega Raichur thermal power plant at the next compound, the
impact of M/s. Shilpa Medicare Ltd. Unit I is negligible in terms of wastewater, air
and solid waste pollution generation.
3.3.6.2 FLORA
Raichur district has 44 sq. km of forest area as per the State of Forest Report 2017,
published by the Forest Survey of India. This accounts for just 2.2% of the total
geographical area. Hence, the districts forest wealth is almost nil. In the study area
the weeds and climbers are found. They neither possess any economic value nor are
they nutritious. The different types of grass growth are not nourishing even to feed
the cattle, but these are used for making thatch roof for Kutcha houses in the
EIA
- 394 -
M/s. Shilpa Medicare Ltd. Unit I
villages. Bellary jali is the predominant shrub. The shrubs are mostly used for fencing
purposes.
In Mahbubnagar district, Telangana which falls in the study area, thorny shrubs,
deciduous (Hardwickia binata) and bamboo type of vegetation is found.
Floral composition in the study area is presented in the table 3.11 below.
Source: District Census Handbook, Raichur & Mahbubnagar validated by field visits.
EIA
- 395 -
M/s. Shilpa Medicare Ltd. Unit I
3.3.6.3 FAUNA
Since the forests in Raichur district are of mixed dry deciduous type consisting of open
scrub jungles, animals belonging to the family of big game variety are not seen. It
seems that few centuries ago, tigers and leopards had their abode in these forests and
sight of these animals was rare. Presently such encounters of these animals are
almost found nil. Animals sighted in these forests are wolves, jackals and deer. Plenty
of snakes, scorpions and lizards are found in these jungles. Among the snakes, the
cobra, Russels viper and small water snakes are found not only in the forest but also
in all regions of the district. Among the game bird, partridges and quails, along the
rivers and streams, the wild duck, teal and waterfowl are also seen in the district.
The composition of fauna in the study area is presented in the table 3.12 below.
EIA
- 396 -
M/s. Shilpa Medicare Ltd. Unit I
The growth of industrial sectors and infrastructure development in and around the
agricultural area i.e. villages and semi-urban settings and towns is bound to create
certain socio-economic impacts on the local populace. The impacts may be either
positive or negative depending on the nature of development. To assess such impact
it is necessary to know the existing socio-economic order of the study area, which will
be helpful in improving the overall quality of life.
The information collected from the secondary sources are from the district census
statistical hand books and the records of the National Informatics Centre, New Delhi
in respect of the population, infrastructure facilities available and the occupational
structures of the study area.
The socio-ecological aspect of the study include the agro based economy, industry
based economy and occupational structure of the workers.
The distribution of population in the study area as per census record of 2011 is
presented in table 3.13 below.
EIA
- 397 -
M/s. Shilpa Medicare Ltd. Unit I
Literacy levels
Raichur District
Raichur district has a literacy rate of 59.6 percent and is placed at penultimate
rank in the State.
There is a substantial percentage increase in the literacy levels from 49.54% during
2001 census to 59.6% during 2011. The literacy rate has improved due to the efforts
under the D.P.E.P. programme and the literacy drive campaign. However, it is still
less when compared to the Karnataka State average of 75.6%.
The male literacy rate in the district is 70.5 percent and the female literacy rate is
48.7 percent.
The male female literacy gap is 21.8 percentage points, which is higher than the
male female literacy gap registered by the State (14.4 percentage points).
In Raichur district there are about 3,150 schools (total upto higher secondary PU
level) controlled by the Department of Education.
Mahbubnagar district
Mahbubnagar district ranks 14th in Andhra Pradesh State (during 2011 cesus, prior
to division into Telangana & Andhra Pradesh) with literacy of 55.04%.
Male literacy rate is 65.21% & female literacy is 44.72%.
Source: EMIS & DISE reports and District census handbook, Raichur & Mahbubnagar,
2011
The Government of Karnataka has also established an industrial area in the year 1987
at Deosugur and Raichur growth center industrial area in the year 2005. By this
industrialization, the town is experiencing economical growth supported by
agriculture. Off-late educational institutions have also come up. Raichur Institute of
Medical Sciences, Navodaya Medical College and Nursing college, SLN Engineering
college, Government Engineering College, Navodaya Engineering College are a
prominent few.
Mahbubnagar district, Telangana which falls under the study area of 10 km radius of
the M/s. Shilpa Medicare Ltd. Unit I, the land-use pattern is predominantly
agricultural & rural.
EIA
- 398 -
M/s. Shilpa Medicare Ltd. Unit I
Infrastructure is the basic physical and organizational structures needed for the
operation of a society or enterprise or the services and facilities necessary for an
economy to function.
The term typically refers to the technical structures that support a society, such as
roads, water supply, sewers, electrical grids, telecommunications and so forth and
can be defined as "the physical components of interrelated systems providing
commodities and services essential to enable, sustain or enhance societal living
conditions.
Viewed functionally from the industrial point of view , infrastructure facilitates are
those that support the production of goods and services, the distribution of finished
products to markets, basic social services such as schools and hospitals.
List of infrastructural facilities available in the vicinity of the industry are tabulated
below. Google map of the same is in fig 3.6.
EIA
- 399 -
M/s. Shilpa Medicare Ltd. Unit I
3.2.8.1 CONNECTIVITY
Connectivity to the project site is detailed in the following table 3.15. Google map
showing the same is appended subsequently in fig 3.7.
Google maps covering a radial distance of 1, 5 & 10 km are in fig 3.8, 3.9 & 3.10.
EIA
- 400 -
M/s. Shilpa Medicare Ltd. Unit I
3
A
B
5
6
1
2 74
Legend:
1: District hospital; 2: GPV hospital; 3: KPCL DAV public school; 4: Vignan School; 5: Government Engineering College;
6: SLN College of Engineering; 7: Raichur Institute of Medical Sciences
A: NH-167 & SH 51; B: Chiksugur railway station; E: Krishna railway station
EIA
- 401 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 402 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 403 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 404 -
M/s. Shilpa Medicare Ltd. Unit I
M/s. Shilpa Medicare Limited, Unit I is located at Deosugar Industrial Area, Raichur,
Karnataka. There are many brick industries located around the industry. In addition,
major industries located in the vicinity are tabulated below and shown in fig 3.11.
2
34
5
6 7
8
EIA
- 405 -
M/s. Shilpa Medicare Ltd. Unit I
The major environmental components in the surroundings along with the distance &
direction from the project site are tabulated below . Google map showing the location
of the environmental parameters are appended as figure 3.13 and topo map of 10 km
radius is appended as Annexure A11. Bhuvan map showing land-use pattern in the
immediate vicinity of the industry is in fig 3.12.
Note:
a) All distances mentioned are aerial.
b) The location of the industry is in a notified KIADB, Karnataka Govt. industrial
area.
EIA
- 406 -
M/s. Shilpa Medicare Ltd. Unit I
PROJECT
SITE
EIA
- 407 -
M/s. Shilpa Medicare Ltd. Unit I
PROJECT
SITE
EIA
- 408 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 409 -
M/s. Shilpa Medicare Ltd. Unit I
CHAPTER 4
A. PROJECT LOCATION
Major environmental impacts due to project location are not anticipated because the
industry is located in Deosugar Industrial Area, Raichur.
B. POSSIBLE ACCIDENTS
1) PPEs
All the personal are provided with adequate number of protective equipments based
on the area of work to ensure safety. Few PPEs provided are listed below.
EIA
- 410 -
M/s. Shilpa Medicare Ltd. Unit I
Helmet
Goggles
Nose masks
Uniform
Aprons
Hand gloves
Safety shoes
Face shield
Eye and body showers
EIA
- 411 -
M/s. Shilpa Medicare Ltd. Unit I
2) Training
Safety training for the employees on need basis depending on the work area is given
at regular intervals to ensure development and maintenance of safety mind-set
amongst the employees.
Safety mock drills are held annually to ensure prompt and safe response during
emergencies.
Shilpa Medicare Ltd. Unit I is an ISO 18001:2007 (Occupational Health and Safety
Management System) certified company. Copy of the certificate is shown in fig 4.3.
The company has an approved health and safety policy and the same is shown in fig
4.4.
4) Health safety
Annual medical health check up is conducted and medi-claim scheme is provided for
all employees.
EIA
- 412 -
M/s. Shilpa Medicare Ltd. Unit I
Fig 4.3: ISO 18001:2007 (Occupational Health and Safety Management System)
certification
EIA
- 413 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 414 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 415 -
M/s. Shilpa Medicare Ltd. Unit I
4) Fire-fighting equipments
Adequate numbers of fire extinguishers are available at necessary locations. Fire
water tank of 200 KL capacity and fire hydrant system is provided all around the
premises and other necessary locations. Photographs are shown in fig 4.5.
Fire
extinguisher
Fire hydrant
line
EIA
- 416 -
M/s. Shilpa Medicare Ltd. Unit I
5) Others
In addition,
The necessary safety documents like Material Safety Data Sheets (MSDS), risk
assessment study report, HAZOP study report, on-site emergency plan are
prepared and made readily available to the concerned persons in case of
emergency.
Electric audit is conducted regularly.
Insurance coverage is provided in case of fire (PLI)
Contact numbers in case of emergencies are displayed at prominent locations.
ENVIRONMENT SAFETY
EIA
- 417 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 418 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 419 -
M/s. Shilpa Medicare Ltd. Unit I
Procedure followed at M/s. Shilpa Medicare Ltd. Unit I for spill control and
management is detailed below. SOPs are in place and care is taken to prevent land,
surface and groundwater contamination.
iii) Gases
In case of leakage evacuate the area, inform the block in-charge and EHS
department/ higher-ups.
All other persons should leave the area till safe conditions return.
EIA
- 420 -
M/s. Shilpa Medicare Ltd. Unit I
In case of major leakage all persons should be warned & evacuated and KSPCB to
be intimated.
suitable cartridge respirator,
rubber gloves, safety goggles, shoes etc.
Approach from the wind wards side so that escaping gas is carried down-wind
In case of large leaks first step is try to stop the flow of gas
Ammonia leakages are controlled by spraying water which will automatically start
In case the leak is in the equipment in which it is being used, stop the valve on the
container at once.
Enter the details of incident in the spill control record.
EIA
- 421 -
M/s. Shilpa Medicare Ltd. Unit I
C. PROJECT DESIGN
Recognition of project specific activities for major impacts is essential for arriving at
suitable mitigation measures. This in turn will ensure maintenance of the existing
environmental quality.
Impacts due to industry on six basic environmental parameters listed below are
studied.
1. Air environment
2. Noise environment
3. Water environment
4. Land environment
5. Biological environment
6. Socio-economic environment
7. Flora & fauna
The impacts on the above parameters have been identified, analysed and classified as
adverse, beneficial impacts and the impact matrix is presented later in the report.
EIA
- 422 -
M/s. Shilpa Medicare Ltd. Unit I
4.1.2.1 SCOPE
1. AIR ENVIRONMENT
Pollutants in the form of oxides of nitrogen, sulfur and SPM from generators and
boilers and acid mist/VOCs from the process section, contribute and cause certain
impacts on the ambient air quality if not controlled.
2. NOISE ENVIRONMENT
DG sets are the major noise generating sources during the operation phase. Also
handling and conveying of raw materials and semi-finished components to
different operations & compressors can be a source of noise pollutio n.
3. WATER ENVIRONMENT
EIA
- 423 -
M/s. Shilpa Medicare Ltd. Unit I
5. SOCIO-ECONOMIC ENVIRONMENT
There are no rare, endemic or endangered species in the study area. Moreover, all
measures are taken for minimizing/offsetting adverse impacts on air, water and soil
as detailed in further sections of this Chapter.
I. AIR ENVIRONMENT
Pollutants like SPM, SO 2, NOx and CO are emitted from the industry mainly due to
burning of fuel in DGs and boilers. Exhausts from these sources are let out from stacks
of adequate height and also suitable air pollution control units are provided as
stipulated by KSPCB.
Mitigation measures for air quality management during operation phase are shown in
table 4.1.
EIA
- 424 -
M/s. Shilpa Medicare Ltd. Unit I
dispersed.
AHUs (Air Handler Unit) are provided for circulation of
fresh air into process area which has a roof height of 5-
5.5 m.
The emissions from DGs and boilers will be let out through
stacks of height 5 m ARL and 30 m AGL respectively.
Boilers are provided with multicyclone.
Stacks and ambient air are monitored at regular intervals.
Sample analysis reports are appended as Annexure A3.
Transport vehicles will be maintained.
Ambient air Ambient air quality monitoring is carried out monthly at
quality two locations within the industry premises. Sample
analysis reports are appended as Annexure A3.
EIA
- 425 -
M/s. Shilpa Medicare Ltd. Unit I
The main sources of noise pollution in the industry are from the operation of
machineries during the manufacturing process, handling and conveying of raw
materials and semi-finished components to different operations.
High noise generating units such as DG sets are provided with acoustic enclosures.
Green belt at the project boundary further acts as noise barrier and helps in
attenuation of noise. Measures for maintaining noise levels within stipulated limits are
presented in table 4.2.
Raw materials will be procured from various locations and transported to the factory
through lorries/tankers by rail/road. Similarly, the final products will be transported
by rail/road to various locations within India and by sea/air to other countries. The
vehicles will move mainly through State and National highways which are tarred
roads. Presently, the traffic on these roads is meagre and vehicle movement to and
from industry does not have any major impact on the existing environment.
Maximum number of vehicles moving in and out of the premises in one day is around
6-7.
EIA
- 426 -
M/s. Shilpa Medicare Ltd. Unit I
V. LAND ENVIRONMENT
EIA
- 427 -
M/s. Shilpa Medicare Ltd. Unit I
All the mitigation measures detailed in the previous section exist and are
implemented. The responsibility of implementation lies with M/s. Shilpa Medicare
Ltd. Unit I.
The significance of the impacts identified in the previous sections for various
environmental parameters are detailed in this section.
EIA
- 428 -
M/s. Shilpa Medicare Ltd. Unit I
Table 4.5 presents impact matrix for the actions identified on various environmental
parameters. A rating scale has been devised to give severity of impacts in the
following manner.
A : Strongly beneficial (positive) impact
B : Low beneficial impact
C : Strong adverse (negative) impact
D : Low adverse impact (localized in nature)
E : No conceivable impacts on environment
EIA
- 429 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 430 -
M/s. Shilpa Medicare Ltd. Unit I
CHAPTER 5
ANALYSIS OF ALTERNATIVES
(TECHNOLOGY & SITE)
Analysis of alternatives (technology and site) was not proposed during the
scoping stage.
CHAPTER 6
Ambient air, stacks, ambient noise, water and wastewater are to be monitored
on regular basis.
EIA
- 431 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 432 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 433 -
M/s. Shilpa Medicare Ltd. Unit I
CHAPTER 7
ADDITIONAL STUDIES
7.1INTRODUCTION
7.1 PUBLIC CONSULTATION
The Deosugar Industrial Area, i.e., the Raichur Growth Center of KIADB,
Government of Karnataka was established on 27-4-1987. Screenshot from
Karnataka Industrial Areas Development Board (KIADB) is in fig 7.0. This is prior
to EIA Notification 2006. The total extent of this industrial area is 214.86 acres.
EIA
- 434 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 435 -
M/s. Shilpa Medicare Ltd. Unit I
7.2INTRODUCTION
7.1 RISK ASSESSMENT
7.2.1 Introduction
7.2.2
7.2 HAZOP
HAZOP analysis
ANALYSIS
Risk assessment is a term used to describe the overall process or method where
hazards and risk factors that have the potential to cause harm are
identified (hazard identification).
the risk associated with that hazard (risk analysis, and risk evaluation)
are analysed and evaluated.
appropriate ways to eliminate the hazard, or control the risk when the
hazard cannot be eliminated (risk control) are determined.
EIA
- 436 -
M/s. Shilpa Medicare Ltd. Unit I
The technique used for the hazard identification is Maximum Credible Accident
(MCA) analysis, which allows identification of an accident with probable
maximum damage distance.
Apart from the solvents, diesel fuel will also be stored in plant premises. The
solvent storage tanks are designed as per the safety norms. Apart from the tanks
small quantities of solvents are stored in flame proof barrels in designated
storage area in a secured manner under cover. The solvent and fuel requirement
for the industry/plant on monthly basis is based on the production schedule.
Probable hazards in the Plant are shown in table 7.1.
EIA
- 437 -
M/s. Shilpa Medicare Ltd. Unit I
The drawing indicating areas earmarked for storage of solvents is shown in the
plant layout of the industry.
Hazards and risks associated with manufacture of ursodeoxy cholic acid, above
ground storage tanks housing flammable solvents, drum storage shed, solvents
loading and unloading, equipments and reactors with existing controls available
are detailed below
EIA
- 438 -
M/s. Shilpa Medicare Ltd. Unit I
Name of Person Undertaking Assessment Date Conducte d Department / Are a (including description of what is be ing asse sse d)
A.M.KULKARNI 04-04-2018 3alpha,7beta-Dihydroxy Cholanic acid / Urso deoxychlolic acid
Re f No Haz ard under re vie w No & Description of Existing Controls Asse sse d Le ve l Furthe r Action Re quire d By (Date )
staff involve d of Risk* + Re vie w
Date
L M H
1 Fire and Explosion Staff -5 Certifying reactor to ensure free of water and X Ensuring of earthing and
-Air and vapour mixture formation while Workmen-10 moisture bonding through recording in
handling Butanol due to spillage, leaks. Casuals-5, Practicing chemical compatibility to avoid butanol BMR
-Air ingress during Butanol distillation. In the entire and Sodium bromate during staging of RM Ele ctrostatic bonding and
-Water/moisture contact with Na Production Block Effective PMP for FLP fixtures and SRV e arthing.
-Contact of Sodium bromate with Butanol LEL detectors instead of smoke detectors. Avoid and prevent personnel
-Failure of FLP fixtures. Non sparking tools acquiring electro static charges
-Non provision of FLP fixtures. Ensuring and recording of Nitrogen blanketing and Re lease of vacuum through
-Formation and discharge of static oxygen monitoring nitrogen
charges. Charging powdered raw materials through Hopper.
-Usage of sparking tools. Effective works permit system.
-External ignition sources. Vents fixed with flame arresters.
-Absence of hot work permits system.
2. Pressure Staff -5 Recording of vent opening in BMR X Effe ctive PMP of SRV
-Closure of vent. Workmen-10 Periodical recording of PG re adings in BMR High pressure alarms and self-
-Nonfunctioning of vent. Casuals and visitors-5 SO P to ensure absence of water in reactor after correcting systems
-Water contact with Sodium metal In the entire cleaning. Use of non-aqueous coolant for
-Absence of coolant in condenser. Production Block jacket and condenser.
3. Exothe rmic Staff -5 Checking of moisture content of the contents before X O rde r of charge to be maintained
Water or aqueous solution contact with Workmen-5 charging Sodium metal strictly.
Sodium. Casuals
In the entire
Production Block
4. Toxicity Staff -5 Supplied air mask while handling Ammonia. X Spill control training.
Due to spillage, leakage, emissions or Workmen-10 Avoidance of employees with premedical conditions Haz ard communication training
reactor pressurization. Casuals-5 for handling Ammonia/Methylene chloride
-Methylene Chloride, Carcinogen(2B) In the entire Respirators approved by NIOSH. EN or equivalent IS
-Ammonia Production Block Spill control materials like sorbent pads and booms.
EIA
- 439 -
M/s. Shilpa Medicare Ltd. Unit I
Name of Person Undertaking Assessment Date De partment / Area (including de scription of what is being asse sse d)
Conducted
A.M.KULKARNI 04-04-2018 ABO VE GROUND STORAGE TANKS HO USING FLAMMABLE SO LENTS
Re f No Haz ard unde r revie w No & Existing Controls Asse ssed Level of Risk* Furthe r Action Re quire d By
De scription (Date
of staff )
involve d +
Re vie
L M H
w
Date
1 SO P for various operations inside the tank X Ide ntification of flammables for air vapours mixture
Fire and Explosion Staff -1 are a to highlight fire safety issues and inside the tank.
-Air and vapour mixture formation while Workmen-1 corrective actions. Vapour space to be filled with inert gas.
loading, unloading sampling and dispensing of Casuals-1 Installation of flame arrester in Ensuring complete discharge of electrostatic
solvents. combination with breather arrangement. accumulation from the tanker using earthrite.
-Formation of air+vapour mixture inside the Tanker unloading permit procedure. LEL dete ctors.
storage tank. Fire protection by sprinkler system around Ele ctrostatic bonding
-Poor control of external ignition sources inside the storage tank and tanker. Avoid and prevent personnel acquiring e lectro static
the tank area. Distances maintained as per statutory charges
-In adequate separation distances from the tank regulations Re lease of vacuum through nitrogen.
are a and adjacent buildings. Se lection of e lectrical installations as per IS-
-Electrical installations not as per haz.area 2148 or any other international body.
classification. Effe ctive PMP for FLP fixtures.
-Failure of FLP fixtures. Ensuring of earthing and bonding through
-Non provision of FLP fixtures. recording in BMR
-Formation and discharge of static charges. Non sparking tools
-Usage of sparking tools. Effe ctive works permit system.
-External ignition sources. Ve nts fixed with flame arresters.
-Absence of hot work permits system. Display of prohibition of spark producing
materials in to tank farm.
2. Pre ssure Staff -1 Sprinkler system with heat detector. X Solvents with high evaporation rate should have
-extreme heat Workmen-1 Adequate maintenance of pressure relieving cooling arrangement.
-sudden cooling Casuals and systems Ine rtising pre ssure regulated.
-choking of flame arrester and breather valve. visitors-2 PMP for breather and flame arresters. Re sidues with potential for de composition to be
-sudden increase in inertising pressure. De sign of tank adequate to sustain pressure avoided.
-impingement of heat due to external fire. and vacuum.
-Nonfunctioning of sprinkler or other cooling
arrangement.
-Decomposition of the product.
3. Exposure hazards. Staff -1 Re spirators approved by NIOSH. EN or X
De rmatitis with prolonged contact with solvents. Workmen-1 equivalent IS. Spill control training.
Severe chemical burns due to splashing of Casuals-1 Full face protection. Hazard communication training
solvents. Eme rgency shower and eye wash
Spill control materials like sorbent pads and
booms.
EIA
- 440 -
M/s. Shilpa Medicare Ltd. Unit I
Name of Person Undertaking Assessment Date De partment / Area (including description of what is be ing asse sse d)
Conducted
A.M.KULKARNI 04-04-2018 DRUM STO RAGE SHED
Re f No Haz ard unde r revie w No & Existing Controls Asse ssed Level of Risk* Furthe r Action Re quire d By (Date )
De scription + Re vie w Date
of staff
involve d
L M H
1 Fire and Explosion Non sparking tools. X LEL dete ctors instead of smoke detectors.
-Air and vapour mixture formation while Staff -2 Effe ctive works permit system. Ele ctrostatic bonding
sampling and dispensing of flammable materials. Workmen-2 Avoid and prevent personnel acquiring
-Usage of air for dispensing solvent from the Casuals-1 e lectro static charges
drum. Usage of extremely low pressure Nitrogen
- dropping and rolling of solvent drums. for dispensing.
-Chemical compatibility not observed.
-Failure of FLP fixtures.
-Non provision of FLP fixtures.
-Formation and discharge of static charges.
-Usage of sparking tools.
-External ignition sources.
-Absence of hot work permits system.
2. Pre ssure Staff -2 -Air moisture sensitive materials stored in X -mechanical arrangements to place the
-Decomposition of the product. Workmen-2 controlled conditions. drums.
-use of uncontrolled pressure of air/nitrogen for Casuals and -He at from external sources prevented. -Integrity of the container maintained
dispensing. visitors-2 -The storage place checked periodically and after sampling.
-exposure to external source of heat. containers for pressure regularly. -Use of low pressure nitrogen.
-admittance of air or moisture in to the drums
containing sensitive materials.
3. Exposure hazards. Staff -2 Re spirators approved by NIOSH. EN or X
De rmatitis with prolonged contact with solvents. Workmen-2 equivalent IS. Spill control training.
Severe chemical burns due to contact of corrosive Casuals-2 Extra-long acid alkali gloves while handling Hazard communication training
che micals. corrosive solids and liquids.
Severe respiratory problems due inhalation of Spill control materials like sorbent pads and
corrosive fumes. booms.
While de aling with spills and similar e mergency Chemical emergencies handled with SCBA
conditions. Water reactive materials stored separately.
Life threatening situations while de aling with
che micals releasing toxic gases like H2S.
4. Re action e xotherm. Staff -2 Mate rials stored as per compatibility. X Hazard communication.
Water reactive materials Workmen-2 Storage conditions mentioned in MSDS are
Air se nsitive materials Casuals-2 obse rved.
Incompatible materials Haz ard display.
Unstable materials
EIA
- 441 -
M/s. Shilpa Medicare Ltd. Unit I
Name of Person Undertaking Assessment Date De partment / Area (including de scription of what is being asse sse d)
Conducte d
A.M.KULKARNI 04-04-2018 PRO CESS EQ UIPMENT-REACTO RS
Re f No Haz ard unde r review No & Existing Controls Asse ssed Level of Risk* Furthe r Action Re quire d By (Date )
Description + Re vie w
of staff Date
involved
L M H
EIA
- 442 -
M/s. Shilpa Medicare Ltd. Unit I
Name of Person Undertaking Assessment Date De partment / Area (including de scription of what is being a sse sse d)
Conducte d
A.M.KULKARNI 04-04-2018 PRO CESS EQ UIPMENT-CENTRIFUGE& Filtration equipment like Nutch Filters Cum driers
Re f No Haz ard unde r review No & Existing Controls Asse ssed Level of Risk* Furthe r Action Re quire d By (Date )
Description + Re vie w
of staff Date
involved
L M H
EIA
- 443 -
M/s. Shilpa Medicare Ltd. Unit I
Name of Person Undertaking Assessment Date Conducte d Departme nt / Are a (including description of what is be ing asse sse d)
A.M.KULKARNI 04-04-2018 SO LVENT UNLO ADING AND LO ADING
Re f No Hazard under revie w No & Description of staff Existing Controls Asse ssed Le ve l of Furthe r Action Re quire d By (Date )
involve d Risk* + Re vie w
Date
L M H
1 Fire and explosion hazard Staff -1 Dematching at the gate X Drum unloading to be done using scissors lift
Workmen-1 Fire and Explosion signs displayed only
Casuals- - Compatibility followed while storing Bonding and e arthing to be ensured.
Drive r -1 Spark arresters e nsured at the gate.
Cleaner -- Spark arresters fixed to the vehicles at
the gate.
Work men training
Hazard communication
Inspection program for earthing and
bonding cable integrity.
Spark arresters inspection and
maintenance.
Spark proof tools to be used.
2. Chemical exposure Staff -1 Caution displayed X Prote ction against inhalation, contact and
Workmen-1 Work men training ingestion to be provided by providing specific
Casuals- Hazard communication RA
Drive r -1 Provision of PPE Staff to e nsure using the same and record
Cleaner - Annual health check up
3. Physical injuries Workmen-1 All workers to be provided with shoes X
Hit by Casuals-1 with toe guards. Present methodology of rolling the drums to be
Crush injuries avoided.
EIA
- 444 -
M/s. Shilpa Medicare Ltd. Unit I
Vehicle movement Staff -1 None X Wheel chokes should be used while parking
Workmen-1 vehicles on slopes.
Casuals-1 Ve hicles should be e nsured for road worthy
conditions.
Traine d drivers should be e nsured for the
vehicles.
7. Lone worker Staff -1 None X Lone worker policy to be installed.
Workmen-1 Lone worker risk assessment to be done to
Casuals-1 provide necessary controls for identified risks.
8. Emergency communication Staff -1 None X Eme rgency communication facilities like siren,
Workmen-1 PA system to be installed
Casuals-1
Emergency Evacuations Staff None X Evacuation routes to be identified and marked
9. Workmen Training
Casuals Allocated assembly points.
Eme rgency lighting
10. Manual Handling Workmen -1 None X Risk assessment of manual handling
and Casuals-1 Training on proper manual handling
techniques.
Emphasis on postures leading to sprains and
strains
11. Insects and other harmful creatures like Staff -1 Anti-snake venom kept in dedicated X All staff and workmen should be made aware of
snakes Workmen-2 place. the antidote location.
Casuals-1 Staff and workmen to be trained and first aid to
treat the injuries specific to the work and
harmful creatures.
EIA
- 445 -
M/s. Shilpa Medicare Ltd. Unit I
Name of Person Undertaking Assessment Date De partment / Area (including de scription of what is being asse sse d)
Conducte d
A.M.KULKARNI 05-04-2018 PRO CESS EQ UIPMENT-RCVD, RVPD, Vacuum Tray Drier,
Re f No Haz ard unde r review No & Existing Controls Asse ssed Level of Risk* Furthe r Action Re quire d By (Date )
Description + Re vie w
of staff Date
involved
1 Fire and Explosion Staff -1 Effe ctive PMP for FLP fixtures and SRV X LEL detectors instead of smoke detectors.
-Air and dust mixture formation inside and Workmen-1 Ensuring of earthing and bonding through Ele ctrostatic bonding
around the eqpt. Casuals-1 recording in BMR Avoid and prevent personnel acquiring e lectro static
-Air ingress during vacuum drying Non sparking tools charges
-Failure of FLP fixtures. Ensuring and recording of Nitrogen Re lease of vacuum through nitrogen
-Non provision of FLP fixtures. blanketing and oxygen monitoring
-Formation and discharge of static charges. Charging powdered raw materials through
-Usage of sparking tools. Hopper.
-External ignition sources. Effe ctive works permit system.
-Absence of hot work permits system. Ve nts fixed with flame arresters.
-
3. Physical injuries Staff -1 Effe ctive safe work system. X Inte rlocks to prevent contact of rotating part.
-Contact of rotating parts Workmen-1 Good house keeping
-Electric shocks Casuals Circuit breakers
-Slip, trip and falls Maint.crew
EIA
- 446 -
M/s. Shilpa Medicare Ltd. Unit I
Name of Person Undertaking Assessment Date De partment / Area (including de scription of what is being asse sse d)
Conducte d
A.M.KULKARNI 05-04-2018 PRO CESS EQ UIPMENT-TRAY DRIER
Re f No Haz ard unde r review No & Existing Controls Asse ssed Level of Risk* Furthe r Action Re quire d By (Date )
Description + Re vie w
of staff Date
involved
1 Fire and Explosion Staff -1 Blowers are Kept outside the drying X LEL detectors instead of smoke detectors.
-Air and dust mixture formation inside and Workmen-1 Chambers keeping HEPA Filters as Ele ctrostatic bonding
around the eqpt. Casuals-1 barriers to avoid the contact of Moving Avoid and prevent personnel acquiring e lectro static
-Air ingress during vacuum drying parts in the Drying chamber charges
-Failure of FLP fixtures. Effe ctive PMP for FLP fixtures and SRV/ Re lease of vacuum through nitrogen
-Non provision of FLP fixtures. EXPLO SIO N VENT
-Formation and discharge of static charges. Ensuring of earthing and bonding through
-Usage of sparking tools. recording in BMR
-External ignition sources. Non sparking tools
-Absence of hot work permits system. Ensuring and recording of Nitrogen
- blanketing and oxygen monitoring
Charging powdered raw materials through
Hoppe r.
Effe ctive works permit system.
Ve nts fixed with flame arresters.
2. Pre ssure Staff -1 Effe ctive PMP of exhaust dampner X Earth interlocks.
-Closure of Exhaust dampner. Workmen-1 High pressure and vacuum failure alarms
-Nonfunctioning of vent. Casuals -1 and self-correcting systems
-Ignition inside
3. Physical injuries Staff -1 Effe ctive safe work system. X Inte rlocks to prevent contact of rotating part.
-Contact of rotating parts Workmen-1 Good house keeping
-Electric shocks Casuals Circuit breakers
-Slip, trip and falls Maint. crew
EIA
- 447 -
M/s. Shilpa Medicare Ltd. Unit I
Name of Person Undertaking Assessment Date De partment / Area (including de scription of what is being asse sse d)
Conducte d
A.M.KULKARNI 05-04-2018 PRO CESS EQ UIPMENT-Multimill & Sfter
Re f No Haz ard unde r review No & Existing Controls Asse ssed Level of Risk* Furthe r Action Re quire d By (Date )
Description + Re vie w
of staff Date
involved
1 Fire and Explosion Staff -1 Effe ctive PMP for FLP fixtures & X LEL detectors instead of smoke detectors.
-Air and dust mixture formation inside and Workmen-1 e quipment Ele ctrostatic bonding
around the eqpt. Casuals-1 Ensuring of earthing and bonding through Avoid and prevent personnel acquiring e lectro static
-Air ingress during vacuum drying recording in BMR charges
-Failure of FLP fixtures. Non sparking tools
-Non provision of FLP fixtures.
-Formation and discharge of static charges. Charging powdered raw materials through
-Usage of sparking tools. Hopper.
-External ignition sources. Effe ctive works permit system.
-Absence of hot work permits system. Ve nts fixed with flame arresters.
-
2. Pre ssure Staff -1 Effe ctive PMP of the Rotating Parts, X Earth interlocks.
. Workmen-1 the reby avoiding the sparks
-Ignition inside Casuals -1
3. Physical injuries Staff -1 Effe ctive safe work system. X Inte rlocks to prevent contact of rotating part.
-Contact of rotating parts Workmen-1 Good house keeping
-Electric shocks Casuals Circuit breakers
-Slip, trip and falls Maint. crew
EIA
- 448 -
M/s. Shilpa Medicare Ltd. Unit I
Name of Person Undertaking Assessment Date De partment / Area (including de scription of what is being asse sse d)
Conducte d
A.M.KULKARNI 5-04-2018 PRO CESS EQ UIPMENT-Boiler 4 TPH @10.54 Kg /Cm2
Re f No Haz ard unde r review No & Existing Controls Asse ssed Level of Risk* Furthe r Action Re quire d By (Date )
Description + Re vie w
of staff Date
involved
L M H
EIA
- 449 -
M/s. Shilpa Medicare Ltd. Unit I
Ref MATERIAL IN HAZARD REVIEW EXISTING CONTROLS RISK LEVEL SUGGESTED ACTION PLAN
No. STORE/ LOCATION
01
L M H
1 Dispensing room Fire SOP X FLP maintenance as per IS-
Ground floor, ware Exposure to chemicals FLP fittings SOP to be reviewed
House PPE Policy to prevent dispensing of
highly reactive materials having
rating of Nr 3,4 Nf 3,4 Oxidizing
and water reactive materials.
Smoke detectors.
Non-sparking tools.
2. Charcoal store. Dust explosion FLP fittings. X FLP fittings should be dust tight.
Ground floor, ware Self-heating. SOP Heat detectors.
house PPE Respirators with N98 filter.
3. Sodium room Fire SOP X Humidity control to maintain dry
Ground floor, Explosion. RCC room air.
Hazardous material Hydrogen detectors
store Special DCP extinguishers.
Warehouse Double door opening.
Non-sparking tools.
EIA
- 450 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 451 -
M/s. Shilpa Medicare Ltd. Unit I
Very high – VH
High – H
Medium – M
Low – L
Likely Minor
C 3 C H
Possible Moderate H
D 4 D
Unlikely Major
E 5 E
Rare Extreme
Identified Hazards (from above) Risk assessment Risk
score
Likelihood (L) Consequence L * C
(C)
Explosion C 4 C4 H
Thermal burns B 3 B3 H
Electrocution C 4 C4 H
EIA
- 452 -
M/s. Shilpa Medicare Ltd. Unit I
1. Fire
2. Electrocution
3. Burn injuries
1. Two SRVs
2. Insulation
3. Trip system
4. Earthing
5. PG
Fire Explosion-High
Electrocution-High
Burn injuries-High
EIA
- 453 -
M/s. Shilpa Medicare Ltd. Unit I
Likelihood
Likely Minor
C 3 C
L M H H H
Possible Moderate
D 4 D
L L M M H
Unlikely Major
E 5 E
L L M M H
Rare Extreme
Very high – VH
High – H
Medium – M
Low – L
Likely Minor
C 3 C H H H
Possible Moderate
D 4 D M M
Unlikely Major
E 5 E
Rare Extreme
Identified Hazards (from above) Risk assessment Risk score
Likelihood (L) Consequence (C) L*C
Fire/explosion risk C 4 C4 H
Electrocution C 5 C5 H
Entanglement D 3 D3 M
Thermal C 3 C3 H
Crushing D 4 D4 M
EIA
- 454 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 455 -
M/s. Shilpa Medicare Ltd. Unit I
Sl. Solvent Risk Worst case Affected range threat Safety measures
no. zone
3. HEXANE FIRE TANK 37.5kW-13M QRC coupled hose connections.
FAILURE 5kW-30M FLP electrical fixtures.
1.6KW-45M Electrostatic control measures.
Spark arrester to the vehicle.
Loading and unloading permit system.
Permit system for prevention of other ignition sources.
Hydrant system; Foam monitor; Sprinkler system for
tanker; Foam tank.
On site emergency plan.
4. TOLUENE FIRE TANK 37.5kW-13M QRC coupled hose connections.
FAILURE 5kW-30M FLP electrical fixtures.
1.6KW-45M Electrostatic control measures.
TOXIC ERPG3(1000ppm)-44M Spark arrester to the vehicle.
LEAK ERPG2(300ppm)-111M Loading and unloading permit system.
ERPG1(50ppm)-475M Permit system for prevention of other ignition sources.
Hydrant system; Foam monitor; Sprinkler system for
tanker; Foam tank.
On site emergency plan.
OHC; Respiratory masks; SCBA; Antidotes.
5. ETHYL FIRE TANK 37.5kW-Less than 10M QRC coupled hose connections.
ACETATE FAILURE 5.0kW-24M FLP electrical fixtures.
1.6kW-36M Electrostatic control measures.
Spark arrester to the vehicle.
Loading and unloading permit system.
Permit system for prevention of other ignition sources.
Hydrant system; Foam monitor; Sprinkler system for
tanker; Foam tank.
On site emergency plan.
EIA
- 456 -
M/s. Shilpa Medicare Ltd. Unit I
Sl. Solvent Risk Worst case Affected range threat Safety measures
no. zone
6. ACETONE FIRE. TANK FAILURE 37.5kW-11M QRC coupled hose connections.
5.0kW-25M FLP electrical fixtures.
1.6kW-37M Electrostatic control measures.
Spark arrester to the vehicle.
Loading and unloading permit system.
Permit system for prevention of other ignition
sources.
Hydrant system; Foam monitor; Sprinkler system
for tanker; Foam tank.
On site emergency plan.
7. BUTANOL FIRE TANK FAILURE 37.5kW-12M QRC coupled hose connections.
5.0kW-26M FLP electrical fixtures.
1.6kW-36M Electrostatic control measures.
Spark arrester to the vehicle.
Loading and unloading permit system.
Permit system for prevention of other ignition
sources.
Hydrant system; Foam monitor; Sprinkler system
for tanker; Foam tank.
On site emergency plan.
EIA
- 457 -
M/s. Shilpa Medicare Ltd. Unit I
1) LIQUID BROMINE
Prepared By:
KULKARNI ANAND M
INDUUSTRIAL SAFETY CONSULTANT
Punekar Compound, 6th Cross
Malmaddi, Dhrawad-50007
91-80-23582346, 9845202089
EMAIL: [email protected]
Prepared For:
Shilpa Medicare Ltd Unit-1
Plot No-1A, 1B, 2, 2A, 3A to3E & 4A to 4C, 5A, 5B
Deosugur Industrial area,
Raichur- Taluk & District
SITE DATA:
Location: RAICHURU, INDIA
Building Air Exchanges per Hour: 60 (user specified)
Time: April 6th, 2018
CHEMICAL DATA:
Chemical Name: BROMINE Molecular Weight: 159.81 g/mol
ERPG-1: 0.1 ppm ERPG-2: 0.5 ppm ERPG-3: 5 ppm
IDLH: 3 ppm
Ambient Boiling Point: 58.3° C
Vapor Pressure at Ambient Temperature: 0.42 atm
Ambient Saturation Concentration: 429,451 ppm or 42.9%
ATMOSPHERIC DATA: (MANUAL INPUT OF DATA)
Wind: 5 meters/second from SE at 3 meters
Ground Roughness: open country Cloud Cover: 0 tenths
Air Temperature: 35° C Stability Class: D
No Inversion Height Relative Humidity: 25%
SOURCE STRENGTH:
Evaporating Puddle
Puddle Area: 1 square meters Puddle Volume: 20 liters
Ground Type: Concrete Ground Temperature: 35°C
Initial Puddle Temperature: Ground temperature
Release Duration: ALOHA limited the duration to 1 hour
Max Average Sustained Release Rate: 1.77 kilograms/min
(Averaged over a minute or more)
Total Amount Released: 50.0 kilograms
EIA
- 458 -
M/s. Shilpa Medicare Ltd. Unit I
THREAT ZONE:
Model Run: Gaussian
Red : 116 meters --- (5 ppm = ERPG-3)
Orange: 399 meters --- (0.5 ppm = ERPG-2)
Yellow: 957 meters --- (0.1 ppm = ERPG-1)
2) HYDROCHLORIC ACID
SITE DATA:
Location: RAICHURU, INDIA
Building Air Exchanges per Hour: 1.11 (unsheltered single storied)
Time: April 6th, 2018
SOURCE STRENGTH:
Leak from hole in vertical cylindrical tank
Non-flammable chemical is escaping from tank
Tank Diameter: 1 meters Tank Length: 1.27 meters
Tank Volume: 1000 liters
Tank contains liquid Internal Temperature: 35° C
Chemical Mass in Tank: 0.81 tons Tank is 100% full
Circular Opening Diameter: 2 inches
Opening is 0.5 feet from tank bottom
Release Duration: 1 minute
Max Average Sustained Release Rate: 12.2 kilograms/sec
(Averaged over a minute or more)
Total Amount Released: 730 kilograms
EIA
- 459 -
M/s. Shilpa Medicare Ltd. Unit I
Note: The chemical escaped as a mixture of gas and aerosol (two phase flow).
THREAT ZONE:
Model Run: Heavy Gas
Red : 1.7 kilometers --- (100 ppm = AEGL-3(60 min))
Orange: 3.0 kilometers --- (22 ppm = AEGL-2(60 min))
Yellow: 7.5 kilometers --- (1.8 ppm = AEGL-1(60 min))
3) ACETIC ANHYDRIDE
SITE DATA:
Location: RAICHURU, INDIA
Building Air Exchanges per Hour: 60 (user specified)
Time: April 6th, 2018
CHEMICAL DATA:
Warning: ACETIC ANHYDRIDE can react with water and/or water vapor. This
can affect the evaporation rate and downwind dispersion. ALOHA cannot
accurately predict the air hazard if this substance comes in contact with water.
SOURCE STRENGTH:
Leak from hole in horizontal cylindrical tank
Flammable chemical is burning as it escapes from tank
Tank Diameter: 1.6 meters Tank Length: 5.0 meters
Tank Volume: 10.1 cubic meters
Tank contains liquid Internal Temperature: 35° C
Chemical Mass in Tank: 1000 kilograms
Tank is 9% full
Circular Opening Diameter: 2 inches
Opening is 0.5 feet from tank bottom
Max Puddle Diameter: Unknown
Max Flame Length: 6 meters Burn Duration: 17 minutes
Max Burn Rate: 62.8 kilograms/min
EIA
- 460 -
M/s. Shilpa Medicare Ltd. Unit I
THREAT ZONE:
Threat Modeled: Thermal radiation from pool fire
Red : less than 10 meters (10.9 yards) --- (37.5 kW/ (sq. m))
Orange: 12 meters --- (5.0 kW/ (sq. m) = 2nd degree burns within 60 sec)
Yellow: 16 meters --- (1.6 kW/ (sq. m))
THREAT AT POINT:
Thermal Radiation Estimates at the point:
Downwind: 18.3 meters Off Centerline: 0.48 meters
Max Thermal Radiation: 1.07 kW / (sq. m)
4) TOLUENE
SITE DATA:
Location: RAICHURU, INDIA
Building Air Exchanges per Hour: 1.11 (unsheltered single storied)
Time: April 6th, 2018
CHEMICAL DATA:
Chemical Name: TOLUENE Molecular Weight: 92.14 g/mol
ERPG-1: 50 ppm ERPG-2: 300 ppm ERPG-3: 1000 ppm
IDLH: 500 ppm LEL: 12000 ppm UEL: 71000 ppm
Ambient Boiling Point: 109.0° C
Vapor Pressure at Ambient Temperature: 0.062 atm
Ambient Saturation Concentration: 64,580 ppm or 6.46%
SOURCE STRENGTH:
Leak from hole in horizontal cylindrical tank
Flammable chemical is burning as it escapes from tank
Tank Diameter: 1.55 meters Tank Length: 5.3 meters
Tank Volume: 10.0 cubic meters
Tank contains liquid Internal Temperature: 35° C
Chemical Mass in Tank: 8000 kilograms
Tank is 94% full
Circular Opening Diameter: 2 inches
Opening is 0.5 feet from tank bottom
EIA
- 461 -
M/s. Shilpa Medicare Ltd. Unit I
THREAT ZONE:
Threat Modeled: Thermal radiation from pool fire
Red : less than 10 meters (10.9 yards) --- (37.5 kW/ (sq. m))
Orange: 20 meters --- (5.0 kW/ (sq. m) = 2nd degree burns within 60 sec)
Yellow: 30 meters --- (1.6 kW/ (sq. m))
5) CHLOROSULPHONIC ACID
SITE DATA:
Location: RAICHURU, INDIA
Building Air Exchanges per Hour: 1.11 (unsheltered single storied)
Time: April 6th, 2018
CHEMICAL DATA:
Warning: CHLOROSULFONIC ACID can react with water and/or water vapor to
produce hydrochloric acid, sulfuric acid and heat. ALOHA cannot accurately
predict the air hazard if a reaction occurs.
SOURCE STRENGTH:
Leak from hole in vertical cylindrical tank
Non-flammable chemical is escaping from tank
Tank Diameter: 1.5 feet Tank Length: 4 feet
Tank Volume: 52.9 gallons
Tank contains liquid Internal Temperature: 35° C
Chemical Mass in Tank: 200 kilograms
Tank is 60% full
EIA
- 462 -
M/s. Shilpa Medicare Ltd. Unit I
THREAT ZONE:
Model Run: Gaussian
Red : 69 meters --- (30 mg/(cu m) = ERPG-3)
Orange: 125 meters --- (10 mg/(cu m) = ERPG-2)
Yellow: 298 meters --- (2 mg/(cu m) = ERPG-1)
6) N-HEXANE
SITE DATA:
Location RAICHURU, INDIA
Building Air Exchanges per Hour: 1.09 (unsheltered single storied)
Time: April 6th 2018
CHEMICAL DATA:
Chemical Name: N-HEXANE Molecular Weight: 86.18 g/mol
TEEL-1: 400 ppm TEEL-2: 3300 ppm TEEL-3: 8600 ppm
IDLH: 1100 ppm LEL: 10500 ppm UEL: 76800 ppm
Ambient Boiling Point: 65.3° C
Vapor Pressure at Ambient Temperature: 0.25 atm
Ambient Saturation Concentration: 275,650 ppm or 27.6%
SOURCE STRENGTH:
Leak from hole in horizontal cylindrical tank
Flammable chemical is burning as it escapes from tank
Tank Diameter: 2 meters Tank Length: 4. meters
Tank Volume: 12.6 cubic meters
Tank contains liquid Internal Temperature: 30° C
EIA
- 463 -
M/s. Shilpa Medicare Ltd. Unit I
THREAT ZONE:
Threat Modeled: Thermal radiation from pool fire
Red : less than 10 meters (10.9 yards) --- (37.5 kW/(sq. m))
Orange: 25 meters --- (5.0 kW/(sq. m) = 2nd degree burns within 60 sec)
Yellow: 37 meters --- (1.6 kW/(sq. m)
THREAT AT POINT:
Thermal Radiation Estimates at the point:
Downwind: -58.4 meters Off Centerline: 27.6 meters
Max Thermal Radiation: 0.236 kW/(sq. m)
Measures for ensuring safety during storage and handling of hazardous raw
materials are listed below
Storage quantities is kept at the bare minimum and planned carefully
depending on production plan. Overstocking or stocking for long time is
avoided. Hence, the risk and effect of any accident like leakage or fire will
be less.
All hazardous raw materials are stored in carboys, drums etc. in a ware
house. The list of non-compatible chemicals is made and displayed in the
ware house.
Safety instructions and MSDS are displayed prominently at the storage area,
both in English as well as local language.
Safety eye showers are available at different locations.
Safe clear distances between the tanks is maintained as per the petroleum
storage rules applicable to the solvents base.
All pump motors, switches, lighting are flameproof.
Loading and unloading procedure for solvents is prominently displayed near
the tanks.
EIA
- 464 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 465 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 466 -
M/s. Shilpa Medicare Ltd. Unit I
Considering the hazardous nature of the process the unit is separated from
the main manufacturing block.
Prior to the start of the process, the integrity of the reactor i s checked and
certified.
Before starting the hydrogenation process inertisation is ensured by
alternating cycles of vacuum and nitrogen.
The system is provided with safety relief valve & rupture disk, both these
connected to a dump tank with water seal, the dump tank is provided with
the flame arrester.
High pressure & high temperature alarms are provided on the equipment.
Sensitive hydrogen leak detectors are provided near the reactor and
manifold.
Flash back arrestor in the manifold to the reactor.
Close system sampling is done & the system is flushed with the water.
Evacuation of hydrogen is done through the dump tank gradually in over one
hour.
Filtration is done in the closed pressure nutch filter & is done with the
nitrogen pressure.
EIA
- 467 -
M/s. Shilpa Medicare Ltd. Unit I
INTRODUCTION
EIA
- 468 -
M/s. Shilpa Medicare Ltd. Unit I
Sl. Reason for anticipated Health Work place Control to prevent the Precautionary engineering
No. hazards hazard hazard controls provided
1 Toxicity, due to Methylene Production Supplied air mask while The condensers are
exposure, spillage, Chloride- area, solvents handling ammonia. provided with chilled water
leakage, emissions or Carcinogen- handling area Avoidance of employees & chilled brine circulation
reactor pressurisation 2(B), with premedical conditions to avoid the emissions.
of ammonia & Ammonia- for handling Ammonia/ Spill control training.
methylene chloride Irritation Methylene chloride. Hazard communication
Respirators approved by training conducted, PPE
NIOSH. EN or equivalent usage training & educating
IS. on the usage of PPE's.
Spill control materials like All the operations are
sorbent pads and booms. carried out in closed
conditions, with scrubbing
systems for emissions.
2 Exposure hazards. Skin & eye Production Respirators approved by Training as above is
Dermatitis with irritation, area, acids & NIOSH. EN or equivalent conducted.
prolonged contact with eyes & skin alkali IS. All the operations are
solvents. burns & dispensing Full face protection. carried out in closed
Severe chemical burns respiratory area Emergency shower and eye conditions, with scrubbing
due to splashing of problems, wash. systems for emissions.
solvents & acids & liver, kidney, Spill control materials like
alkalis. CNS, sorbent pads and booms.
Severe respiratory peripheral
problems due inhalation nervous
of corrosive fumes. system
EIA
- 469 -
M/s. Shilpa Medicare Ltd. Unit I
Sl. Reason for Health hazard Work place Control to prevent the hazard Precautionary engineering
No. anticipated controls provided
hazards
3 Exposure to Ursodeoxy cholic Production area All the solid chemicals & finished Hazard communication
finished acid, Nifedipine, products handling is done without training will be conducted,
products Phenylephrine HCl, manual intervention, directly PPE usage training &
Sildenafil Citrate - handled in closed conditions by educating the usage of
skin & eye vacuum conveying respirators PPE's.
irritation, approved by NIOSH. EN or All the operations are
excessive chronic equivalent IS. Full face carried out in closed
ingestion may be protection. conditions, with powder
toxic to blood, Emergency shower and eye wash. scrubbing systems for
CVS, CNS Spill control materials like finished products with
sorbent pads and booms. detoxification liquids.
4 Physical Contact with Production Good housekeeping Effective interlocks
injuries rotating parts area, Circuit breakers
-Slip, trip and falls mechanical Effective work permit system
-electric shocks workshop,
electrical panel
boards
EIA
- 470 -
M/s. Shilpa Medicare Ltd. Unit I
Sl. Solvent/ Chemical Target organs Parameters for occupational Health Frequency
No. exposure monitoring
EIA
- 471 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 472 -
M/s. Shilpa Medicare Ltd. Unit I
The importance of this point for the future of the industry is well taken, as the
wellbeing and safety of the employees has a direct bearing on the performance of
the industry. Therefore, all the measures as envisaged in the Risk analysis & Hazop
studies will be implemented with due care.
o All the employees are provided with personal protective equipments like safety
helmets, goggles, face shields, heat resistance shoes, dust masks/respirators,
self-contained breathing apparatus, breathing air masks etc. as per
requirement. Details are in fig 4.1, Chapter 4 of this report.
o Mock drills as per on site emergency plan as approved by Chief Inspector of
factories are conducted for fire hydrant systems, firefighting equipment. All
the emergency systems shall be placed in good working condition & shall be
made available in all emergency conditions by adopting effective preventive
maintenance, emergency preparedness of teams as per the onsite emergency
plan. This shall be ensured by conducting training by mock drills including
evacuation plans.
o All the emergency team members are trained for firefighting & first aid, all
the employees are trained for using the firefighting equipments,
evacuation path, head count etc. by mock drills.
o The Company has made an agreement with the multispecialty hospital
for medical checkups and emergency services.
o All the work places are provided with the MSDS of chemicals & materials being
handled. All equipment operating & production operating, chemicals handling,
procedures are laid down. The concerned employees are trained and all the
employees are made aware of the hazards in handling the chemicals.
o Inspection and preventive & breakdown maintenance of all the equipment
including pollution control equipment is undertaken by proper work permit
systems.
EIA
- 473 -
M/s. Shilpa Medicare Ltd. Unit I
5 Vision
6 Central Nervous System (CNS)
7 Respiratory System-Lung Function (RS)
8 Cardio Vascular System (CVS)
9 Electro Cardio Gram (ECG)
10 Chest X-ray
11 Total Leucocyte Count (TC)
12 Differential Leucocyte Count (DLC)
13 Absolute Eosinophil Count (AEC)
14 Complete Urine Examination [Physical / Chemical /Albumin,
Sugar & Bile Salt etc.
15 Random blood Sugar (RBS)
16 Sputum for Acid fast Bacillus (AFB for Tuberculosis)
EIA
- 474 -
M/s. Shilpa Medicare Ltd. Unit I
7.3.1 Introduction
EIA
- 475 -
M/s. Shilpa Medicare Ltd. Unit I
Standards (NAAQS). The models also serve to assist in the design of effective
control strategies to reduce emissions of harmful air pollutants.
Prediction of impacts on the air environment has been carried out employing Lakes
Environmental Software, Version 9.6 and designed for multiple sources for
predicting the maximum ground level concentration (GLC).
In the present study, the baseline analysis reports and the routine monthly
monitoring reports clearly indicate that the parameters are well within NAAQS.
However, modeling studies are carried out to ascertain compliance to the
standards during peak loads. Moreover, when compared to the mega Raichur
thermal power plant at the next compound, the impact of M/s. Shilpa Medicare
Ltd. Unit I is negligible.
The major air emissions at the site of M/s. Shilpa Medicare Ltd. Unit I, are SPM,
SO2 and NOx from boilers (4 THP). They are provided with stacks of adequate
height and multicyclone. DG sets are another source of pollution which is provided
with stack per KSPCB stipulations. Manufacturing process involves reactions in
completely closed reactors. Therefore, no emissions are anticipated. The site-
specific details considered as input data for the software (AERMOD by Lakes
Environmental) to predict the impacts on the air environment are given in table
7.2.
EIA
- 476 -
M/s. Shilpa Medicare Ltd. Unit I
Table 7.3 shows the predicted incremental short-term concentrations due to the
industry. The isotherms for Suspended Particulate Matter (PM10), Sulfur di-oxide
(SO2) and Oxides of nitrogen (NO x ) are in fig 7.2, 7.3 & 7.4.
EIA
- 477 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 478 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 479 -
M/s. Shilpa Medicare Ltd. Unit I
iii) Annual
EIA
- 480 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 481 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 482 -
M/s. Shilpa Medicare Ltd. Unit I
iii) Annual
EIA
- 483 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 484 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 485 -
M/s. Shilpa Medicare Ltd. Unit I
iii) Annual
EIA
- 486 -
M/s. Shilpa Medicare Ltd. Unit I
COMMENTS
EIA
- 487 -
M/s. Shilpa Medicare Ltd. Unit I
According to MoEF air quality standards (as per the notification dated 16 th
November 2009 for industrial, residential & rural areas) 24 hourly or 8 hourly or 1
hourly monitored values, as applicable, shall be complied with 98% of the time in a
year; 2% of the time, they may exceed the limits but not on two consecutive days
of monitoring.
Therefore the 98% values are considered for estimation of the incremental
concentration.
The above table indicates that the cumulative resultant ambient air quality at
peak loads of industrial operation will be within the ambient air quality limits
specified by MoEF as per the notification dated 16 th November 2009 for industrial,
residential & rural areas.
EIA
- 488 -
M/s. Shilpa Medicare Ltd. Unit I
CHAPTER 8
PROJECT BENEFITS
The project has generated direct and indirect employment opportunities for the
local people.
The total no. of employees in the industry are 150. Out of these, about 105 local
people are employed.
EIA
- 489 -
M/s. Shilpa Medicare Ltd. Unit I
M/s. Shilpa Medicare Ltd. Unit I will be allocating an amount of about 98 Lakhs
for CER. The activities proposed to be taken up will include infrastructure for
drinking water supply, sanitation, health, skill development, solar power, solid
waste management facilities, rainwater harvesting, avenue plantation, plantation
in community areas etc.
The Company has been conscious of its Corporate Social
Responsibility (CSR) and Corporate Environmental Responsibility (CER) & has been
undertaking, implementing activities by establishing a trust called Shilpa
Foundation to provide financial assistance to the poor and needy and to give
donations to promote various social, cultural and philanthropic activities.
The various projects envisaged by the Company as part of CSR/CER is listed below.
(a) Setting up of old age homes/ orphanages;
(b) Motivating students of rural area by providing scholarships;
(c) Providing purified drinking water to people living in the villages and
surrounding areas;
(d) Development of infrastructural facilities like roads, water supply etc. in the
surrounding villages;
(e) Supplying plants and development of agroforestry in consultation with local
in the surrounding areas.
The Company has allocated Rs.244.93 Lakhs to Shilpa Foundation, a trust formed
by the Company for CER activities as on 31st March 2017.
The Company, has invested about Rs. 38 crore on renewable energy i.e wind mills at
various locations. Details are tabulated below.
Apart from this, few major CER activities carried out during years is detailed in table
8.2
EIA
- 490 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 491 -
M/s. Shilpa Medicare Ltd. Unit I
Maheshwari Vidya
26 21,000 16.08.2016 Mumbai
Pracharak Mandal
Payment orphanage
27 23,000 18.11.2016 Raichur
children fees and books
Jawahar Nagar Payment for
28 2,50,000 30.06.2017 Raichur (Green reforestation and
Raichur) regaining of green cover.
Payment for
29 92,030 15.07.2017 Green Raichur (NGO) reforestation and
regaining of green cover.
Payment for
30 42,400 01.08.2017 Green Raichur (NGO) reforestation and
regaining of green cover.
Vijaya Bharat Seva Charity payment to
31 30,000 28.08.2017
Trust Vijaya Bharati Seva.
2nd Cross Shaktinagar
Payment for maintaining
32 25,000 28.08.2017 Sugureshwara
cleanliness
Temple Raichur
Payment for Basic
Yermaurs Raichur
33 90,500 20.09.2017 needs is SM Vidyalam
(Shashal)
School
Shri Manik Phabhu
Payment welfare trust
34 2,00,000 07.11.2017 School for Blind
towards development
Raichur
Health Camp at
35 5,00,000 Oct 2017 Mantralyam for the --
public with medicines
Hegsanahalli Benches for school
36 1,20,000 13.1.2018
Government School children
Rangapur Government Benches for school
37 66,080 30.3.2018
School children
Kannada Sahitya
38 50,00,000 Dec 2016 Funding from
Sammelana, Raichur
Seventy Four Lakhs Twenty Four Thousand
74,24,446 TOTAL
Four Hundred And Forty Six Only
EIA
- 492 -
M/s. Shilpa Medicare Ltd. Unit I
1) Windmills
EIA
- 493 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 494 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 495 -
M/s. Shilpa Medicare Ltd. Unit I
CHAPTER 9
Cost Benefit Analysis (CBA) for M/s. Shilpa Medicare Ltd. Unit I is detailed below
The major natural resources consumed/utilized by M/s. Shilpa Medicare Ltd. Unit
I are
M/s. Shilpa Medicare Ltd. Unit I had obtained Consent to Operate (CTO) from
Karnataka State Pollution Control Board vide order no. PCB/HPI/053/2015-16/1245
dated 8th Oct 2015 (appended as Annexure A2) for manufacture of 30 APIs and
intermediates with total production capacity of 317.304 MT/annum. Details are in
Chapter 2, Section 2.6.1, Table 2.5 of this report. However, actual production is
very less. Comparative statement of consented and actual production for last
three years is tabulated below.
EIA
- 496 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 497 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 498 -
M/s. Shilpa Medicare Ltd. Unit I
B. Water consumption
All the air pollution sources detailed in Chapter 2 of this EIA report have been
provided with pollution control equipments and measures as stipulated in the
CTO.
To ensure compliance, monthly monitoring is done to check ambient air
quality. Also emissions from stacks, DG, boilers and process section are
analyzed monthly.
To substantiate, sample monitoring reports are appended as Annexure A3. The
emissions from all the sources are within the stipulated limits. Also ambient air
quality is within the standards stipulated by MoEF under Nation Ambient Air
Quality Standards dated 16th November 2009.
Domestic sewage is treated in septic tank and soak pit and industrial effluent is
sent to M/s. Shilpa Medicare Ltd. Unit II located close by (4 km aerial distance
from Unit I) as stipulated in CTO by KSPCB.
The quantity of process wastewater generated is proportionate to actual
production and hence is lesser than the consented quantity.
Sample wastewater transfer slips are appended as Annexure A5.
EIA
- 499 -
M/s. Shilpa Medicare Ltd. Unit I
The industry has generated direct employment opportunities for 150 people out
of which 70% (105) are local people. Also, security, housekeeping manpower
are locally employed.
Indirect employment opportunities to the truck drivers transporting raw
materials and products are generated.
Company manufactures lifesaving anti-cancer drugs which are made available
at an affordable price. Also, some of it is being exported to various other
countries and hitherto it has earned valuable foreign exchange.
EIA
- 500 -
M/s. Shilpa Medicare Ltd. Unit I
Assessment of ecological damage with respect to air, water, land and other
environmental attributes has been done. Sampling and analysis has been carried
out by MSV Analytical Laboratories and Eco Green Solution Systems Pvt. Ltd. They
are NABL accredited/MoEFCC approved laboratory. Report is enclosed as Chapter
13.
EIA
- 501 -
M/s. Shilpa Medicare Ltd. Unit I
CHAPTER 10
It has been evaluated that the project area will not be affected significantly with
proposed project. Mitigation measures at the source level and an overall
Management Plan at the site level are elicited so as to not cause any major impact
on the surrounding environment.
All activities of the industry which can cause impact on the environment are
identified and mitigation measures are implemented. The same is explained in
detail in Chapter 4 of this EIA report.
EIA
- 502 -
M/s. Shilpa Medicare Ltd. Unit I
Details of resource allocation for monitoring are in Chapter 6, Section 6.1.4 of this
EIA report.
MD
General Manager
Manager - EHS
EIA
- 503 -
M/s. Shilpa Medicare Ltd. Unit I
CHAPTER 11
The metrological data and environmental attributes have been studied, analysed and
evaluated to understand the environmental setting of the project site. Also , the
ecological features of the location including flora & fauna, socio-economic
environment, the demographic structure have been studied and evaluated.
Assessment of ecological damage with respect to air, water, land and other
environmental attributes has been done. Sample analysis has been carried out by MSV
Analytical Laboratory, Bellary. It is a NABL accredited and MoEFCC approved
laboratory.
Based on the these studies, an Environmental Impact Statement has been prepared to
ascertain the impacts of each activity of the industry on the environmental
parameters like air, water, land and socio-economic environment vis-à-vis mitigation
measures. An impact matrix has been prepared based on these observations.
Detailed risk assessment study is carried out to evaluate the risks involved due to
storage of various solvents & precautionary measures to be taken for
prevention/management of such risks. Fire and explosion index has been calculated
for the hydrogenation process.
Conclusions drawn from the above study relates to the fact that the APIs and
intermediates manufacturing industry M/s. Shilpa Medicare Ltd. Unit I has certain
level or marginal impacts on the local environmental setting, which will not affect the
natural environmental setting of the study zone either drastically or otherwise. This is
because due care is taken by establishing and implementing pollution control
equipments and measures. Also, certain beneficial impacts in terms of the
employment opportunities have been created for the local population. Also, there is
economic growth at the regional level.
EIA
- 504 -
M/s. Shilpa Medicare Ltd. Unit I
EIA
- 505 -
M/s. Shilpa Medicare Ltd. Unit I
CHAPTER 12
INTRODUCTORY PROFILE
SAMRAKSHAN is a Bangalore, Karnataka based Environmental Engineering Consultancy
Company. SAMRAKSHAN is an off shoot of AQUATECH ENVIRO ENGINEERS, Bangalore.
We are leading solutions providers of B2B solutions in the field of Environment since
two decades. SAMRAKSHAN is a specialized solution provider; we serve varied
industries like Distillery, Sugar, Fertilizers, Pharmaceuticals, Power generation,
Service industries, Common waste disposal facilities etc.
EIA
- 506 -
508
STAY ORDER
564
EIA
565
512
566
513
567
514
568
515
M/s. Shilpa Medicare Ltd. – Unit I
ANNEXURES
Annexures
- 569 -
M/s. Shilpa Medicare Ltd. – Unit I
LIST OF ANNEXURES
Annexure Details Pg no.
no. new
A1 ToR letter no. F. No. J-11011/191/2017-IAII(I) dated 14th June 2018 issued by MoEF&CC 571-574
Authorizations from Karnataka State Pollution Control Board (KSPCB) 575-607
A2 Consent For Consent no. Validity 576-583
Operation (CFO) From To
dated
1. 8th Oct 2015 No:PCB/HPI/053/2015-16/1245 1st July 2015 30th June 2016
st
2. Hazardous waste No. PCB/WMC/SEO/69748/2014- 1 July 2014 30th June 2019 584-585
authorization 15/309
dated 23rd June
2014
3. Consent For NO. KSPCB/HPI/053/Shilpa- - - 586-594
Establishment I/CFEx/2010-11/86
(CFE) dated 7th
May 2011
4. Consent for Combined consent order no. AWH- 1st July 2016 30th June 2021 595-607
Operation for 301739
Unit II dated 27th
Dec 2016
A3 1. Compliance report to the latest CFO dated 8 th Oct 2015 valid from 1st July 2015 to 608-633
30th June 2016
2. Routine monthly monitoring and analysis reports (for March 2018)
Ambient air
Process section – scrubbers & boiler, DG stacks
Ambient noise
Effluent
VOC (3 months once)
Soil (annual)
A4 Actual production record 634-635
A5 Wastewater transfer slips (from Unit I to Unit II) 636-640
A6 Summarized safety data including incidents/accidents, emergency response teams, 641-642
trainings etc.
A7 Sample log book records for scrubber 643-644
A8 License for storage of solvents from PESO 645-648
A9 HAZOP analysis 649-785
A10 Land records and gazette notification 786-853
Hazardous waste contracts
A11 Maps and drawings 854-858
1. Topo map – 10 km radius
2. Site plan
3. Layout of industrial area
4. Maximum credible accident scenario
Annexures
- 570 -
ANNEXURE A1
571
572
573
574
ANNEXURE A2
575
· / Fax: . 25581383,25589112
25588151,25588270
{1€r..:DeE'Y / E-maIl: [email protected]
(j8)6c\ nW,-,j6/ Website: http://kspcb.gov.in 25588142,25586520
Consent is granted to "The Managing Director, MIs. Shilpa Medicare Ltd., Unit-I, Plot
No.4, Deosugur Industrial Area, Raichur Taluk & District" authorizing him to operate
the industrial plant at the above said premises and to make discharge of effluents and
emissions and subject to the terms and conditions as detailed in the schedule annexed to this
order.
Discharge of effluents under the Water Act:
SENIOR ENVIRONMENTA'J;;;FICER
B. WATER CESS:
1. The industry shall comply with the provisions of Water (Prevention & Control of Pollution) Cess
Act, 1977, by installing water meters, filing water cess returns in Form-I and other provisions as
contained in the said Water (Prevention & Control of Pollution) Cess Act, 1977 and 2003.
.
u.. r(,
SENIOR ENVIRONMENTAL OFFICER
14. The applicant shall comply with the guidelines under Corporate Responsibilities for
Environment protection 2003 issued by Ministry of Environmental Forests and CPCB
15. There shall not be public complaint against the'industry regarding any kind of pollution.
16. The applicant, his heirs, legal representatives or assigns shall have no claims what so ever
to the continuation or renewal of this consent after expiry of the period of consent.
17. The applicant shall provide alternative power supply sufficient to operate all Pollution
control equipments utilized by the applicant to maintain compliance with the terms and
conditions of this consent.
SENIOR ENVIRONMEJTAZ OFFICER
Chim. Chimney attached to Minimum Chimney Rate of Constituents to Tolerance Air Pollution Control Date of which air pollution I
No. height to be provided emission be controlled in limits equipment to be Control equipment shall be
3fHr
above ground level Nm the emission mg/Nnr' installed, in addition to provide to achieve the
chimney height as per stipulated tolerance limits
Col.(3). and chimney heights
conforming to stipulated
heights.
1 2 3 4 5 6 7 8
l. Boiler of 4 TPH 30mAGL - Particulate 150 Chimney Ht, as per At an times
matter column No.3 with
802 - multicyclone and bag filter I
..
SENIOR ENVIRONMENTAL OFFICER
583
586
587
588
589
590
591
592
593
594
(This document contains 6 pages including annexure & excluding additional conditions)
Combined Consent Order No. AWH-301739 PCB ID: 28295 Date: 27/12/2016
Combined consent for discharge of effluents under the Water (Prevention and Control of Pollution)
Act , 1974 and emission under the Air (Prevention and Control of Pollution)Act , 1981
Consent is hereby granted to the Occupier under Section 25(4) of the Water (Prevention & Control of Pollution) Act, 1974 (
herein referred to as the Water Act) & Section 21 of Air (Prevention & Control of Pollution) Act, 1981, ( herein referred to as
the Air Act) and the Rules and Orders made there under and authorized the Occupier to operate /carryout industry/activity &
to make discharge of the effluents & emissions confirming to the stipulated standards from the premises mentioned below and
subject to the terms and conditions as detailed in the Schedule Annexed to this order.
Location:
Name of the Industry: Shilpa Medicare Ltd 100% Eou
Address: Plot no 33,33A,40 TO 47, Raichur Growth Centre
Industrial Area: Raichur Growth Centre I.A, Chiksugur,
Taluk: Raichur, District: Raichur
Conditions:
S NANDA KUMAR
(This document contains 6 pages including annexure & excluding additional conditions)
To,
Shilpa Medicare Ltd 100% Eou
COPY TO:
The Environmental Officer, KSPCB, Regional Office Raichur for information and necessary action.
2. Master Register.
3. Case file.
SCHEDULE
2(a). The sewage/domestic effluent shall be treated in septic tank and with soak pit. No overflow from the soak pit
is allowed. The septic tank and soak pit shall be as per IS 2470 Part-I & Part-II.
2(b). The treated sewage effluent discharged shall conform to the standards specified in Annexure-I.
3(a). The trade effluent generated in the industry shall be treated in the ETP and treated effluent shall confirm to the
standards stipulated by the Board in Annexure-1
3(b). The trade effluent shall be handed over to CETP and maintain logbook of effluent generated & sent every day.
4. The applicant shall install flow measuring/recording devices to record the discharge quantity and maintain the
record.
5. The applicant shall not change or alter either the quality or the quantity or the place of discharge or temperature
or the point of discharge without the previous consent/ permission of the Board.
6. The applicant shall not allow the discharge from the other premises to mix with the discharge from his premises.
Storm water shall not be allowed to mix with the effluents on the upstream of the terminal manhole where the flow
measuring devices are installed.
7. The daily quantity of domestic effluent and trade effluent from the industry shall not exceed the limits as
indicated in this consent order:
8. The applicant shall discharge the effluents only to the place mentioned in the Consent order and discharge of
treated/untreated outside the premises is not permitted.
B. EMISSIONS:
1. The discharge of emissions from the premises of the applicant shall pass through the air pollution control
equipment and discharged through stacks/chimneys mentioned in Annexure-II where from the Board shall be free
to collect the samples at any time in accordance with the provisions of the Act and Rules made there under.The
tolerance limits of the constituents forming the emissions in each of the stacks shall not exceed the limits laid down
in Annexure-II.
2. The applicant shall provide port holes for sampling of emission, access platforms for carrying out stack sampling,
electrical points and all other necessary arrangements including ladder as indicated in Annexure-II.
(This document contains 6 pages including annexure & excluding additional conditions)
C. WATER CESS:
1. The applicant shall provide water meter at all the intake points as specified under Section (5) of the Water Cess
Act, 1977 and shall file the Water Cess returns regularly before fifth of every month and also pay the Cess assessed
with the time stipulated.
D.MONITORING & REPORTING:
1. The applicant shall get the samples of effluents & emissions collected and get them analyzed once a
month/either by in house monitoring laboratory or through EP approved laboratories for the parameters as Indicated in
Annexure I & II.
2. The applicant shall maintain log books to reflect the working condition of pollution control systems and also self monitoring
results and keep it open for inspection.
1.The applicant shall segregate solid waste from Hazardous Waste, Municipal Solid Waste and store it properly till
treatment/disposal without causing pollution to the surrounding Environment.
2.The solid waste generated shall be handled & disposed by scientific method without causing eye sore to the
general public and to the surrounding environment.
1. The industry shall ensure that the ambient noise levels within its premises shall not exceed the limits i.e 75 dB(A) Leq
during day time and 70 dB(A) Leq during night time as specified in under the Air (Prevention and Control of Pollution)
Act, 1981.
The applicant shall comply with the provisions of the Hazardous Wastes (Management, Handling & Transboundry
Movement) Rules 2008.
H. GENERAL CONDITIONS:
1. The applicant shall not allow the discharge from the other premises to mix with the discharge from his
premises.
2. The applicant shall promptly comply with all orders and instructions issued by the Board from time to time or
any other officers of the Board duly authorized in this behalf.
3. The applicant shall set-up Environmental Cell comprising of qualified and competent personnel for complying
with the conditions specified.
4. The Board reserves the right to review, impose additional conditions, revoke, change or alter terms and
conditions of this consent.
5. The applicant shall forthwith keep the Board informed of any accidental discharge of emissions/effluents into
the atmosphere in excess of the standards laid down by the Board. The applicant shall also take corrective steps to
mitigate the impact.
6. The applicant shall provide alternative power supply sufficient to operate all Pollution control equipments.
7. The entire premises shall always be kept clean. The effluent holding area, inspection chambers, outlets, flow
measuring points should made easily approachable.
8. The applicant shall display the consent granted in a prominent place for perusal of the inspecting officers of the
Board.
9. The applicant his heirs, legal representatives or assignee shall have no claims what so ever to the continuation or
renewal of this consent after expiry of the validity of consent.
(This document contains 6 pages including annexure & excluding additional conditions)
10. The applicant shall make an application for consent for subsequent period at least 45 days before expiry of this consent.
11. The applicant shall develop and maintain adequate green belt all around the periphery.
12. The applicant shall provide rain water harvesting system and shall provide proper storm water management
system.
13.This consent is issued without prejudice to any Court Cases pending in any Hon’ble Court
14. The applicant shall furnish the Environmental statement for every financial year ending with 31st March in
Form-V as per Environment (Protection) Rules, 1986. The statement shall be furnished before the end of
September.
15.The applicant shall display flow diagram of the pollution control system near the pollution contol system/s.
NOTE:
The following Conditions A[2(b),3(b)] & G mentioned in the schedule are not applicable.
Additional Conditions:
Please see additional condition to the consent order. The Annexure-I & II is applicable for discharge of effluent and
emission regulation.
S NANDA KUMAR
Note: All efforts should be made to remove colour and unpleasant odour as far as practicable.
(This document contains 6 pages including annexure & excluding additional conditions)
Chi Chimne Capacity/ Minimum Constituents to be Tolerance Fuel Air pollution Date of which air
m.N y KVA chimney controlled in the limits Control pollution control
o. attached Rating height to be emission mg/NM3 equipment to equipments shall
to provided be be provided to
above installed,in achieve the
ground addition to stipulated
level chimney tolerance limits
(in Mts) height as per and chimney
col.(3) heights
conforming to
stipulated
heights.
SCR : Scrubber
Note:
1. The Noise levels within the premises shall not exceed 75 dB (A) leq during day time and 70 dB(A) leq during night
time respectively.
2. The DG set shall be provided with acoustic measures as per SI.No.94 in Schedule-I of Environment
(Protection)Rules.
Portholes shall be provided for all chimneys, stacks and other sources of emission. These shall serve as
the sampling points. The sampling point should be located at a distance equal to atleast eight times the
stack or duct diameters downstream and two diameters upstream from source of low disturbance such as
a Bend, Expansion, Construction Valve, Fitting or Visible Flame for rectangular stacks, the equivalent
diameter can be calculated from the following equation.
2 (Length x Width)
Equivalent Diameter = -----------------------
(Length + Width)
2. The diameter of the sampling port should not be less than 100 mm dia”. Arrangements should be made so
that the porthole is closed firmly during the non sampling period
3. An easily accessible platform to accommodate 3 to 4 persons to conveniently monitor the stack emission
from the portholes shall be provided. Arrangements for an Electric Outlet Point of 230 V 15 A with suitable
switch control and 3 Pin Point shall be provided at the Porthole location.
4. The ladder shall be provided with adequate safety features so as to approach the monitoring location with ease.
608
M/s. Shilpa Medicare Ltd. – Unit I
January-17 to February-18
CFO compliance
609
M/s. Shilpa Medicare Ltd. – Unit I
Treating the
The Applicant shall not change or alter either the quality or the Effluent as per the
Being
5. quantity or the rate of discharge or temperature or the route of limits given in the
followed
discharge without the previous written permission of the Board. consent.
Agreed.
Flow meter
Online Flow meter
The applicant shall provide flow measuring devices at both inlet and and camera
(separate energy
outlet of ETP along with separate energy meter for the ETP and photos are in
6. meter) installed and
maintain log book for hourly recording for verification of inspecting EIA report,
Log books
officers. Chapter 6,
maintained.
Fig 6.1.
Effluent not Strom drain
discharged outside photos are in
premises. Effluent EIA report,
7. No effluent shall be discharged outside the premises.
sent to Unit-II as Chapter,
per CFO for further Chapter 2,
treatment. Fig 2.15.
III. Strom water management
Rain water
Rain water
harvesting system
The applicant shall not allow the discharge from the other premises to harvesting
in place.
mix with the discharge from his premises. Storm water shall not be system photos
The storm water
1. allowed to mix with the trade and/ or sewage effluent on the upstream are in EIA
drains are separate
of the terminal manholes where the flow measuring devices will be report,
and effluent does
installed. The applicant shall establish rain water harvesting system. Chapter 2,
not mix in the
Fig 2.15.
storm water drains.
B. WATER CESS
The industrial shall comply with the provisions of Water (Prevention Filing water cess Acknowledge
1. & Control of Pollution) Cess Act 1977, by installing water meters, monthly till July- ment copies
filling water cess returns in Form-1 and other provision as contained 2017. There after are appended
in the said water (prevention &control of pollution) Cess Act,1977 monthly data is as Annexure
and 2003. being submitted. A5.
C. DISCARGE OF EMISSIONS UNDER THE AIR ACT,1981
I. Emissions
Stack emissions are
checked every
The discharge of emissions from the premises of the Applicant shall
month by the Emissions test
pass through the air pollution control equipment and discharged
authorized Reports are
1. through stacks/chimneys mentioned in Annexure-I where from the
laboratories. The appended as
Board shall be free to collect the samples at any time in accordance
discharge of Annexure A9.
with the provisions of the Act and Rules made there under.
emissions is within
the limits.
Complied Emissions test
The type of emissions, rate of emissions, and the tolerance limits,
Stack emissions are Reports are
2. stack heights and the air pollution equipment shall be as specified
checked every appended as
Annexure-I.
month by Annexure A9.
CFO compliance
610
M/s. Shilpa Medicare Ltd. – Unit I
authorized
laboratories.
We are routinely Ambient air
The industry shall ensure that the ambient air quality in premises shall
checking ambient Reports are
3. conform to the new national ambient Air quality standards specified in
air quality in our appended as
Environment (Protection) Rules.
premises. Annexure A9.
The industry shall upgrade/modify/replace/change the control Air pollution
4. equipment’s/chimney heights if they are found inadequate to meet the control
-
standards stipulated. Prior permission of the Board shall be obtained equipment’s are
for the same. found adequate
Double
Double condenser condenser
The industry shall prevent solvent loss by installing double condenser
system is provided photos are in
5. systems and connecting the vent to carbon tower to minimize the
for all the process EIA report,
fugitive emissions
equipment’s . Chapter 2, Fig
2.13.
Centrifuge to
scrubber
All Centrifuge
connection
vents are connected
photos are
6. Centrifuge vents shall be connected to scrubbers to the scrubber for
attached as
controlling of
EIA report,
fugitive emissions.
Chapter 2, Fig
2.14.
In plant control measures for checking emission from all the Dust collector is
vulnerable sources shall be provided. Fugitive emissions shall be provided to boiler
controlled by providing closed storage. Closed handling & for controlling of
conveyance of chemical/materials, multi cyclone separator and water dust emissions at
sprinkling system. Dust suppression system including water sprinkling Boiler.
system shall be provided at loading and unloading areas to control
dust emissions, fugitive emissions in the work zone environment, i. All the Raw Raw material
product, raw materials storage area etc. Shall be regularly monitored materials and storage area
& the emissions shall conform to the limits. The industry shall chemicals are photos in EIA
monitor VOC’s within its premises for which a monitoring plan stored in closed report,
indicating the parameters relevant to the industry, location and the drums, vessels, Chapter 2, Fig
7.
frequency shall be submitted within 30 days. carboys & 2.5.
For further control of fugitive emissions, following steps shall be containers.
followed: Solvents are
transferred in
i. Closed handling system shall be provided for chemicals. closed condition. VOC
monitoring
ii. Reflux details are
condenser is appended as
provided to Annexure A9.
ii. Reflux condenser shall be provided over reactor. reactors. Every 3
months VOC
CFO compliance
611
M/s. Shilpa Medicare Ltd. – Unit I
emissions are
checked by
authorized
iii. The acid shall be vented through trap receiver and laboratories.
condenser operated on chilled water.
iii. Double
condenser system
is provided for all
the process
equipment’s.
iv. Cathodic protection shall be provided to the underground Primary
solvent storage tanks. condenser
connected to CT
water and
secondary
condenser Complied
connected to
Chilled water line
to prevent the
acid fumes.
iv. We are
providing cathodic
protection to
underground
storage tanks for
controlling
corrosiveness.
D. Solvent management
Double
Double condenser condenser
system is provided photos are in
1. Reactors shall be connected to chilled brine condenser system
for all the process EIA report,
equipment’s. Chapter 2,
Fig 2.13.
Rectors and solvent
handling pumps
Reactor and solvent handling pump shall have mechanical seals to
2. have mechanical Complied
prevent leakages.
seals for preventing
leakages.
Details are in
All the adequate
the EIA
heat exchanger is
The condensers shall be provided with sufficient HTA and residence report,
3. given to get the
time so as to achieve more than 95% recovery. Chapter 2,
recovery of solvent
Section
more than 95%.
2.8.5.1.
CFO compliance
612
M/s. Shilpa Medicare Ltd. – Unit I
CFO compliance
613
M/s. Shilpa Medicare Ltd. – Unit I
Photos are in
EIA report,
The Applicant shall provide acoustic measures to the D.G. sets as per Acoustics are
2. Chapter 2,
sl.No.94 in schedule-1 of environment (Protection) rules. provided
Fig 2.16.
CFO compliance
614
M/s. Shilpa Medicare Ltd. – Unit I
Flow diagrams of
The applicant shall display flow diagram of the pollution control pollution control
3. Complied.
system at the site. system are
displayed.
The applicant shall not change or alter quality or the rate of discharge
4. or temperature or the route of discharge without the previous consent Accepted -
of the Board.
The applicant shall promptly comply with all orders and instructions
5. issued from time to time by the Board or any other officers of the Accepted -
Board duly authorized in this behalf.
The industry shall not change or alter (a) raw materials or
6. Accepted -
manufacturing process. (b) Change the products or product mix (c)
CFO compliance
615
M/s. Shilpa Medicare Ltd. – Unit I
CFO compliance
616
M/s. Shilpa Medicare Ltd. – Unit I
The applicant shall comply with the guidelines under corporate responsibilities for environment protection
2003 issued by ministry of Environmental forest and CPCB.
1. Segregation of waste streams: Waste streams should be segregated
into high COD waste toxic waste, low COD waste, inorganic waste Effluent
Wastewater is sent transfer slips
etc, for the purpose of providing appropriate treatment. to the Unit-II for are appended
Implementation by December, 31, 2003 and action plan to be further treatment. as Annexure
submitted to SPCB by June 30, 2003. A14.
2. Detoxification and treatment of high COD waste streams: High ETP flow
chart is in EIA
COD streams should be detoxified and treated in XTP or thermally High COD waste
report,
destroyed in incinerator – Implementation by March 2004 and action stream is treated in Chapter 2,
plan to be submitted to SPCB by June 2003. ETP of Unit II.
Section
2.8.2.1.
We are providing
adequate PPE’s
(Hand gloves,
3. Management of solid waste: Proper facilities should be provided Respirator masks
for handling and storage of hazardous waste. For final disposal of etc.) for handling of
Hazardous
hazardous waste, recycling and reuse should be given priority, either hazardous waste.
waste annual
within the premises or outside with proper manifest system. In case of Impervious storage
returns in
incinerable waste, property designed incinerator should be installed facilities are
Form IV are
14. provided.
within the premises or outside as a common facility. The non- appended as
Spent solvent, used
incinerable hazardous waste should be disposed off in properly Annexure A6.
oil and discarded
designed secure landfill either within the industry’s premises or in a containers are sent
common facility implementation by march 2004 and action plan to be to recyclers/
submitted to SPCB by June 2003. reprocessors. The
rest are disposed
through authorized
channels.
4. Minimum scale of production to afford cost of pollution control For
new industries which are not connected with CETP & TSDF and NA as effluent is
which do not have the economics to install treatment facilities may treated in ETP at
not be considered for granting consent to establishment. Industry Unit II and
--
hazardous waste is
association shall submit proposal to SPCB/CPCB – implementation disposed through
by December 31, 2003 and action plan to be submitted to SPCB by authorized agencies.
June 30, 2003.
5. Long term strategies for reduction in waste: Consent for
establishment and consent for operation under the Water Act will be Water balance
based on pollution load and concentration of pollutants. Each industry chart is in EIA
Water balance chart
report,
will submit pollution load, concentration of final discharge along with is available
Capter2, Fig
water balance to SPCB/CPCB for formulation of strategy – action 2.10.
plan to be submitted to SPCB by June 30, 2003.
CFO compliance
617
M/s. Shilpa Medicare Ltd. – Unit I
Benzene, Carbon
tetra chloride, 1-4
6. Control of air pollution: Industry will take up in priority the control di-oxane, mercaptan
VOC
of hazardous air pollutants (such as benzene carbon tetrachloride 1-4 materials are not
monitoring
used.
diocane, methanol, toluene, methyl chloride etc). and odorous reports are
Methanol, hydrogen
compounds (mecapatan & hydrogen sulphide) – Implementation by sulphide. toluene,
appended as
Dec. 2004 and action plan to be submitted to SPCB by June 2003. Annexure A9.
methyl chloride is
used. VOC testing
done.
7. Self – regulation by Industry through regular monitoring and
environmental auditing: Industries on their will carry out monitoring Monitoring
environmental parameters, audit it at regular interval and submit the We are routinely reports are
monitoring ambient appended as
same to SPCB- Implementation by June 2003. Comment of BDMA-
air, VOC, noise etc. Annexure A9.
There shall be a policy for accreditating the auditors and the policy
guidelines may be issued by MoEF.
8. Organistional restructuring and accreditation of Environmental
Manager of Industry (a) Environment management cell will be We have appointed
created for each industry reporting to CEO directly- Implementation qualified Organogram is
by June 2003. (b) There should be a certification system for the environmental in EIA report,
environmental managers at individual level and common facility manager and Chapter 10,
level. BDMA may 2003 the programme along with SPCB/ CPCB Environmental Fig 10.1.
Implementation by March 31, 2000 and action plan to be submitted to engineers.
SPCB by July 2003.
9. Optimizing the inventory of hazardous chemicals: The Information
Hazardous chemical
shall be submitted to SPCB regularly along with rational- action plan inventory --
to be submitted to SPCB by May 31, 2003. maintained
We have full-
fledged pollution
There shall not be public complaint against the industry regarding any control facilities for
15. Complied.
kind of pollution. controlling any kind
of pollution.
CFO compliance
618
M/s. Shilpa Medicare Ltd. – Unit I
Daily general
The entire premises shall be always kept clean. The effluent holding
cleaning is done in
18. area, inspection chambers, outlet, and flow measuring point should Complied.
the entire industry
made easily approachable
premises.
ISO
We are an ISO 14001:2015
The applicant shall maintain the environmental management system 14001:2015 certificate is in
19.
in conformity with ISO 14001:2004 standards. accredited EIA report,
Company. Chapter 4,
Fig 4.6.
The industry shall display the CFE, CFO, EC, compliance to consent Displayed the CFE
20. and EC conditions, monitoring results on their website. The in the website of the --
environmental statement shall also be posted on their web site. industry.
We have submitted
The applicant shall make an application for consent at least 120 days consent application Complied
21.
before expiry of this consent. within 120 days to
the regional office.
We have submitted
Industry shall comply with all the consent conditions and furnish -
22. compliance to the
report within 30 days to the Regional Office.
regional office.
CFO compliance
619
620
621
622
Powered by TCPDF (www.tcpdf.org)
623
Powered by TCPDF (www.tcpdf.org)
624
Powered by TCPDF (www.tcpdf.org)
625
Powered by TCPDF (www.tcpdf.org)
626
627
628
629
630
631
Powered by TCPDF (www.tcpdf.org)
632
Powered by TCPDF (www.tcpdf.org)
633
Powered by TCPDF (www.tcpdf.org)
ANNEXURE A4
634
635
ANNEXURE A5
636
637
638
639
640
ANNEXURE A6
641
Shilpa Medicare Limited Unit-1
Yearly Data
S.No Discription
2012 2013 2014 2015 2016 2017
1 No.of minor incident/accidents from 9 10 8 11 4 5
2 No.of major incident/accidents from 0 0 0 0 0 0
3 No.of occupational health diseases reported 0 0 0 0 0 0
4 No.of hot work permits 120 85 75
5 No.of height work permits 13 11 12
6 No.of vessel/confined space entry work permits 65 88 95
7 No.of training programs conducted on OH&S 65 55 45 70 89 95
8 No.of persons under gone training 104 190 185 201 250 259
No.of competitions conducted for creating awareness on
5 5 5 5 5 5
9 safety among employees
10 Emergency response team 10 10 10 10 15 15
11 First aid trainings conducted 0 0 0 0 1 1
12 Emergency control system 1 1 1
642
ANNEXURE A7
643
644
ANNEXURE A8
645
646
647
648
ANNEXURE A9
HAZOP analysis
649
M/s. Shilpa Medicare Ltd. – Unit I
HAZOP ANALYSIS
1) HAZOP- Acebrophylline
650
M/s. Shilpa Medicare Ltd. – Unit I
651
M/s. Shilpa Medicare Ltd. – Unit I
652
M/s. Shilpa Medicare Ltd. – Unit I
653
M/s. Shilpa Medicare Ltd. – Unit I
654
M/s. Shilpa Medicare Ltd. – Unit I
655
M/s. Shilpa Medicare Ltd. – Unit I
656
M/s. Shilpa Medicare Ltd. – Unit I
657
M/s. Shilpa Medicare Ltd. – Unit I
658
M/s. Shilpa Medicare Ltd. – Unit I
659
M/s. Shilpa Medicare Ltd. – Unit I
660
M/s. Shilpa Medicare Ltd. – Unit I
661
M/s. Shilpa Medicare Ltd. – Unit I
662
M/s. Shilpa Medicare Ltd. – Unit I
663
M/s. Shilpa Medicare Ltd. – Unit I
4) HAZOP- Nifedipine
664
M/s. Shilpa Medicare Ltd. – Unit I
665
M/s. Shilpa Medicare Ltd. – Unit I
666
M/s. Shilpa Medicare Ltd. – Unit I
667
M/s. Shilpa Medicare Ltd. – Unit I
668
M/s. Shilpa Medicare Ltd. – Unit I
669
M/s. Shilpa Medicare Ltd. – Unit I
670
M/s. Shilpa Medicare Ltd. – Unit I
671
M/s. Shilpa Medicare Ltd. – Unit I
672
M/s. Shilpa Medicare Ltd. – Unit I
673
M/s. Shilpa Medicare Ltd. – Unit I
674
M/s. Shilpa Medicare Ltd. – Unit I
675
M/s. Shilpa Medicare Ltd. – Unit I
676
M/s. Shilpa Medicare Ltd. – Unit I
677
M/s. Shilpa Medicare Ltd. – Unit I
678
M/s. Shilpa Medicare Ltd. – Unit I
679
M/s. Shilpa Medicare Ltd. – Unit I
680
M/s. Shilpa Medicare Ltd. – Unit I
681
M/s. Shilpa Medicare Ltd. – Unit I
682
M/s. Shilpa Medicare Ltd. – Unit I
683
M/s. Shilpa Medicare Ltd. – Unit I
684
M/s. Shilpa Medicare Ltd. – Unit I
685
M/s. Shilpa Medicare Ltd. – Unit I
686
M/s. Shilpa Medicare Ltd. – Unit I
687
M/s. Shilpa Medicare Ltd. – Unit I
688
M/s. Shilpa Medicare Ltd. – Unit I
689
M/s. Shilpa Medicare Ltd. – Unit I
690
M/s. Shilpa Medicare Ltd. – Unit I
691
M/s. Shilpa Medicare Ltd. – Unit I
692
M/s. Shilpa Medicare Ltd. – Unit I
693
M/s. Shilpa Medicare Ltd. – Unit I
Charging of sodium Fire hazard due to Use fully Personnel protective equipment and kept in
metal open with air kerosene use nitrogen blanket.
Operational control - checkpoint shall be included in
Bottom valve
the batch sheet to indicate whether the bottom valve
Charge Sodium metal opened, or Leakage
has been closed prior to charging Butanol & is not
and Butanol into of Bottom Valve
Charging of leaking.
Stage- Stage-V.
Butanol Butanol addition pipe is kept to the Bottom of the
VI
Fire hazard due to reactor.
static electricity Pipe lines are all SS and equipment motors are flame
proof.
Distillation of All charging is done by vacuum sucking to avoid
Solvent recovery Butanol 2 into No specific hazard spillages and through the closed SS pipe lines.
reaction mass
694
M/s. Shilpa Medicare Ltd. – Unit I
695
M/s. Shilpa Medicare Ltd. – Unit I
9) HAZOP- Anastrozole
Hazop Study - Process – for Anastrozole
Possible Hazards /
Stages Process Operation Remedial Action
failures
Instruction is Laid in the SOP , To Avoid
Spillage out side the spillage outside the Equipment,Lay down the
Charging of , , , ,-
reactor, Poly Bags to Collect the spilled Material,&
tetramethyl-5-( methyl)-
Transfer to the reactor
1,3- benzene
Fire hazard due to SS scoops to avoid static electricity. The
diacetonitrile
static electricity reactor is earthed by conducting wires
Reaction of , , , ,- Irritation to skin & Using hand gloves & goggles.
tetramethyl-5-( methyl)- eyes
1,3- benzene diacetonitrile
Operational control - checkpoint shall be
with Acetonitrile, n-bromo
Bottom valve included in the batch sheet to indicate
succinamide, Ethyl acetate
opened, or Leakage whether the bottom valve has been closed
and Water then separate the
Stage-1 of Bottom Valve prior to charging Acetonitrile & is not
organic layer and
Acetonitrile Leaking.
distillation organic layer
Acetonitrile addition pipe is kept to the
and added cyclohexane
Fire hazard due to Bottom of the reactor
static electricity Pipe lines are all SS and equipment motors
are flame proof.
Instruction is Laid in the SOP , To Avoid
Spillage out side the spillage outside the Equipment,Lay down the
reactor, Poly Bags to Collect the spilled Material,&
Transfer to the reactor
n-bromo succinamide
Fire hazard due to SS scoops to avoid static electricity. The
static electricity reactor is earthed by conducting wires
Irritation to skin & Using hand gloves & goggles.
eyes
696
M/s. Shilpa Medicare Ltd. – Unit I
697
M/s. Shilpa Medicare Ltd. – Unit I
698
M/s. Shilpa Medicare Ltd. – Unit I
699
M/s. Shilpa Medicare Ltd. – Unit I
700
M/s. Shilpa Medicare Ltd. – Unit I
701
M/s. Shilpa Medicare Ltd. – Unit I
702
M/s. Shilpa Medicare Ltd. – Unit I
703
M/s. Shilpa Medicare Ltd. – Unit I
10) Hazop-Bendamustin
704
M/s. Shilpa Medicare Ltd. – Unit I
705
M/s. Shilpa Medicare Ltd. – Unit I
706
M/s. Shilpa Medicare Ltd. – Unit I
707
M/s. Shilpa Medicare Ltd. – Unit I
708
M/s. Shilpa Medicare Ltd. – Unit I
709
M/s. Shilpa Medicare Ltd. – Unit I
710
M/s. Shilpa Medicare Ltd. – Unit I
Charging of MLR
Hazardous waste after All charging is done by vacuum sucking to
Solvent recovery No specific hazard
distillation avoid spillages and through the closed SS
pipe lines.
Stage III Operational control - checkpoint shall be
Bottom valve opened, or included in the batch sheet to indicate
Leakage of Bottom Valve whether the bottom valve has been closed
prior to charging methanol & is not Leaking.
Charging of methanol
methanol addition pipe is kept to the Bottom
Fire hazard due to static of the reactor
electricity Pipe lines are all SS and equipment motors
are flame proof.
Instruction is Laid in the SOP , To Avoid
Spillage out side the spillage outside the Equipment, Lay down
reactor, the Poly Bags to Collect the spilled
Addition of stage II
Material,& Transfer to the reactor
product
Fire hazard due to static SS scoops to avoid static electricity. The
electricity reactor is earthed by conducting wires
Irritation to skin & eyes Using hand gloves & goggles.
The Filtration Operation is Carried out in
Closed SS Line, Filter cloth cleaned for
Spillage, Filter Cloth
Filtration Every Batch & this Cleaning of the Filter
Block
along with Cloth is Incorporated In the BPR
711
M/s. Shilpa Medicare Ltd. – Unit I
Charging of MLR
Hazardous waste after All charging is done by vacuum sucking to
Solvent recovery No specific hazard
distillation avoid spillages and through the closed SS
pipe lines.
RCVD is fitted with flame proof motors.
Drying Separation of solvents Drying of the product in Unloading into the bins by actuated valve,
No specific hazard
operation from the product Rotocone vacuum Dryer Hence No- Less Exposure
Hand gloves & goggles should be used.
712
M/s. Shilpa Medicare Ltd. – Unit I
713
M/s. Shilpa Medicare Ltd. – Unit I
714
M/s. Shilpa Medicare Ltd. – Unit I
715
M/s. Shilpa Medicare Ltd. – Unit I
716
M/s. Shilpa Medicare Ltd. – Unit I
717
M/s. Shilpa Medicare Ltd. – Unit I
hydrochloric acid into Fire hazard due to MDC addition pipe is kept to the Bottom of the reactor. Pipe lines
methanol. static electricity are all SS and equipment motors are flame proof.
Bottom valve Operational control - checkpoint shall be included in the batch
opened, or Leakage sheet to indicate whether the bottom valve has been closed prior to
Charging of of Bottom Valve charging methanol & is not Leaking.
methanol Fire hazard due to methanol addition pipe is kept to the Bottom of the reactor. Pipe
static electricity lines are all SS and equipment motors are flame proof.
Hydrochoric acid The Addition of Hydrochloric acid is charged through the Closed
HCl Addition Spillage & lines, without any Spillage, personnel Protective Equipments are
Irritation Used to avoid the Exposure & tackle the irritation
Charging of
sodium Corrosive nature Use properly personnel protective equipment.
hydroxide
Distillation of The temperature is raised by slow heating till reflux; the methanol
Loss of MDC and
Solvent recovery MDC and Vapour Loss is due to Excessive heat, Instruction is Given in SOP,
methanol.
methanol. To Open the steam valve to Optimum so as to maintain the reflux
Bottom valve Operational control - checkpoint shall be included in the batch
Charging of
opened, or Leakage sheet to indicate whether the bottom valve has been closed prior to
toluene
Charge toluene into of Bottom Valve charging toluene & is not Leaking.
reaction mass Fire hazard due to Toluene addition pipe is kept to the Bottom of the reactor. Pipe
static electricity lines are all SS and equipment motors are flame proof.
718
M/s. Shilpa Medicare Ltd. – Unit I
719
M/s. Shilpa Medicare Ltd. – Unit I
720
M/s. Shilpa Medicare Ltd. – Unit I
721
M/s. Shilpa Medicare Ltd. – Unit I
722
M/s. Shilpa Medicare Ltd. – Unit I
723
M/s. Shilpa Medicare Ltd. – Unit I
724
M/s. Shilpa Medicare Ltd. – Unit I
725
M/s. Shilpa Medicare Ltd. – Unit I
726
M/s. Shilpa Medicare Ltd. – Unit I
727
M/s. Shilpa Medicare Ltd. – Unit I
728
M/s. Shilpa Medicare Ltd. – Unit I
729
M/s. Shilpa Medicare Ltd. – Unit I
730
M/s. Shilpa Medicare Ltd. – Unit I
731
M/s. Shilpa Medicare Ltd. – Unit I
732
M/s. Shilpa Medicare Ltd. – Unit I
733
M/s. Shilpa Medicare Ltd. – Unit I
734
M/s. Shilpa Medicare Ltd. – Unit I
after distillation
The centrifuge is earthed by conducting wires.
The filtration is carried out through a centrifuge. Centrifuges
are high speed machines and sources of hazard in a chemical
plant. Ample precautions are taken to carry out the
centrifuging as hazard free as possible. We are using a 48
inch dia SS316 centrifuge, bottom driven and top discharge.
Fire hazard due to this is a four point suspension machines which are put on
static electricity, special vibra mount for smooth vibration free noiseless
To separate the
operator hazard if any operation. The speed is controlled by a variable frequency
Centrifuging Ist Stage From
loading / unloading drive and the feeding of the centrifuge is done by
the liquid
activity carried out in a pneumatically controlled valves at lower RPM under
running centrifuge nitrogen purging. Even the bearing housing of the centrifuge
is provided with a nitrogen purging facility. An interlocking
system is provided for ensuring that the lids cannot be
opened while the centrifuge is running and thereby
preventing any operational hazard by human error . All the
limits switches and the safety interlocking switches are
flame proof including the VFD controls.
Stage II Instruction is Laid in the SOP , To Avoid spillage outside
Addition of stage Spillage out side the
the Equipment,Lay down the Poly Bags to Collect the
I product reactor,
spilled Material,& Transfer to the reactor
NaOH is charged through the Closed lines, without any
Addition of
Spillage & Irritation Spillage,personnel Protective Equipments are Used to avoid
NaOH
the Exposure & tackle the irritation
Bottom valve opened, Operational control - checkpoint shall be included in the
or Leakage of Bottom batch sheet to indicate whether the bottom valve has been
Charging of Valve closed prior to charging MDC & is not Leaking.
MDC MDC Charging SS pipe is Fixed to the Bottom of the
Fire hazard due to
reactor
static electricity
Pipe lines are all SS and equipment motors are flame proof.
735
M/s. Shilpa Medicare Ltd. – Unit I
Charging of
MLR All charging is done by vacuum sucking to avoid spillages
Solvent recovery Hazardous waste No specific hazard and through the closed SS pipe lines.
after distillation
736
M/s. Shilpa Medicare Ltd. – Unit I
737
M/s. Shilpa Medicare Ltd. – Unit I
738
M/s. Shilpa Medicare Ltd. – Unit I
739
M/s. Shilpa Medicare Ltd. – Unit I
740
M/s. Shilpa Medicare Ltd. – Unit I
741
M/s. Shilpa Medicare Ltd. – Unit I
742
M/s. Shilpa Medicare Ltd. – Unit I
Distillation Loss of Methanol, The temperature is raised by slow heating till reflux; the methanol
of reaction Ammonium Vapour Loss is due to Excessive heat, Instruction is Given in SOP, To
mass benzoate Open the steam valve to Optimum so as to maintain the reflux
Bottom valve Operational control - checkpoint shall be included in the batch sheet to
opened, or indicate whether the bottom valve has been closed prior to charging
Charge methanol and Charging of Leakage of Bottom methanol & is not Leaking.
Stage-II Valve
carbon into stage-I methanol
Fire hazard due to methanol addition pipe is kept to the Bottom of the reactor. Pipe lines
static electricity are all SS and equipment motors are flame proof.
743
M/s. Shilpa Medicare Ltd. – Unit I
Hydrochoric acid The Addition of Hydrochloric acid is charged through the Closed lines,
Charge HCl into filtered
Hcl Addition Spillage & without any Spillage,personnel Protective Equipments are Used to
reaction mass
Irritation avoid the Exposure & tackle the irritation
The centrifuge is earthed by conducting wires.
The filtration is carried out through a centrifuge. Centrifuges are high
speed machines and sources of hazard in a chemical plant. Ample
precautions are taken to carry out the centrifuging as hazard free as
Fire hazard due to possible. We are using a 48 inch dia SS316 centrifuge, bottom driven
To separate
static electricity, and top discharge. This is a four point suspension machines which are
the
operator hazard if put on special vibra mount for smooth vibration free noiseless
Gemcitabine
Centrifuging any loading / operation. The speed is controlled by a variable frequency drive and the
stage-II
unloading activity feeding of the centrifuge is done by pneumatically controlled valves at
from the
carried out in a lower RPM under nitrogen purging. Even the bearing housing of the
liquid
running centrifuge centrifuge is provided with a nitrogen purging facility. An interlocking
system is provided for ensuring that the lids cannot be opened while the
centrifuge is running and thereby preventing any operational hazard by
human error. All the limits switches and the safety interlocking
switches are flame proof including the VFD controls.
744
M/s. Shilpa Medicare Ltd. – Unit I
Charging of
ML’s All charging is done by vacuum sucking to avoid spillages and through
Solvent recovery Hazardous No specific hazard the closed SS pipe lines.
waste after
centrifuging
Drying of VTD is fitted with flame proof motors. Unloading into the bins by
Drying Separation of solvents the product actuated valve, Hence No- Less Exposure
No specific hazard
operation from the product in Vacuum Hand gloves & goggles should be used.
tray Dryer
The Filtration Operation is Carried out in Closed SS Line, Filter cloth
Spillage, Filter
cleaned for Every Batch & this Cleaning of the Filter along with Cloth
Cloth Block
Charge Gemcitabiene Fitration is Incorporated In the BPR
Stage-II into purified Fire hazard due to Carbon Charging SS pipe is Fixed to the Bottom of the reactor
Stage-III water and filter the mass static electricity Pipe lines are all SS and equipment motors are flame proof.
then acetic acid and HCl Bottom valve Operational control - checkpoint shall be included in the batch sheet to
add into reaction mass Charging of opened, or indicate whether the bottom valve has been closed prior to charging
Acitic acid Leakage of Bottom Acitic acid & is not Leaking.
Valve
745
M/s. Shilpa Medicare Ltd. – Unit I
Acitic acid addition pipe is kept to the Bottom of the reactor. Pipe
Fire hazard due to
lines are all SS and equipment motors are flame proof.
static electricity
Hydrochoric acid The Addition of Hydrochloric acid is charged through the Closed
Hcl Addition Spillage & lines, without any Spillage, personnel Protective Equipments are
Irritation Used to avoid the Exposure & tackle the irritation
Bottom valve Operational control - checkpoint shall be included in the batch
opened, or sheet to indicate whether the bottom valve has been closed prior to
Charge acetone into Charging of Leakage of Bottom charging Acetone & is not Leaking.
filtered reaction mass Acetone Valve
Fire hazard due to Acetone addition pipe is kept to the Bottom of the reactor. Pipe
static electricity lines are all SS and equipment motors are flame proof.
Charging of
ML’s Hazardous All charging is done by vacuum sucking to avoid spillages and
Solvent recovery No specific hazard
waste after after through the closed SS pipe lines.
ANFD
Drying of the ANFD is fitted with flame proof motors. Unloading into the bins
Drying Separation of solvents product in by actuated valve, Hence No- Less Exposure
No specific hazard
operation from the product Agitated nutsche Hand gloves & goggles should be used.
filter dryer
746
M/s. Shilpa Medicare Ltd. – Unit I
747
M/s. Shilpa Medicare Ltd. – Unit I
748
M/s. Shilpa Medicare Ltd. – Unit I
749
M/s. Shilpa Medicare Ltd. – Unit I
750
M/s. Shilpa Medicare Ltd. – Unit I
751
M/s. Shilpa Medicare Ltd. – Unit I
752
M/s. Shilpa Medicare Ltd. – Unit I
753
M/s. Shilpa Medicare Ltd. – Unit I
754
M/s. Shilpa Medicare Ltd. – Unit I
755
M/s. Shilpa Medicare Ltd. – Unit I
756
M/s. Shilpa Medicare Ltd. – Unit I
757
M/s. Shilpa Medicare Ltd. – Unit I
758
M/s. Shilpa Medicare Ltd. – Unit I
Fire hazard due to static SS scoops to avoid static electricity. The reactor is earthed by
electricity conducting wires
Irritation to skin & eyes Using hand gloves & goggles.
Operational control - checkpoint shall be included in the batch
Bottom valve opened, or sheet to indicate whether the bottom valve has been closed prior to
Charging of Leakage of Bottom Valve charging Dimethyl sulphoxide & is not Leaking.
Dimethyl
sulphoxide Dimethyl sulphoxide addition pipe is kept to the Bottom of the
Fire hazard due to static
reactor. Pipe lines are all SS and equipment motors are flame
electricity
proof.
Instruction is Laid in the SOP , To Avoid spillage outside the
Spillage out side the reactor, Equipment,Lay down the Poly Bags to Collect the spilled
Charging of Material,& Transfer to the reactor
carbon Fire hazard due to static SS scoops to avoid static electricity. The reactor is earthed by
electricity conducting wires
Irritation to skin & eyes Using hand gloves & goggles.
The Filtration Operation is Carried out in Closed SS Line, Filter
Spillage, Filter Cloth Block cloth cleaned for Every Batch & this Cleaning of the Filter along
Filtration with Cloth is Incorporated In the BPR
Fire hazard due to static Carbon Charging SS pipe is Fixed to the Bottom of the reactor
electricity Pipe lines are all SS and equipment motors are flame proof.
Distillation of
Solvent DMF, Ethyl All charging is done by vacuum sucking to avoid spillages and
No specific hazard
recovery acetate into through the closed SS pipe lines.
reaction mass
Instruction is Laid in the SOP , To Avoid spillage outside the
Charge
Charging Spillage out side the reactor Equipment, Lay down the Poly Bags to Collect the spilled
Potassium
Potassium Material,& Transfer to the reactor
bromide
bromide Fire hazard due to static SS scoops to avoid static electricity. The reactor is earthed by
into reaction
electricity conducting wires
mass.
Irritation to skin & eyes Using hand gloves & goggles.
759
M/s. Shilpa Medicare Ltd. – Unit I
760
M/s. Shilpa Medicare Ltd. – Unit I
761
M/s. Shilpa Medicare Ltd. – Unit I
Distillation of
Acetonitrile All charging is done by vacuum sucking to avoid spillages and
Solvent recovery No specific hazard
into reaction through the closed SS pipe lines.
mass
The centrifuge is earthed by conducting wires.
The filtration is carried out through a centrifuge. Centrifuges are
high speed machines and sources of hazard in a chemical plant.
Ample precautions are taken to carry out the centrifuging as hazard
free as possible. We are using a 48 inch dia SS316 centrifuge,
Fire hazard due to
bottom driven and top discharge. This is a four point suspension
static electricity,
machines which are put on special vibra mount for smooth
To separate the operator hazard if
vibration free noiseless operation. The speed is controlled by a
Centrifuging bicalutamide any loading /
variable frequency drive and the feeding of the centrifuge is done
from the liquid unloading activity
by pneumatically controlled valves at lower RPM under nitrogen
carried out in a
purging. Even the bearing housing of the centrifuge is provided
running centrifuge
with a nitrogen purging facility. An interlocking system is provided
for ensuring that the lids cannot be opened while the centrifuge is
running and thereby preventing any operational hazard by human
error. All the limits switches and the safety interlocking switches
are flame proof including the VFD controls.
Drying of the VTD is fitted with flame proof motors. Unloading into the bins by
Drying Separation of solvents product in actuated valve, Hence No- Less Exposure
No specific hazard
operation from the product Vacuum tray Hand gloves & goggles should be used.
Dryer
Bottom valve Operational control - checkpoint shall be included in the batch
Charge Stage-I,DMF, sheet to indicate whether the bottom valve has been closed prior to
opened, or Leakage
Potassium carbonate, charging DMF & is not Leaking.
Charging of of Bottom Valve
Stage-II 1,2,4-Triazole,
DMF DMF addition pipe is kept to the Bottom of the reactor. Pipe lines
and Ethyl acetate Fire hazard due to
into Water. are all SS and equipment motors are flame proof.
static electricity
762
M/s. Shilpa Medicare Ltd. – Unit I
763
M/s. Shilpa Medicare Ltd. – Unit I
764
M/s. Shilpa Medicare Ltd. – Unit I
765
M/s. Shilpa Medicare Ltd. – Unit I
Charging of ML’s
Solvent
Hazardous waste No specific hazard All charging is done by vacuum sucking to avoid spillages and through the
recovery
after centrifuging closed SS pipe lines.
Dryi Separation Drying of the VTD is fitted with flame proof motors. Unloading into the bins by actuated
ng of solvents product in valve, Hence No- Less Exposure
No specific hazard
oper from the Vacuum tray Hand gloves & goggles should be used.
ation product Dryer
Instruction is Laid in the SOP , To Avoid spillage outside the Equipment, Lay
Spillage out side the
down the Poly Bags to Collect the spilled Material,& Transfer to the reactor
reactor,
Charge Charging of
Stage-I, Oxalic acid Fire hazard due to SS scoops to avoid static electricity. The reactor is earthed by conducting
Oxalic acid static electricity wires
and Silver Irritation to skin & eyes Using hand gloves & goggles.
oxide into Spillage out side the Instruction is Laid in the SOP , To Avoid spillage outside the Equipment, Lay
purified reactor, down the Poly Bags to Collect the spilled Material,& Transfer to the reactor
water. Charging of
Fire hazard due to SS scoops to avoid static electricity. The reactor is earthed by conducting
Silver oxide
static electricity wires
Stag Irritation to skin & eyes Using hand gloves & goggles.
e-II Instruction is Laid in the SOP , To Avoid spillage outside the Equipment, Lay
Spillage out side the
Charge down the Poly Bags to Collect the spilled Material,& Transfer to the reactor
reactor,
carbon into Charging of
reaction carbon Fire hazard due to SS scoops to avoid static electricity. The reactor is earthed by conducting
mass static electricity wires
Irritation to skin & eyes Using hand gloves & goggles.
The Filtration Operation is Carried out in Closed SS Line, Filter cloth cleaned
Spillage, Filter Cloth
for Every Batch & this Cleaning of the Filter along with Cloth is Incorporated
Block
Filtration In the BPR
Fire hazard due to Carbon Charging SS pipe is Fixed to the Bottom of the reactor
static electricity Pipe lines are all SS and equipment motors are flame proof.
766
M/s. Shilpa Medicare Ltd. – Unit I
767
M/s. Shilpa Medicare Ltd. – Unit I
768
M/s. Shilpa Medicare Ltd. – Unit I
769
M/s. Shilpa Medicare Ltd. – Unit I
Charging of MLR
All charging is done by vacuum sucking
Hazardous waste after
Solvent recovery No specific hazard to avoid spillages and through the closed
distillation
SS pipe lines.
Separation of solvents Drying of the product in
Drying operation No specific hazard
from the product Rotocone vacuum Dryer
Instruction is Laid in the SOP , To Avoid
Addition of stage III spillage outside the Equipment,Lay
Spillage out side the reactor,
product down the Poly Bags to Collect the spilled
Material,& Transfer to the reactor
Operational control - checkpoint shall be
included in the batch sheet to indicate
Bottom valve opened, or
Charging of MDC whether the bottom valve has been
Leakage of Bottom Valve
closed prior to charging MDC & is not
STAGE Leaking.
IV MDC addition pipe is kept to the Bottom
Fire hazard due to static of the reactor
electricity Pipe lines are all SS and equipment
motors are flame proof.
Operational control - checkpoint shall be
included in the batch sheet to indicate
Bottom valve opened, or
Charging of Acetone whether the bottom valve has been
Leakage of Bottom Valve
closed prior to charging acetone & is not
Leaking.
770
M/s. Shilpa Medicare Ltd. – Unit I
771
M/s. Shilpa Medicare Ltd. – Unit I
772
M/s. Shilpa Medicare Ltd. – Unit I
773
M/s. Shilpa Medicare Ltd. – Unit I
774
M/s. Shilpa Medicare Ltd. – Unit I
775
M/s. Shilpa Medicare Ltd. – Unit I
776
M/s. Shilpa Medicare Ltd. – Unit I
777
M/s. Shilpa Medicare Ltd. – Unit I
778
M/s. Shilpa Medicare Ltd. – Unit I
779
M/s. Shilpa Medicare Ltd. – Unit I
Fire hazard due to static Carbon Charging SS pipe is Fixed to the Bottom of the reactor
electricity Pipe lines are all SS and equipment motors are flame proof.
Distillation of The temperature is raised by slow heating till reflux; the DMSO
Solvent recovery DMSO into Loss of DMSO Vapour Loss is due to Excessive heat, Instruction is Given in SOP,
reaction mass To Open the steam valve to Optimum so as to maintain the reflux
The centrifuge is earthed by conducting wires.
The filtration is carried out through a centrifuge. Centrifuges are
high speed machines and sources of hazard in a chemical plant.
Ample precautions are taken to carry out the centrifuging as hazard
free as possible. We are using a 48 inch dia SS316 centrifuge,
bottom driven and top discharge. This is a four point suspension
Fire hazard due to static
machines which are put on special vibra mount for smooth
To separate the electricity, operator hazard if
vibration free noiseless operation. The speed is controlled by a
Centrifuging Thalidomide any loading / unloading
variable frequency drive and the feeding of the centrifuge is done
from the liquid activity carried out in a
by pneumatically controlled valves at lower RPM under nitrogen
running centrifuge
purging. Even the bearing housing of the centrifuge is provided
with a nitrogen purging facility. An interlocking system is provided
for ensuring that the lids cannot be opened while the centrifuge is
running and thereby preventing any operational hazard by human
error. All the limits switches and the safety interlocking switches
are flame proof including the VFD controls.
Charging of
ML’s All charging is done by vacuum sucking to avoid spillages and
Solvent recovery Hazardous No specific hazard through the closed SS pipe lines.
waste after
centrifuging
Drying of the VTD is fitted with flame proof motors. Unloading into the bins by
Separation of
Drying product in actuated valve, Hence No- Less Exposure
solvents from the No specific hazard
operation Vacuum tray Hand gloves & goggles should be used.
product
Dryer
780
M/s. Shilpa Medicare Ltd. – Unit I
781
M/s. Shilpa Medicare Ltd. – Unit I
Distillation of
Dimethylamine
All charging is done by vacuum sucking to avoid spillages and
Solvent recovery Formaldehyde No specific hazard
through the closed SS pipe lines.
into reaction
mass
Bottom valve Operational control - checkpoint shall be included in the batch
opened, or Leakage sheet to indicate whether the bottom valve has been closed prior to
Charging of of Bottom Valve charging acetic acid & is not leaking.
acetic acid Acetic acid addition pipe is kept to the Bottom of the reactor
Fire hazard due to
Charge wet material and static electricity Pipe lines are all SS and equipment motors are flame proof.
acetic acid into reactor The Filtration Operation is Carried out in Closed SS Line, Filter
Spillage, Filter
cloth cleaned for Every Batch & this cleaning of the Filter along
Cloth Block
Filtration with Cloth is Incorporated in the BPR.
Fire hazard due to Water charging SS pipe is Fixed to the Bottom of the reactor
static electricity Pipe lines are all SS and equipment motors are flame proof.
Distillation
acetic acid of All charging is done by vacuum sucking to avoid spillages and
No specific hazard
into reaction through the closed SS pipe lines.
mass
Drying of the RCVD is fitted with flame proof motors. Unloading into the bins
Drying Separation of solvents product in by actuated valve, Hence No- Less Exposure
No specific hazard
operation from the product Rotocone Hand gloves & goggles should be used.
vacuum Dryer
Hydrochoric acid The Addition of Hydrochloric acid is charged through the Closed
Hcl Addition Spillage & lines, without any Spillage,personnel Protective Equipments are
Add Stage-I, HCl and Irritation Used to avoid the Exposure & tackle the irritation
Stage-II
carbon into purified water. Charging of Instruction is Laid in the SOP , To Avoid spillage outside the
Spillage out side
carbon to Equipment,Lay down the Poly Bags to Collect the spilled
the reactor,
organic layer Material,& Transfer to the reactor
782
M/s. Shilpa Medicare Ltd. – Unit I
Fire hazard due to SS scoops to avoid static electricity. The reactor is earthed by
static electricity conducting wires
Irritation to skin & Using hand gloves & goggles.
eyes
The Filtration Operation is Carried out in Closed SS Line, Filter
Spillage, Filter
Filtration cloth cleaned for Every Batch & this Cleaning of the Filter along
Cloth Block
with Cloth is Incorporated In the BPR
The centrifuge is earthed by conducting wires.
The filtration is carried out through a centrifuge. Centrifuges are
high speed machines and sources of hazard in a chemical plant.
Ample precautions are taken to carry out the centrifuging as hazard
free as possible. We are using a 48 inch dia SS316 centrifuge,
Fire hazard due to
bottom driven and top discharge. This is a four point suspension
static electricity,
machines which are put on special vibra mount for smooth
To separate the operator hazard if
vibration free noiseless operation. The speed is controlled by a
Centrifuging 2nd Stage From any loading /
variable frequency drive and the feeding of the centrifuge is done
the liquid unloading activity
by pneumatically controlled valves at lower RPM under nitrogen
carried out in a
purging. Even the bearing housing of the centrifuge is provided
running centrifuge
with a nitrogen purging facility. An interlocking system is provided
for ensuring that the lids cannot be opened while the centrifuge is
running and thereby preventing any operational hazard by human
error. All the limits switches and the safety interlocking switches
are flame proof including the VFD controls.
Drying of the RCVD is fitted with flame proof motors. Unloading into the bins
Drying Separation of solvents product in by actuated valve, Hence No- Less Exposure
No specific hazard
operation from the product Rotocone Hand gloves & goggles should be used.
vacuum Dryer
783
M/s. Shilpa Medicare Ltd. – Unit I
Fire hazard due to static Iso-propyl alcohol addition pipe is kept to the Bottom
electricity of the reactor
784
M/s. Shilpa Medicare Ltd. – Unit I
785
ANNEXURE A10
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
ANNEXURE A11
854
TOPO MAP - M/s. SHILPA MEDICARE LIMITED, UNIT I
48
PEN AR
N
GODOW
RITY GATE
74 SECU
ROOM
ERT
CULV
ERT
CULV
T
VER OAD
CUL TING R
EX I S
.80
44030
T
VER
CUL